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Abstract
Angiogenesis, the sprouting of new capillaries from preexisting microvasculature, is a 
key phenomenon for many physiological and pathological processes. Physiological 
angiogenesis occurs during embryogenesis and for a healthy adult it occurs during wound 
healing and the female ovarian/menstrual cycle. Uncontrolled or dysfunctional 
angiogenesis on the other hand, has been shown to be associated with ischemia of the 
heart, atherosclerosis, rheumatoid arthritis and tumour growth and metastasis. Control of 
angiogenesis occurs via a signal network of activators and repressors, known as 
angiogenesis-stimulating factors (angiogenic factors) and angiogenesis inhibitors 
(angiostatins). Proteins involved in this key process include nucleoside phosphorylases as 
well as the tissue inhibitors of metalloproteinases (TIMPs).
Nucleoside phosphorylases catalyse the reversible phosphorolysis of purine and 
pyrimidine nucleosides, a reaction of key importance for the nucleotide salvage pathway. 
Pyrimidine phosphorylases (PyNPs), which cleave the glycosidic bond of pyrimidines 
readily catalyses the reversible phosphorolysis (having primarily a catabolic function) of 
thymidine and 2'-deoxyuridine to their respective base and to 2-deoxy-D-ribose-l- 
phosphate, as well as that of some pyrimidine analogues. Thymidine phosphorylase (TP) 
was found to induce the [ H] thymidine incorporation, endothelial cell migration in vitro 
and angiogenesis in vivo. This is achieved by retaining a constant and correct supply of 
deoxyribonucleoside triphosphates (dNTPs) for DNA repair and replication. TP has also 
been shown to play a crucial role in pathological angiogenesis; TP overexpression has 
been related to various carcinomas while TP deficiency has been related to certain 
clinical conditions. Here we report the crystal structures of hTP in two forms: unbound 
(native hTP) and bound with a small molecule inhibitor, 5IUR, which greatly resembles 
the chemotherapeutic agent currently used, 5FUR. Additionally, mutagenesis and 
enzymatic activity assays provide some novel information on the significance of certain 
active site residues and their role in the phosphorolytic reaction catalysed by hTP.
Extracellular matrix (ECM), which surrounds tissues and organs, has been shown to 
influence cell behaviour. Turnover of ECM components is therefore a crucial process for 
the control of cellular behaviour. It is essential in morphogenesis and tissue remodeling, 
which occur during embryonic development, wound healing and angiogenesis, while 
misregulation of ECM components turnover, has been linked to a series of pathological 
conditions. Enzymes involved in proteolytic systems that ECM turnover include the 
matrix-degrading proteinases known as Matrix Metalloproteinases (MMPs) or matrixins. 
The role of these molecules is highly controlled under physiological conditions, primarily 
by endogenous inhibitors, known as the tissue inhibitors of metalloproteinases (TIMPs). 
TIMPs have attracted a lot of interest due to their potential use in therapeutics. 
Understanding the structural features that are essential for TIMP potency against MMPs 
is thus of outmost importance. A bioinformatic analysis of an ‘ancestral’ TIMP form, 
TIMP from Drosophila melanogaster (cTTIMP) allows the understanding of the 
evolutionary relationships that link TIMPs from different species, and raises questions 
about the significance of certain conserved TIMP features.
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Chapter - 1 -
Introduction to X-ray crystallography
1.1 Introduction
Determination of the three dimensional structure of biological macromolecules using X- 
rays is known as X-ray crystallography. It is one of the most powerful techniques for 
structure determination allowing for details near or at atomic level resolution to be 
obtained. Information obtained from X-ray crystallography aids in the understanding of 
the structural characteristics, the enzymatic mechanism and protein -  protein recognition 
of a biological macromolecule. Structure elucidation of enzymes interacting with 
substrates and identification of conformational changes or key amino acid residues can 
subsequently lead to the design and development of drugs that target the enzymatic 
activity. It is thus appropriate to say that X-ray crystallography attracts the interests of 
various scientific fields including biochemistry, physics, chemistry and mathematics. 
Advances in technology have lead to the development of synchrotrons (more powerful X- 
ray sources), fast computers, computer software and robotics that have greatly enhanced 
all the steps involved in the determination of macromolecular structures. The steps 
involved in macromolecular structure determination are shown in Figure 1.1.
Starting form the gene of interest, cloning, expression and purification lead to the 
production of the protein of interest. The purity of the protein is of paramount importance 
in crystallographic studies; obtaining good quality diffracting crystals can greatly 
enhance subsequent steps, such as data collection and processing. Significant 
improvements in the computer programs have greatly aided phase determination, model 
building and refinement, all of which are part of structure elucidation process. The 
significance of each of these steps in obtaining a macromolecular structure as well as 






































This is the first step for the production of protein which will be subsequently used in 
crystallographic experiments. Identification of the gene of interest followed by its 
amplification is a process known as cloning. Initially, the DNA sequence of interest is 
amplified through a process known as polymerase chain reaction (PCR). The amplified 
DNA sequence is then introduced into a suitable cloning vector, a ‘DNA vehicle’. The 
choice of vector can affect following steps of protein expression and purification and 
should be thus done very carefully. Plasmids and bacteriophages are most commonly 
used for cloning, while bacterial artificial chromosomes (BACs; Shizuya etal., 1992) and 
yeast artificial chromosomes (YACs; Foote et al., 1992) are also available for this 
purpose. Vectors containing ready to use affinity tags are especially useful as they can 
greatly enhance subsequent steps. The presence of a specific promoter in the vector is 
essential for control of expression and is usually included along with multiple cloning 
sites and a selectable marker (e.g. antibiotic resistance) (Figure 1.2). Once the vector to 
be used is decided, both vector and DNA of interest are cleaved with specific enzymes, 
known as restriction enzymes that produce different types of ‘ends’; enzymes that 
produce blunt or sticky ends are most commonly used. The vector and insert (gene of 





Figure 1.2: Gene cloning in the vector of choice. Shown here are the promoter, a






Protein expression in vivo (directly from wild type sources) can be expensive and 
impractical. For this purpose expression systems have been developed of both 
prokaryotic and eukaryotic origins. Prokaryotic recombinant protein expression systems 
provide ease of culture and rapid cell growth as well as controllable induction of protein 
expression using IPTG (isopropyl-beta-D-thiogalactopyranoside). One of the most 
commonly used prokaryotic expression systems is E.coli. More complex molecules that 
need post-translational modification in order to be fully active and acquire their native 
conformation are expressed using eukaryotic expression systems. These include yeast 
cells (e.g. Pichia pastoris), insect cells (e.g. Drosophila melanogaster) and mammalian 
cells (e.g. Baby hamster kidney cells). Conditions used in expression of the recombinant 
protein, such as temperature, pH and nutrients are of key importance and often need to be 
optimised in order to achieve better yield; as a lot of material is required for 
crystallisations, an expression method that yields significant amounts of protein is 
required.
1.4 Protein purification
Protein purification is one of the most complex steps in obtaining homogeneous protein. 
Several types of chromatographic methods have been developed for protein purification. 
Most commonly more than one of these methods is required for obtaining pure protein. 
Protein purification methods include affinity chromatography, ion-exchange 
chromatography and size exclusion chromatography. Affinity chromatography is one of 
the most widely used methods for protein purification, and is especially useful for 
proteins that have been expressed with a fusion tag. Most commonly used tags include 
hexa-histidine (His6), glutathione S-transferase (GST) and maltose binding protein 
(MBP). The principle of affinity chromatography is the affinity of a biospecific ligand 
immobilised covalently on the chromatographic bed material for which the sample of 
interest has affinity. Sample and ligand will bind due to affinity interactions, while any 
unbound material will be washed off. It is essential that methods for desorbing the bound 
sample of interest are available. Ion-exchange chromatography separates proteins 
according to the charge of the protein. This type of chromatography makes use of the
5
reversible adsorption of charged solute molecules to an immobilised ion matrix of 
opposite charge. Two types of exchangers are available: anion exchangers, which are 
negatively charged and cation exchangers, which are positively charged. Bound protein is 
eluted using a salt gradient. Size exclusion chromatography separates proteins according 
to their molecular weight. A porous gel matrix is used through which molecules in the 
sample loaded are separated according to differences in their size, with the larger 
molecules being eluted first from the column. Size exclusion chromatography is usually 
one of the last steps in protein purification and is not affected greatly by buffer 
composition as molecules do not bind to the gel matrix. Usually each purification step 
involves some loss of protein. This can, however, be minimised by selecting the most 
suitable methods and optimising each of the steps involved in obtaining pure protein. To 
ensure the purity of the protein of interest SDS-PAGE is carried out after each step of 
purification. Once sufficiently purified, the protein of interest is concentrated using filters 
with an appropriate molecular weight cutoff. Concentrated protein samples are tested 
again using SDS-PAGE for any remaining impurities or heterogeneity which can greatly 
affect subsequent steps.
1.5 Protein crystallisation
Crystals are regular arrays of molecules with a repeating pattern that extends in all three 
spatial dimensions (see Figure 1.5). Obtaining crystals of good diffracting quality is one 
of the most difficult stages in structure determination. This is mainly due to the number 
of variables that are involved in crystallisation a few of them being protein concentration 
and homogeneity, pH, temperature, salt and precipitant concentration. There are two 
steps in protein crystallisation: nucleation and crystal growth. Nucleation refers to the 
formation of the first aggregates of molecules that act as nuclei for further crystal growth. 
Once the first nuclei are formed crystal growth can result from supersaturation in the 
medium where the first aggregates appeared. This process of controlled precipitation of 




Figure 1.3: Phase diagram for protein crystallisation. The x-axis represents the protein 
concentration, while the y-axis represents the precipitant concentration. In low protein 
and precipitant concentrations, the solution is undersaturated, while the use of high 
precipitant and protein concentrations usually lead to the opposite extreme. Reaching the 
metastable zone is essential for nucleation which can lead to crystal growth.
Different methods can be employed for protein crystallisation. These include the batch 
method, dialysis button method and vapour diffusion method. Hanging drop vapour 
diffusion is the most commonly used method for protein crystallisation; Figure 1.4. This 
method is advantageous in that it requires small amounts of protein sample. In the 
hanging drop method, a drop of about 1-3 pi of protein mixed with an equal amount of 
solution (mother liquor) that contains all the precipitants is placed on a siliconised 
coverslip. The coverslip is then placed on top of a reservoir containing mother liquor and 
is sealed with grease. The two solutions tend towards equilibrium and this causes vapour 
diffusion from the protein solution to the reservoir as the latter is of higher concentration. 
Vapour diffusion results in a more concentrated protein solution through which 










Figure 1.4: Hanging drop vapour diffusion method for protein crystallisation. The 
reservoir contains the mother liquor and sealed on top of the reservoir is the drop 
containing the protein sample mixed with reservoir solution. The higher concentration of 
precipitant in the reservoir solution causes vapour diffusion from the drop to the 
reservoir, resulting in supersaturation of the protein sample.
As there is a wide range of precipitants, salts and buffers to be screened initial 
crystallisation trials include the use of pre-made screens which cover a range of these 
conditions. Initial hits usually require further optimisation in order to obtain good quality 
diffracting crystals.
1.6 Crystals and symmetry
Crystals are highly ordered three dimensional arrays of molecules with a pattern that is 
repeated at regular intervals. This repeating motif is the fundamental block of a crystal 
and is known as the unit cell. A unit cell is defined by its three edges a, b, c and three 
angles a, the angle between b and c, P, the angle between a and c and y, the angle 
between a and b; Figure 1.5. The unit cell contains all the information required to 
elucidate the structure of the macromolecule crystallised. The asymmetric unit is the 
smallest repeating object in a crystal lattice. Symmetry operations on contents of the 
asymmetric unit generate a unit cell and subsequently the rest of the crystal; Figure 1.5. 
Each asymmetric unit may consist of one molecule, one subunit or a complex of more 
than one molecule.
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Figure 1.5: Schematic representation of the unit cell (A), with three edges a, b and c and 
three angles a, |3 and y. Application of symmetry operations on the unit cell generates the 
crystal lattice (B).
Based on their symmetry, crystals can be grouped into seven crystal systems, starting 
from triclinic, which is the lowest order of symmetry (Table 1.1). These seven crystal 
systems are also known as the primitive lattices. Bravais described another seven non­
primitive lattices. The seven primitive lattices along with the seven non-primitive lattices 
are collectively known as the Bravais lattices (Blundell and Johnson, 1976).
Symmetry operations like rotation, mirror plane and inversion that pass through a single 
point form the point group symmetry. These symmetry operators about a point constitute 
the 32 point groups. Further symmetry can be observed in space groups, which are the 
two-dimensional representations of a three-dimensional object (Blundell and Johnson, 
1976). Symmetry operators in space groups include translations, screw axes and glide 
planes. There are 230 space groups, which arise from the 32 point groups and the 
fourteen Bravais lattices. Protein macromolecules however consisting of amino acids, 
can only crystallise in one of the 65 ‘allowed’ space groups as mirror planes of amino 
acids do not exist in nature. Amino acids (except for glycine) have a chiral carbon atom 
adjacent to the carboxyl group (CO2’) and those found in proteins occur in the L- 
configuration about the chiral carbon atom. D-amino acids are not naturally found in 
proteins and are not involved in the metabolic pathways of eukaryotic organisms.
Table 1.1: Spacegroups, Bravais lattice types and conditions required for
categorisation.
Name Bravais Lattice types Conditions
Triclinic P &  b^ c; <# p^ y
Monoclinic p,c a^ b^ c; a=y=90° ± p
Orthorhombic p, c, I, F b^ c; a=p=y=90o
Tetragonal P,I a=b^ c; a=p =y=90°
Trigonal P a=b^ c; a=P=90°, y=120°
orR a=b=c; a=p=y<120°. ^ 90°
Hexagonal P a=b^ c; a=p=90°, y =120°
Cubic P,I,F a=b=c; a=p=y=90°
1.7 Bragg’s law
W. L. Bragg (Bragg, 1913) visualised the scattering of X-rays by a crystal and identified 
its resemblance to ordinary reflection. According to Bragg’s law, constructive 
interference between rays scattered from successive planes in the crystal will only take 





Figure 1.6: Bragg’s law. Where 
Pi and P2 are two successive 
crystal planes, separated by 
distance d. Where Ii, I2, Ri and R2 
are the incoming and reflected X- 
rays respectively, at an angle 0 of 
the crystal planes.
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Where, Ii, R\ and I2, R2 is the incident and the reflected beam by planes Pi and P2 
respectively. Where 0 is the angle of the incident and the reflected beam. The distance 
between the two planes of the crystal lattice is d. The law of diffraction states that two 
waves are in phase when their path difference is an integral multiple of the wavelength, X 
(units of wavelength X is A=10'8cm). As seen in Figure 1.6, the path difference between 
the two waves is equal to AC+CB. In order for the two waves to be in phase AC+CB has 
to be an integral multiple of the wavelength. Hence,
AB+B C=2AC=nX [1]
Trigonometrically however, AC can also be expressed as:
AB=d sin0 [2]
Combining equations [1] and [2]:
nX=2d sin0 ( Bragg’s law)
Bragg’s law allows the prediction of the position of any diffracted ray in space. 
Considering that the wavelength of the X-rays going in to the crystal is known and the 
angle 0 of the diffracted X-rays coming out of the crystal can be measured, the inter- 
planar spacing can be calculated.
1.8 Ewald sphere and reciprocal space
According to Bragg’s law the closer the planes in a crystal lattice the wider the 
diffraction observed in the diffraction pattern, while lattices with larger interplanar 
distance produce a closer diffraction pattern. Hence the diffraction observed is in 
reciprocal space rather in real space (instead of interplanar distance d in real space, it is 
1/d in the reciprocal space). Not all points in a crystal lattice will contribute in the 
production of a diffraction pattern. A geometric construction by Ewald (Ewald, 1921) 









Radius lfk Direct beam
Figure 1.7: Ewald sphere construction is a three-dimensional representation of Bragg’s 
law. It is a sphere of 1/A, radius, where the crystal is located at the centre and rotated 
perpendicular to the incoming X-ray beam. Diffraction is produced when the angle of the 
diffracted beam is equal to 20 and Bragg’s law is satisfied.
Ewald sphere has a radius of MX. The crystal is located at the center of the sphere. The 
incoming beam terminates at the origin of the reciprocal space. A diffraction “spot” will 
only be produced by those points that lie in the circumference of the sphere, hence 
reciprocal lattice points. When the angle between the incoming and outgoing beam will 
be equal to two times theta and the length of the diffraction vector S will be equal to 1/d, 
Bragg’s law will be satisfied. These points will thus contribute in the production of a 
diffraction pattern. Each point observed in the diffraction pattern is assigned a set of three 
indices which are used to define the orientation of crystallographic planes within a 
crystal. These are known as the Miller indices h, k, I. The origin of the reciprocal space is 
taken as the central beam position as seen in a diffraction pattern. Miller indices for the 
origin of the reciprocal space are hhl = 0, 0, 0 or h=0, k=0 and 1=0.
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1.9 Diffraction pattern and resolution
When a crystal is “hit” by X-rays and Bragg’s law is satisfied a diffraction pattern will be 
produced; Figure 1.8. This pattern can be used for deriving preliminary information 
required for structure elucidation. A single diffraction pattern allows the determination of 
the unit cell, the spacegroup and the resolution. Parameters such as mosaicity of the 
crystal, the exposure time required for a complete data set and the crystal-to-detector 
distance can be decided upon observation of a diffraction pattern. The pattern produced 
by a diffracting crystal provides information about the position of atoms given by the 
Miller indices and the intensity of each “spot” at that particular position, I/*/.
Figure 1.8: Diffraction pattern produced by eosinophil derived neurotoxin crystal (EDN; 
unpublished data). Shown in pink are the resolution shells; the furthest from the centre of 
the beam, the higher the resolution.
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A very important parameter in data collection is resolution as the level of detail that will 
be obtained for the structure of a macromolecule depends on the resolution of the 
collected data (Table 1.2; Blundell and Johnson, 1976). Resolution is used to describe the 
distance between two very proximal spots observed on the diffraction image. Resolution
o
is measured in Angstroms, which is a unit of length, equal to 10' cm.
Table 1.2: Effect of resolution on the structural information obtained by a crystal.
Resolution (A) Structural information obtained
6.0 Outline of the molecule, secondary structural features such as helices 
and strands can be identified.
3.0 Course of the polypeptide chain can be traced and topology of the 
folding can be established. With the aid of amino acid sequence, it is 
possible to place the side chains within the electron density map.
2.0 Main chain conformations can be established with great accuracy. 
Details of side chains conformations, bound water molecules, metal 
ions and cofactors can be identified.
1.5 Individual atoms are almost resolved. It is possible to make out the 
solvent structure.
1.0 Hydrogen atoms may become visible.
The technology used for X-ray data collection and processing has improved immensely. 
Laboratory sources such as sealed tube and rotating anode devices accelerate electrons 
towards a metal source, usually copper, that then emit X-rays at a characteristic 
wavelength: CuKa, 1.54A wavelength; if shorter wavelengths are required molybdenum 
can be used as an anode (MoKa, 0.71 A). The X-rays produced are filtered through a 
crystal monochromator and then focused by curved mirrors. Laboratory sources are about 
100-1000 times less powerful than synchrotron radiation sources; laboratory sources 
accelerate electrons to around 45-50kV while in synchrotrons accelerated electrons reach
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a final energy of lGeV to 8GeV. The development of synchrotrons has greatly enhanced 
the process of data collection; instead of the low intensity beam (proportional to the 
number of electrons emitted at any given time) emitted by the in-house X-ray sources, 
synchrotrons produce electromagnetic radiation. Detector improvement has also 
contributed immensely to the better quality and fast data collection. Nowadays, use of 
CCD (Charged Couple Device) provides better count rate, better spatial resolution and 
lower noise detection.
1.10 Data collection
Data collection is a critical step in the process of structure elucidation. Several limiting 
factors can affect data collection, the most important being the quality of the crystal and 
hence the quality of the collected data. Parameters that need to be considered for data 
collection include exposure time, crystal mosaicity, crystal-to-detector distance and 
oscillation. Longer exposure time is required for crystals that produce weak high 
resolution reflections. Increasing the exposure time can increase the intensity of the spots 
collected. This however can result to saturation of some reflections, seen as spots in the 
diffraction pattern, and can also increase the radiation damage caused to the crystal. In 
such a case data of lower resolution can be collected, where the exposure time is reduced. 
Crystal mosaicity refers to the internal disorder of a crystal; this occurs as not all 
molecules that form the crystal lattice share the same orientation. Mosaicity causes the X- 
ray beam to become spread into a narrow cone and can be one of the reasons for some 
reflections to be recorded as a spread over two or more images; these are termed partial 
reflections. Reflections that are recorded in a single image are termed full reflections. 
Mosaicity can be easily detected from the diffraction pattern as spots look broadened. 
High mosaicity can result in overlapping spots and data loss. Crystal to detector distance 
determines the resolution of the collected data. It also affects spot size in the diffraction 
pattern. The further the detector from the crystal the lower the resolution and the 
background noise from the scattered radiation from the crystal (Blow, 2002). The angle 
of oscillation required in order to collect a complete data set depends on the symmetry of 
the unit cell of the crystal. The higher the symmetry of the crystal, the less angle of 
rotation is required in order to collect a complete data set. Usually more reflections are
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collected in order to decrease the signal-to-noise ratio and increase the redundancy of the 
data collected.
Data collection can take place either at room temperature or under cryogenic conditions. 
Room temperature data collection involves the use of thin walled glass or quartz 
capillaries where the crystal is drawn by suction; mother liquor is also drawn in the 
capillary but excess liquid is removed. The tube is sealed off with wax so as to prevent 
the crystal from drying out. Data collection under cryogenic conditions has proven to 
produce higher quality data compared to those collected at room temperature. In this case 
of data collection the macromolecular crystal is usually dipped in a solution containing 
mother liquor and some cryoprotecting agent; cryoprotecting agents most commonly 
include polyols, such as glycerol and polyethylene glycols of various molecular weights. 
The crystal is then mounted on to a loop where it is held by means of surface tension and 
it is flash frozen in a stream of liquid nitrogen which solidifies the solution on the loop 
and holds the crystal stable and under low temperature. Cryogenic conditions generally 
protect the crystal from radiation damage; damage caused to the crystal by the absorption 
of the energy released by the X-rays, which increases the internal disorder of the crystal, 
leads to the production of free radicals and reduces the intensity of scattering (Blow, 
2002). Radiation damage can lead to lower quality data as well as data and crystal loss; 
the use of cryogenic conditions however usually allows the collection of a full dataset 
from a single crystal.
1.11 Data processing -  reduction and scaling
Data processing refers to the indexing of each reflection observed in the diffraction 
pattern and subsequently of all the diffraction patterns in the collected dataset. What is 
observed in the diffraction pattern is the intensity of the reflections measured; during data 
processing these intensities are converted to amplitudes. Data processing comprises of 
two steps: data reduction and scaling. Several automated computer programmes have 
been developed for data processing. These include MOSFLM (CCP4, 1994) and the HKL 
package (Otwinowski, 1993a; Otwinowski, 1993b). HKL package includes DENZO for
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autoindexing, refinement and integration, XdisplayF for visualising each image and 
SCALEPACK for scaling the indexed dataset.
Data processing starts with autoindexing of the diffraction pattern, where the symmetry 
of the unit cell and the symmetry of the crystal are used to produce a list of lattice types 
on the basis of the symmetry rules in the International Tables for crystallography (Hahn, 
1987) and a percentage of distortion. The space group that will be used as an input in the 
following steps of data processing is chosen as the best combination of highest symmetry 
and lowest percentage distortion. Data reduction also refines the crystal and detector 
parameters.
Scaling averages the processed data while accounting for errors that occur during data 
collection (e.g. crystal decay). Scaling output produces a list of statistics that help 
determine the quality of data collected, such as percent completeness, Rsym or R merge and 
I/oI. Percent completeness refers to the completeness of the data; the higher the 
percentage, the more information will be derived by data processing. Rsym gives the 
estimate between the measured and the observed intensities. When more than one dataset 
are scaled together, then this value is known as R merge• Vol is the error in measuring the 
intensity of a reflection. A value of I/al above 2.0 is indicative of an acceptable resolution 
limit for data scaling.
1.12 Phase problem
Structure determination by X-ray crystallography aims at using diffraction data and 
translating it into distribution of the electron density in the unit cell. Calculation of 
electron density requires both amplitudes and phases of the recorded reflections. During 
diffraction data collection phases are lost and it is not possible to identify the atomic 
positions based only on the information obtained from the amplitudes. Hence, calculation 
of the phases from the diffraction images is not possible. This is known as the phase 
problem.
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Structure factor can be defined as the effective number of scattering electrons and 
depends on the distribution of atoms in the unit cell and the scattering direction. The 
structure factor is given by the formula:
p hkj=Y, y,€2jti(hx+ky+zl)
Where F i s  structure factor of the atom at position hkl 
Where f j  is the atomic scattering factor (for any atom j)
From the above formula it can be seen that structure factor is the sum of scattered waves 
describing one particular reflection. The number of electrons per unit volume (V) is 
known as electron density p(x,y,z) and is given by the formula:
p(x,y,z)=(l/V) e-2,ri(hx+k5'+lz>
Where p(x,y,z) is the electron density over volume V
Phases however cannot be measured directly; hence one of the two requirements for the 
calculation of the electron density is missing. Methods used for phase determination are 
discussed later in this chapter.
1.13 Methods for phase determination
There are three most commonly used methods to derive the phases (cp); molecular 
replacement, isomorphous replacement and anomalous scattering.
1.13.1 Molecular replacement
Molecular replacement (MR) method is one of the most popular methods for 
determination of a macromolecular structure when a structure which shares >30% 
sequence identity with the unknown protein target is available. Sequence homology and
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quality of the search model are two very important parameters for a successful MR 
solution.
Two methods used for molecular replacement are the maximum likelihood-based method 
and the Patterson-based method. In maximum likelihood method a set of observations is 
given and the method detects the model parameters that are most consistent with the 
observations. It is a very accurate and sensitive method for the calculation of rotation and 
translation functions. Maximum likelihood method also accounts for different sources of 
errors in the model, such as coordinate errors, missing atoms and errors in the B-factors 
(thermal vibration factor). Molecular replacement programmes that make use of this 
method include Beast (Read, 2001) and Phaser (Read, 2001; Storoni et al, 2004).
Patterson based method requires a total of six parameters to be specified; three 
parameters (angles) are required for the rotational search and another three for the 
translational search (three-dimensional space). This method of molecular replacement 
breaks down the six parameters required by separately calculating the rotation and then 
the translation of the molecule. A Patterson function is a fourier transform of the 
measured intensities squared, but not phased. This produces a density map of the vectors 
between scattering objects in the unit cell, rather than an electron density map. Two types 
of vectors are used in Patterson function: inter-atomic and intra-atomic vectors. Intra- 
atomic vectors or self-vectors arise from the same molecule and are used to determine the 
relative orientation of individual atoms in the crystal by using the rotation function. Once 
the orientation is known, it can be used for the intermolecular vector calculation. Inter­
atomic vectors or cross-vectors determine the relative position of these molecules and are 
used by the translation function (Rossmann and Blow, 1967). Programmes using the 
Patterson function based method for molecular replacement include MOLREP (Vagin 
and Teplyakov, 1997) and AMoRe (Navaza, 1994). The principle of molecular 










Figure 1.9: Principle of the molecular replacement method. The search model is 
illustrated in blue. Rotation R and translation of molecule A yields molecule B, which is 
the target molecule.
Molecular replacement programmes most often provide solutions for the rotation and 
translation of the molecule in the unit cell, each associated with a residual factor and a 
correlation coefficient. The residual factor is an estimate error between the observed and 
the calculated structure factors; the closer the agreement the lower the residual factor, the 
better the MR solution. The correlation coefficient describes the relationship of the two 
variables; observed and calculated structure factors. These parameters usually indicate 
whether a successful solution has been obtained.
1.13.2 lsomorphous replacement
Isomorphous replacement refers to the replacement of solvent molecules or light salt ions 
by the introduction of a heavy atom in the structure (Green et al., 1954). This method 
exploits the principle that each atom in the molecule contributes independently to the
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scattering factor. In Isomorphous replacement at least two crystals are required; the 
parent, which is that of the native protein and the derivative, which is the crystal 
containing the heavy atom(s). Heavy atoms can be introduced by soaking or by a 
chemical reaction. The introduced “heavy” atom of the derivative crystal will contribute 
disproportionately to the overall intensity. It inevitably disturbs the environment around 
the protein and usually forces some solvent molecules out of the crystal, which results in 
non-isomorphism. Data collection from both crystals (parent and derivative) and 
calculation of Patterson maps will lead to the identification of the location of the heavy 
atoms in the crystals and their contribution to the structure factor. Single Isomorphous 
Replacement (SIR) and Multiple Isomorphous Replacement (MIR) (Green et al., 1954) 
are two methods used widely for the calculation of phases for a new protein. The use of 
one only derivative is usually not enough for the determination of phases. In practice two 
derivative crystals are usually required in order for the phase angle to be determined 
accurately.
1.13.3 Anomalous scattering
The method of anomalous scattering resembles the method of isomorphous replacement 
but differs in that heavy atoms, integral to the protein under study are used in order to 
exploit differences in scattered intensities. This method requires the use of tunable 
wavelength and is very popular for use at the synchrotrons. In anomalous scattering 
method, Friedel’s law (Friedel, 1913), according to which Fhid=F.h-k-i (where Fhkiand F_h-k- 
i are Braggs reflections that have the same magnitude but phases of opposite signs) is 
breached. Tuning the wavelength close to the energy of electronic transition of the 
anomalous scatterer (absorption edge) can bring the latter to an excited state. In this case 
the radiation energy of the excited atom is not in phase with the incident beam, while the 
scattering of the “normal” component is reduced. As the wavelength is tuned and the 
crystal remains the same, this method has the advantage of accuracy. Anomalous 
scattering can take place either as Single-wavelength Anomalous Dispersion (SAD) or 
via Multiple-wavelength Anomalous Dispersion (Hendrickson, 1991; MAD). An even 
more powerful method for phase determination is the combination of Isomorphous 
replacement with anomalous scattering, if the anomalous scattering atoms are the same as
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the heavy atoms used in an Isomorphous replacement experiment. Single wavelength 
Isomorphous replacement and anomalous scattering (SIRAS) and Multiple wavelength 
Isomorphous replacement and anomalous scattering (MIRAS) are two ways in which 
Isomorphous replacement and anomalous scattering can be combined to derive more 
information about the phases.
1.14 Model building and refinement
Once the phases have been obtained by molecular replacement, isomorphous replacement 
or anomalous scattering refining the agreement between the diffracted data and the 
calculated phases is the next step for structure elucidation. The structure image is in the 
form of an electron density map, electron density being the number of electrons per unit 
volume (electron density is the fourier transformation of structure factors). Electron 
density maps provide a wealth of information not only for the structure but for the 
progress of refinement as well. Difference density maps are calculated after every step of 
refinement. Two types of maps are most commonly used; F0-Fc and 2F0-FC maps. Fc-Fc 
electron density maps are difference maps where the observed and calculated structure 
factors have been given the same weight. Positive regions in the F0-Fc maps will signify 
features that exist but have not been represented by the model. Negative regions in an Fc- 
Fc map will represent features that are present in the model but not supported by the 
observations. Double difference map, or 2F0-FC, where the observed structure factors 
have double the contribution of the calculated structure factors will more strongly 
represent uninterpreted features in the structure. The initial electron density maps will 
inevitably have several areas that need correction. It is essential though to check that 
significant agreement exists between the model and the data (electron density map) 
before proceeding to the refinement of the structure. In cases where molecular 
replacement has been used for phase determination, the backbone chain of the search 
model used should agree and follow the mainchain of the electron density map, even at 
low resolutions. When a novel protein is under study and the phases have been 
determined by isomorphous replacement or anomalous scattering it is essential to take 
extra care in fitting the protein sequence (i.e. amino acids) into the electron density map.
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The agreement between the observed and calculated structure factors can be significantly 
improved with iterative cycles of refinement and manual model building. Refinement 
programs that are most commonly used are REFMAC (Murshudov et al., 1997) and CNS 
(Briinger et al., 1998). Several parameters are refined during this process. These include 
positional parameters (coordinates x, y, z) and thermal parameters (atomic thermal 
factors). Satisfactory refinement of these parameters depends on the available number of 
observations. The observation: parameter ratio can in some cases prove to be a limiting 
factor in refinement. If such a ratio is low then not enough information is available from 
the collected data in order to account for all the parameters that need to be refined. The 
observation to parameter ratio is usually not high enough to account for the refinement of 
all parameters for each atom. Hence restraints and constraints are used in the refinement 
process. In restrained refinement parameters are allowed some freedom of movement. A 
type of restrained refinement is B-factor refinement, which refines the individual atomic 
thermal vibration. Restrained refinement improves the observation to parameter ratio, 
improving thus the refinement. In constrained refinement parameters are treated as rigid 
bodies and no distortion is allowed; no deviation from a user-specified value. A 
parameter where constraints can be applied is the occupancy, to which a certain value is 
given and no distortion from this value is allowed during refinement. Constrained 
refinement reduces the number of parameters requiring refinement, improving the 
observation to parameter ratio.
There are two methods for refinement: least squares refinement (LSQ) and maximum 
likelihood refinement (MLH). In least squares refinement the best values for a set of 
parameters are those which minimise the sums of the squares of the weighted differences 
between the observed and the calculated values. LSQ method for refinement is used by 
REFMAC (Murshudov et a l , 1997). The goal of the maximum likelihood method is to 
determine the probability of a set of measurements to occur, given the model, and 
estimates of its errors and of errors in the measured intensities. Errors that need to be 
accounted for in the maximum likelihood method include coordinate errors, missing 
atoms and errors in the B-factors. The maximum likelihood method is used in CNS 
(Briinger et al., 1998) and TNT refinement (Tronrud, 1997).
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Improvement of the quality of the electron density map is the result of improvement of 
the model via model building and refinement. One such refinement process is simulated 
annealing. Annealing is a physical process in which a solid is heated to a temperature 
high enough to make it liquid and then cooled down slowly so as for each and every atom 
to reach the lowest energy state. In simulated annealing the model is heated to a 
temperature defined by the user (usually 3,000-5,000K) and then it is allowed to cool 
down in small steps so that every atom can reach its minimum energy state. The quality 
of the model is thus improved in consecutive steps of refinement and the calculated 
atomic parameters being refined (spatial parameters and atomic thermal factor) are 
brought closer to the observed values.
Automated refinement corrects errors in the model and improves the agreement between 
observed and calculated structure factors. Gross errors however in the model cannot be 
corrected by refinement programs. Manual model building is essential in the 
improvement and interpretation of the electron density map. Through model building it is 
possible to check whether all electron density has been accounted for and whether the 
best possible interpretation has been given to the electron density map. Model building 
involves monitoring the refined model and electron density maps in molecular graphics 
programs such as COOT (Emsley and Cowtan, 2004) and O (Jones et al., 1991). 
Examination of the difference density (positive and negative) will indicate whether 
refinement is proceeding in the correct direction. Electron density for solvent atoms, ions 
and any ligands present should also be accounted for, nearing the end of the refinement in 
order to avoid misinterpretation or bias the electron density map. Programs for automated 
identification of solvent atoms are available (e.g. WATERPICK in CNS; Briinger et al., 
1998) while ions and ligands have to be defined by the user. A database where several 
popular ligands are deposited is the HIC-Up web-server (Kleywegt and Jones, 1998).
The measure of a refining structure is given by the reliability index or R-factor. As 
refinement progresses the agreement between the structure factors Fs, calculated Fcaic and 
observed F0^ , improves and as a result the R-factor drops. The R-factor is calculated 
from the following formula:
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h^kl ||F0fc| - k|FCfl/c||
Rc/yj/ —
^ h k l |Fo6.y|
Where, Xhki is the sum of the differences of ||F0| - |FC|| over h, k, 1 
Where, |F0| and |FC| are the observed and calculated structure factor amplitudes
Where k is the scale factor
To avoid overfitting the data during crystallographic refinement, Alex Briinger (1992) 
introduced another parameter, R^ .ec, which states the quality of a structure and is a cross- 
validation parameter. Prior to refinement the total number of reflections obtained by data 
collection is separated into two groups prior refinement; a working set and a test set. 
Working set indicates the agreement, between the observed and calculated data. It 
decreases when favourable changes are made to the model. The test set, Rfree, consists of 
around 750-1000 reflections (~5% of the total number of reflections) picked randomly 
and separated from the total number of unique reflections. Rfree is calculated against the 
data instead of against the model; hence there is no model-bias in the refinement of the 
test set. If the errors that occur during model refinement are only statistical and the model 
is correct then both R-factors should decrease. Iterative cycles of model building and 
refinement come to an end when all the electron density has been interpreted or there is 
no observable change in the R-factors.
1.15 Structure validation, analysis and deposition
Validation is a necessary step for the assessment of the refined structure. Several 
programs are available for structure validation. The most commonly used program to 
asses the geometry of the refined structure is PROCHECK (Laskowski et al., 1993). 
PROCHECK provides a Ramachandran plot (Figure 1.10; Ramachandran et al., 1963) 
which indicates the number of residues in the allowed and disallowed conformations 
based on cp and \|/ angles defining the polypeptide backbone. Ideally, a refined structure 
should have 0% of the residues in disallowed conformations with the vast majority in the
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most favourable region. This program also produces a list of distorted geometry in terms 
of bond angles, bond lengths and planar groups. Outliers noticed in the Ramachandran 
plot or in the distorted geometry output files have to be checked carefully. Divergence 
from the expected values can either be because of inaccuracy or they might indicate a 












Figure 1.10: Representation of a Ramachandran plot. The x-axis represents the cp angles, 
between C-N while the y-axis represents the y angles, between C-C. The red regions of 
the plot represent the secondary structure elements with top left comer representing the 
beta sheet, the bottom left comer the right-handed alpha helix and the top right comer the 
left handed alpha helix. Regions shown in yellow represent the additionally allowed 
regions. Regions shown in beige are the generously allowed regions while white regions 
represent the disallowed amino acid conformations. A represent glycines while ■ 
represent all other amino acids.
26
Similarly, model_stats in CNS (Briinger et a l , 1998) provides an output list file with 
information about the geometry and violations, close contacts and crystal contacts. Root 
mean square deviation (rmsd) values given for bond lengths and bond angles are 
parameters indicative for the quality of the geometry of the refined structure. Close 
contacts and crystal contacts have to be examined in order to correct any errors in the 
refined structure.
MOLPROBITY (Davis et al., 2004) is a web-based program, which checks for close 
contacts and interactions amongst residues in the refined structure. A crystal structure of 
good quality would ideally have no close contacts. If any close contacts are detected in 
the refined structure the program produces a list of alternative amino acid side chain 
conformations that can be checked in order to improve the quality of the structure.
Only after validation can the interpretation of the structure, in the form of structure 
analysis, begin. Several programs are available for examining different aspects of the 
structure. For assigning the secondary structure elements in the structure DSSP (Kabsch 
and Sander, 1983) is the program most commonly used. CONTACT from the CCP4 suite 
(CCP4, 1994) produces a list of all interactions (hydrogen bonds and van der Waal 
interactions) detected in the structure. This is particularly useful if ions and ligands are 
present in the structure as well as for examining the interactions of certain residues with 
others, or with solvent atoms. HBPLUS (McDonald and Thornton, 1994) is the most 
commonly used program for the detection of hydrogen bonds as it calculates hydrogen 
bond lengths and donor to acceptor angles. Burried_surface (Lee and Richards, 1971) is a 
very useful program when complexes or ligands are examined in a structure. It provides 
the total surface area of a single chain molecule and upon formation of a complex (or 
when a ligand is bound to a specific site on the molecule) it provides the surface area that 
becomes buried. Several other programs can be used if more specific areas are to be 
analysed when interpreting the structure and possible function of a macromolecule.
A structure that has been validated and analysed can then be deposited with the Research 
Collaboratory for Structural Bioinformatics Protein Data Bank. The PDB (Bernstein et
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al., 1977) contains structures determined by NMR, X-ray crystallography and some 
deposited theoretical models. Structure deposition includes the deposition of atomic 
coordinates, structure factors, experimental details as well as details about data collection, 
processing and refinement.
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Angiogenesis can be defined as the sprouting of new capillaries from preexisting 
microvasculature. The process of angiogenesis is similar to that of vasculogenesis, the 
latter describing however the de novo formation of the vascular system. Angiogenesis is a 
key phenomenon for many physiological and pathological processes. Physiological 
angiogenesis occurs during embryogenesis, while for a healthy adult it occurs during 
wound healing and the female ovarian/menstrual cycle. Uncontrolled or dysfunctional 
angiogenesis has been shown to be associated with ischemia of the heart, atherosclerosis, 
rheumatoid arthritis and tumour growth and metastasis (Folkman, 1971; Arnold et al., 
1987; Folkman, 1995; Norrby, 1997; Folkman, 1998). Control of angiogenesis occurs via 
a signal network of activators and repressors, which act as ‘on’ and ‘off switches. 
Activators of angiogenesis are known as angiogenesis-stimulating factors (angiogenic 
factors) while repressors of angiogenesis are known as angiogenesis inhibitors 
(angiostatins).
Endothelial cells are essential for angiogenesis. They are normally quiescent but become 
stimulated during an angiogenic response leading to degradation of the basement 
membrane and chemotactic migration. Ultimately, they undergo division and form 
functioning capillaries. These events are all essential for recovery of homeostasis.
2.2 Physiological angiogenesis
Physiological angiogenesis occurs as a response to inflammatory cells or injury, where 
angiogenic growth factors such as vascular endothelial growth factor (VEGF), fibroblast 
growth factor (FGF), angiogenin and platelet-derived endothelial cell growth factor/ 
thymidine phosphorylase (PD-ECGF/TP), are released. The vessel wall of mature 
capillaries consists of a lining of endothelial cells, a basement membrane and a layer of 
pericytes, which surround the endothelium. The released angiogenic factors bind to 
receptors on the endothelial cell lining and stimulate them. This leads to endothelial cell 
growth and to the secretion of proteases, such as the matrix metalloproteases (MMPs), 
which digest the basement membrane surrounding the vessel and allow the endothelial
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cell projections to migrate towards the diseased or injured tissue. The tissue surrounding 
the newly formed blood vessel is remodeled by MMPs, while pericytes form a structural 
support network, essential for stabilising the new capillary. Individual capillaries are 
linked together to form blood vessel loops through which blood circulates. Once the new 
vessel has been formed, blood flow initiates. The process of angiogenesis as a response to 
a stimulus stops when a balance between the positive and negative regulators of the 
process has been restored. A representation of the steps involved in angiogenesis is given 
in Figure 2.1 (Folkman, 2007).
A. Blood vessel, coloured in pink and 
the endothelial cell lining coloured in 
cream.
B. Upon the release of an angiogenic 
factor the endothelial cell lining begins 
to beak away and endothelial cells are 
released.
C. Endothelial cells migrate and sprout 
to form a new capillary (newly formed 
capillary shown in cream).
D. Endothelial cells attract pericytes, 
which form a structural support 
network, completing in this way the 
formation of a new blood vessel.
Figure 2.1: Schematic representation of the steps (A-D) involved in an angiogenic 
response.
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23  Pathological angiogenesis
Dysfunctional and uncontrolled angiogenesis has been shown to be involved in many 
pathological conditions. Increase in the expression of angiogenesis activators triggers 
leads to excessive angiogenesis, responsible for diseases such as cancer, psoriasis and 
rheumatoid arthritis (Figure 2.2). In such cases newly formed blood vessels provide 
nutrients and oxygen to diseased tissues allowing and promoting the diseased state. 
Insufficient angiogenesis occurs in diseases such as coronary artery disease, stroke and 
delayed wound healing (Figure 2.2) and is caused by an increase in the expression of 
angiogenesis inhibitors. This in turn leads to inadequate blood vessel growth and 










Figure 2.2: Pathological angiogenesis, excessive or insufficient, and its implication in 
several pathological conditions.
2.3.1 Tumour growth and metastasis
Tumour growth and metastasis has been shown to be dependent on angiogenesis in 1972 
(Gimbrone et al., 1972). In humans, most tumours in the early stages exist in an 




of blood supply (Folkman, 2002). Such types of tumours can persist for months or years 
before becoming detectable. For tumours to increase in size and become detectable an 
angiogenic switch must be triggered. Once triggered the expression of angiogenesis 
activators increases and the balance between activators and inhibitors of is disrupted. In 
some cases tumours have been shown to express proangiogenic factors, such as vascular 
endothelial growth factor (VEGF; Kleespies et al, 2005), that allow the angiogenic 
switch to take place. Formation of new blood vessels allows the transport of nutrients and 
oxygen to proliferating cancer cells, allowing tumour growth. Blood circulation provides 
an ‘escape’ route for cancer cells so that they can circulate and lodge on normal host 
tissue and other organs causing tumour metastases. Interestingly, apoptosis (programmed 
cell death), a process that occurs in normal tissue and maintains homeostasis, can be 
blocked in tumour cells. Mutations in specific genes and over-expression of proteins that 
suppress cell death allow tumour cell survival and promote tumour growth.
2.4 Regulation of angiogenesis
Regulation of angiogenesis is crucial and depends on the balance between activators and 
inhibitors. Angiogenesis stimulators include the VEGF, placenta growth factor (P1GF), 
FGF, angiogenin and PD-ECGF/TP (Milkiewicz et al, 2006). PD-ECGF/TP has been 
shown to stimulate DNA synthesis and chemotaxis of endothelial cells in vitro and 
angiogenesis in vivo (Miyazono et al, 1989). Its angiogenic activity has been shown to 
be dependent on the enzymatic activity, which is the reversible phosphorolysis of 
thymidine to thymine and 2-deoxy-D-ribose-l-phosphate. A key role is also attributed to 
proteins that are involved in the steps that lead to the formation of a new blood vessel. 
One class of such enzymes are the matrix metalloproteinases (MMPs), involved in the 
degradation of the extracellular matrix during the formation of a new blood vessel (Vu 
and Werb, 2000). Several types of MMPs with specific roles have been identified in 
humans, such as stromelysins, collagenases, gelatinases. The turnover of extracellular 
matrix in which these enzymes are involved is regulated by another class of enzymes, the 
tissue inhibitors of metalloproteinases TIMPs: the endogenous inhibitors of MMPs (Brew 
et al, 2000; Wei et al, 2003). In humans, four types of TIMPs have been identified and 
are responsible for the inhibition of the different types of MMPs. TIMPs have attracted a
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lot of scientific interest as their role in inhibition of MMPs could be exploited for 
therapeutic purposes.
Balance between positive and negative regulators of angiogenesis includes several more 
proteins (Figure 2.3), involved in a complex network of interactions. Understanding the 
control of angiogenesis and the roles of regulators (positive and negative) as well as all 
the molecules that can trigger an angiogenic response is of paramount importance. 
Advances made through research have greatly aided towards this purpose and future 














Figure 23: Angiogenesis regulation depends on the balance between angiogenic 
(positive regulators) and angiostatic molecules (negative regulators); imbalance in either 
positive or negative regulators can lead to excessive or insufficient angiogenesis.
Several enzymes that are involved in angiogenesis have been studied and characterised to 
date. PD-ECGF/TP has been the main focus of my PhD study. Crystallographic and 
molecular biology techniques have been applied to acquire more information about this 
enzyme and better understand its structure and function; see Chapter ID for details.
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Due to the number of diseases linked to excessive angiogenesis, its negative regulators 
have attracted a lot of interest. One such regulator, TIMP from Drosophila melanogaster, 
dTIMP, has been studied during my PhD. Modeling work on </TIMP, a homologue of 
/zTIMP (human TIMP), provides insights in the evolutionary relationship of TIMPs from 
different organisms, (see Chapter IV for details) especially since functional similarity 
does not always imply structural similarity.
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Chapter -  III -  
Human Thymidine Phosphorylase
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3.1 Introduction to nucleoside phosphorylases
Nucleoside phosphorylases catalyse the reversible phosphorolysis of purine and 
pyrimidine nucleosides, a reaction of key importance for the nucleotide salvage pathway. 
The phosphorolysis of purine and pyrimidine nucleosides occurs by the cleavage of the 
C-N glycosidic bond by a phosphate ion to yield a free base and 2-deoxy-D-ribose-l- 
phosphate. Two families of nucleoside phosphorylases have been described: purine 
phosphorylases (PNPs), which cleave the glycosidic bond of purines (Figure 3.1) and 
pyrimidine phosphorylases (PyNPs), which cleave the glycosidic bond of pyrimidines 
(Figure 3.2), while no phosphorylase has been described to cleave the glycosidic bond of 
cytidine (Levene and Medigreceanu, 1911).
Phosphate Adenine 2-deoxy-D-ribose-l-phosphateAdenosine
Figure 3.1: Schematic representation of the reaction catalysed by adenosine 
phosphorylase, a member of the purine nucleoside phosphorylase superfamily (PNP); 
adenosine and phosphate are used as substrates (for the catabolic reaction) while adenine 
and 2-deoxy-D-ribose-l-phosphate are the products of the reaction.
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Thymidine Phosphate Thymine 2-deoxy-D-ribose-l-phosphate
Figure 3.2: Schematic representation of the (catabolic) reaction catalysed by thymidine 
phosphorylase, a member of the pyrimidine nucleoside phosphorylase superfamily 
(PyNP). Thymidine and phosphate are used as substrates while thymine and 2-deoxy-D- 
ribose-l-phosphate are the products of the reaction.
PNPs are single-domain molecules, with either a trimeric or hexameric quaternary 
structure; this topology appears to be conserved among all members of the family 
(Pugmire and Ealick, 2002). PyNPs are two-domain molecules with a dimeric quaternary 
structure, a conserved topology amongst the members of the family and a significant 
percentage of sequence identity (>30%) (Walter et al., 1990; Pugmire and Ealick, 1998; 
Pugmire et al., 1998). In lower organisms PyNPs accept both thymidine and uridine, 
while in mammals and other higher organisms there are two types which distinguish 
between the two: one specific for uridine and one specific for thymidine (Paege and 
Schlenk, 1952). The differences in the fold between PNPs and PyNPs suggest that the 
two families have evolved separately despite the similarity of the reactions they catalyse.
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3.2 Thymidine phosphorylase (TP) and platelet-derived endothelial cell growth 
factor (PD-ECGF)
Mammalian thymidine phosphorylase (TP) and its role in the nucleotide salvage pathway 
was first described by Friedkin and Roberts in 1954 (Friedkin and Roberts, 1954). 
Biochemical characterisation of TP demonstrated that it has low substrate specificity 
(Desgranges et al., 1981) and readily catalyses the reversible phosphorolysis (having 
primarily a catabolic function; Iltzsch et al., 1985) of thymidine and 2'-deoxyuridine to 
their respective base and to 2-deoxy-D-ribose-l-phosphate, as well as that of some 
pyrimidine analogues (Piper and Fox, 1982; Desgranges et al., 1983; Verri et al., 2000). 
TP accepts and acts only on naturally occurring D-thymidine and D-thymidine analogs 
but not on their L-counterparts, signifying the enantioselectivity of the enzyme (Spadari 
et al., 1995).
In 1987 a protein found to induce the [3H] thymidine incorporation, endothelial cell 
migration in vitro and angiogenesis in vivo was isolated from human platelets (Miyazono 
et al., 1987; Ishikawa et al., 1989) and was thus given the name platelet-derived 
endothelial cell growth factor (PD-ECGF). Purified PD-ECGF is a single chain 
polypeptide which appears to act as a homodimer of ~90kD molecular weight (Ishikawa 
et al., 1989). The gene for PD-ECGF was later identified (Hagiwara et al., 1991) to 







Figure 33: Schematic representation of chromosome 22 and the gene encoding for TP. 
Ten exons (represented by black boxes) are present in the TP gene, which is dispersed 
over a 4.3kb region. (Figure adapted from data produced by the Chromosome 22 Group 
at the Sanger Institute; Collins etal., 2003).
Interestingly the promoter region of human PD-ECGF seems to lack characteristic 
features of eukaryotic promoters, such as a ‘TATA’ box or a ‘CCAAT’ box (Miyazono et 
al., 1991). Post-translational modification and glycosylation do not seem to take place in 
the case of PD-ECGF; the enzyme stays inside the cell and is secreted very slowly 
without any further processing, making it a ‘non-classical’ secretory protein (Usuki etal., 
1989). The only post-translational modification that the enzyme seems to undergo is the 
phosphorylation of serine residues; this could be a way to facilitate its secretion, 
otherwise impossible due to the lack of a signal peptide (Asai etal., 1992b). Amino acid 
sequence analysis and gel chromatography revealed that PD-ECGF is identical to TP 
(Usuki etal., 1992). In 1992 Asai and co-workers identified PD-ECGF/TP to be identical 
to gliostatin (GLS), a glial growth inhibitory factor from human neurofibroma (Asai et 
al., 1992).
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3.3 PD-ECGF/TP in physiological angiogenesis
Angiogenesis is the generation of new capillary blood vessels from pre-existing 
vasculature. It occurs in several physiological and pathological processes (see Chapter 
II). As a multi-step process it involves a wide number of mediators, positive (up- 
regulation) and negative (down-regulation). The implication of TP in angiogenesis has 
been demonstrated by its ability to stimulate endothelial cell migration in vitro 
(Miyazono et al., 1989) and angiogenesis in vivo, in models such as the chick 
chorioallantoic membrane (CAM) and in MCF-7 breast cancer cells, where TP induced 
an increase in the levels of tumour vascularisation (Haraguchi et al., 1994; Moghaddam 
et al., 1995; Liekens et al., 2002).
In contrast to other angiogenic factors which bind to cell surface receptors and activate 
signal transduction pathways, TP has not been shown to recognise and bind any. 
Enzymatic activity assays on TP where active site residues have been mutated, 
demonstrated that its catalytic activity is indispensable for its angiogenic activity; 
limiting the enzymatic activity of TP results in abolishing the angiogenic activity of the 
enzyme (Haraguchi et al., 1994; Moghaddam et al., 1995; Miyadera et al., 1995).
One of the key roles of TP is the maintenance of a balance in the nucleotide pool and 
control of nucleic acid homeostasis. This is achieved by retaining a constant and correct 
supply of deoxyribonucleoside triphosphates (dNTPs) for DNA repair and replication 
(Figure 3.4). It is important to note that inadequate supply of dNTPs can be lethal while 















(repair & replication) Salvage pathway
Figure 3.4: The role of TP in nucleic acid homeostasis. TP catalyses the phosphorolysis of 
thymidine to thymine and 2-deoxy-D-ribose-l-phosphate. Of the two products, the latter is 
dephosphorylated in the cytoplasm and can leave the cell; 2-deoxy-D-ribose has also been 
shown to have angiogenic activity. Cytostatic thymidine enters the cell in a non-energy 
dependent manner and is cleaved by TP, driving in this way the salvage pathway and 
maintaining a constant supply of nucleotides for DNA repair and replication. Imbalances in 
this cycle affect both nucleic acid homeostasis and angiogenic activity of TP, possibly 
mediated by 2-deoxy-D-ribose. (Figure adapted from: Brown and Bicknell, 1998).
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One of the products of the reaction catalysed by TP is 2-deoxy-D-ribose-l-phosphate 
(2dRlP), proposed to be responsible for the angiogenic activity of the enzyme. More 
specifically 2dRlP, is dephosphorylated in the cytoplasm to 2-deoxy-D-ribose, which is 
cell permeant and can thus leave the cell (Figure 3.4). This monosaccharide, which is an 
endothelial cell chemoattractant has also been shown to induce angiogenesis (Haraguchi 
et al., 1994; Moghaddam et al., 1995; Miyadera et al., 1995), probably in a manner 
similar to that of glucose, which by acting as an energy source attracts endothelial cells 
along its concentration gradient (Vogel et al., 1993).
In contrast to other chemoattractants that bind to specific endothelial cell surface 
receptors, 2-deoxy-D-ribose has not been shown to bind any. The exact mechanism by 
which TP and 2-deoxy-ribose induce angiogenesis is not yet completely understood; 
Brown and co-workers proposed a hypothesis regarding the implication of 2-deoxy-D- 
ribose in angiogenesis (Brown et al., 2000). This hypothesis was based on the nature of 
2-deoxy-D-ribose as a strongly reducing sugar; its presence can generate oxygen radicals 
that induce oxidative stress response angiogenic factors, like VEGF, MMPs and IL-8.
3.4 PD-ECGF/TP in pathological angiogenesis
TP has been shown to play a crucial role in pathological angiogenesis (Figure 3.5). Cases 
of carcinomas and excessive angiogenesis where TP was found to be overexpressed have 
been widely reported while TP deficiency has also been related to certain clinical 
conditions.
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Psoriatic IessionsIBD MNGIE Ulcer
Figure 3.5: Factors that induce TP upregulation include hypoxia, cytokines, 
chemotherapeutic drugs, stress, changes in tumour environment and irradiation. 
Overexpression of TP has been observed in various pathological conditions, such as 
cancer, ulcers, rheumatoid arthritis, psoriatic lesions, irritable bowel disease and MNGIE.
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3.4.1. PD-ECGF/TP and cancer
TP has been shown to overexpress in various types of tumours (Figure 3.5); histological 
analyses have revealed increased levels of TP in tumours compared to those of non­
neoplastic regions of the same organs. Due to its angiogenic activity, increase in TP 
expression leads to increase in the microvasculature and has been observed in cases such 
as colorectal, gastric, breast, pancreatic, cervical, renal, prostate and endometrial tumours 
(Reynolds et al., 1994; Toi et al., 1995; Takebayashi et al., 1996; Imazano et al., 1997; 
Takao et al., 1998; Yao et al., 2001; Sivridis et al., 2002). Additionally carcinomas that 
were TP-positive were linked to poorer prognosis compared to TP-negative carcinomas, 
implicating thus TP in the development of malignancy in tumours (Akiyama et al., 2004). 
Hence, increase in tumour growth, poorer prognosis and resistance to apoptosis are three 
key processes in which TP has been shown to be involved, mostly due to its angiogenic 
activity.
Inflammatory mediators associated with physical stress have also been shown to 
upregulate TP (Figure 3.5). More specifically, even in early stages of non-invasive 
cancers, hypoxic environments are developed which are rich in cytokines. Cytokines such 
as tumour necrosis factor (TNF) a and interleukin 1 can alter the phenotype of 
neighbouring stromal cells and have been shown to upregulate the expression of TP in 
malignant cells (Eda et al., 1993; Goto et al., 2001; Zhu et al., 2003). Upregulation of TP 
in conditions of environmental stress and inflammation has been confirmed by the 
stimulation of its expression in hypoxia or hypoglycaemia (Griffiths et al., 1997).
TP has been shown to co-express with other angiogenic molecules, such as VEGF, an 
important mediator of vascular development and growth. This suggests that the two 
molecules may act cooperatively in neovascularisation. One of the products of the 
catabolic reaction catalysed by TP, 2-deoxy-D-ribose has also been implicated in 
neovascularisation of tumours as it has been shown to stimulate cell migration in the 
endothelium, necessary for the development of new capillaries and maintenance of 
oxygen and nutrients for tumour growth, progression and metastasis (Zhang et al., 1995).
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3.4.2. PD-ECGF/TP in cancer treatment
Overexpression of TP has also been shown to be induced by several types of cancer 
treatment. Chemotherapeutic drugs, such as taxanes (Sawada et al., 1998; Endo et al., 
1999) and cyclophosphamide (Sawada et al., 1998; Endo et al., 1999) as well as 
irradiation have proved to induce expression of TP in various solid tumours (Figure 3.5). 
This is probably due to the induction of its expression via cytokines (e.g. TNF-a) which 
are upregulated by the use of chemotherapeutic drugs. Treatments which aim at altering 
the tumour environment, either by changes in the pH or by inducing hypoxia have also 
been shown to induce TP. Hence, combinatorial treatments that aim at inactivating TP 
and target tumour growth and progression are considered to be essential for cancer 
treatment.
3.4.3. PD-ECGF/TP and protumour stroma
Studies on tumour stromal cells revealed TP overexpression in tumour-associated 
macrophages as well as in stromal cells, suggesting TP is implicated in poorer prognosis 
in cases such as breast cancer, astrocytic tumours and uterine endometrial cancers (Toi et 
al., 1995b; Seki et al., 1999; Yao et al., 2001). The implication of TP in such cases is 
considered to be mediated by its metabolite 2-deoxy-D-ribose-l-phosphate, which is 
assumed to change the property of stromal cells from non-protumour or antitumour to 
protumour, via the stimulation of angiogenic, inflammatory, tissue digestive and 
steroidogenic molecules (Brown et al., 2000). Based on these findings, Toi and co­
workers proposed the conversion of TP-positive to TP-negative stroma as a treatment for 
cancer, suggesting that protumour stroma can change back to antitumour stroma (Toi et 
al., 2005).
3.4.4. PD-ECGF/TP and apoptosis
Implication of TP in many solid tumours is not only based on its angiogenic properties 
that stimulate neovascularisation; TP has also been shown to mediate inhibition of 
tumour cell apoptosis. Hypoxia (lack of oxygen) enhances apoptosis (cell death), which 
in turn induces the expression of angiogenic factors, such as VEGF and TP (Figure 3.4; 
Sheweiki et al., 1992; Yao et al., 1995; Graeber et al., 1996). During tumour growth it is
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common for the centre of the tumour to become hypoxic, leading to apoptosis and 
necrosis. This is however usually limited to the centre of the tumour, suggesting that 
there are specific mechanisms recruited by the remaining tumour cells in order to 
maintain tumour progression. TP has been shown to be involved in one of these 
mechanisms: it appears to provide resistance to apoptosis when the latter is induced by 
conditions such as hypoxia (Kitazono et al., 1998). The enzymatic activity of TP did not 
seem to be essential for this role although its metabolite, 2-deoxy-D-ribose, has also been 
shown to prevent hypoxia-induced cell apoptosis, indicating that both enzyme and 
metabolites are cytoprotective. Due to its angiogenic activity and cooperation with other 
angiogenic molecules, TP appears to be crucial for the escape of tumour cells from 
apoptotic signals, including physical stress and anticancer treatment (Toi et al., 2005).
3.4.5. PD-ECGF/TP and VEGF
In several cases of highly vascularised tumours, such as head, neck, breast, lung, 
colorectal, cervical and endometrial tumours, TP has been found to co-express with 
VEGF (Toi et al., 1995a; Fukuiwa et al., 1999; O’Byme et al., 2000; Yao et al., 2001; 
Kabuubi et al., 2006). The presence of an SP1 transcription factor binding site in the 
promoter regions of both TP and VEGF explains the similar transcription regulation of 
TP and VEGF genes (Hagiwara et al., 1991), hence the cooperative action of VEGF and 
TP. Experiments in stage I lung adenocarcinoma revealed that TP induction is mostly 
noticed on the tumour stroma while VEGF induction is most clearly seen in the tumour 
cells (Kojima et al., 2002); it can be thus assumed that cooperation of TP and VEGF may 
result in a more aggressive tumour phenotype.
3.4.6. PD-ECGF/TP in inflammatory diseases
Apart from its implication in various types of tumours TP has also been shown to be 
involved in various inflammatory and angiogenic diseases (Figure 3.5). Hammerberg and 
co-workers (Hammerberg et al., 1991) have identified TP overexpression in psoriatic 
lesions. Higher TP concentration has also been detected in sections of colonic mucosa of 
inflammatory bowel disease (IBD), predominately in macrophages and fibroblasts, while 
increase in microvessel density was observed in the inflamed mucosa (Saito et al., 2003).
47
Kasugai and co-workers identified its implication in gastric ulcers (Figure 3.5). The 
human plasma concentration of GLS/PD-ECGF/TP was significantly higher in patients 
with intractable gastric ulcer. The tissue content was significantly higher at the gastric 
ulcer edge than in either the fiindic or pyloric region. GLS/PD-ECGF infusion delayed 
ulcer healing in a dose-dependent manner (Kasugai et al., 1997). These results suggest 
that gastric tissue and/or circulating GLS/PD-ECGF are part of the pathology of gastric 
ulcers.
Gliostatin, previously identified to be identical to PD-ECGF/TP, has been implicated in 
rheumatoid arthritis (RA; Figure 3.5; Asai et al., 1993; Takeuchi et al., 1994). Presence 
of TP in synovial fluid was considered to be indicative of neovascularisation in 
rheumatoid synovial tissues (Waguri et al., 1997). Implication of TP in RA is proposed to 
be via the production of cytokines such as TNF-a and IL-1 from fibroblast-like 
synoviocytes, which in turn stimulate the production and secretion of TP (Waguri et al., 
1997). The ability of TP to induce MMP production would further explain the extensive 
joint destruction observed in RA (Muro et al., 1999; Ieda et al., 2001).
The gene encoding for TP is located on chromosome 22 (see 3.2). Mutation on the origin 
of this gene has been shown to cause an autosomal recessive disease, known as 
mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). Deficiency in TP 
activity leads to increased levels of thymidine and deoxyuridine, as these are not 
catalysed. Imbalances caused by elevated thymidine concentrations can alter cell growth 
and viability (Barclay et al., 1982), by inducing deletions and point mutations in 
mitochondrial DNA (Spinazzola et al., 2002). Further research on TP and its association 
with MNGIE revealed that the mutation in the origin of the gene noticed in MNGIE cases 
is also present in some individuals with normal TP activity, while overlapping on the 
same chromosome was found to be a gene encoding for SC02 (Haraguchi et al., 2002). 
SC02 is a COX assembly gene (cytochrome c oxidase), located next to human TP gene 
(exon 10), which has been previously reported in patients with foetal infantile 
cardioencephalomyopathy and has also been shown to be associated with severe COX 
deficiency in heart and skeletal muscle (Haraguchi et al., 2002).
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It is thus evident that the wide number and severity of diseases in which TP has been 
shown to be involved (either directly or via its metabolites) make the need for suitable 
and effective inhibitors of its enzymatic activity imperative.
3.4.7. Inhibitors o f PD-ECGF/TP
As TP is involved in various inflammatory, angiogenic and cancer conditions inhibition 
of its activity has been the target of several research groups. Even when the target is the 
angiogenic activity of TP, the enzymatic activity has to be abolished as the first is 
dependent on the latter. Several types of inhibitors have been previously designed and 
tested for their inhibitory activity. An example is 7-Deazaxanthine (7DX), the first purine 
derivative, which inhibited thymidine phosphorylase in a concentration dependent 
manner (Balzarini et al., 1998). Using 7DX as a basis and covalently linking it to an alkyl 
phosphonate moiety, lead to the design of a new inhibitor; TP65. The latter inhibitor, 
(Liekens et al., 2002), was later proposed to inhibit thymidine phosphorylase by keeping 
it in an inactive conformation. Another type of inhibitor designed for thymidine 
phosphorylase had a homopthalmide skeleton. A potent inhibitor of this class was 2-(2,6- 
diethyl)-7-nitro-l,2,3,4-tetrahydroisoquinoline-l,3-dione, which was shown to cause a 
mixed-type inhibition of thymidine phosphorylase (Kita et al., 2001). Fukushima et al., in 
2000, reported one of the most potent inhibitors designed for thymidine phosphorylase, 
(5-chloro-6-[l-(2-iminopyrrolidinyl)methyl] uracil hydrochloride), TPI. TPI was 
described to have an IC50 value of 35nM (Fukushima et al., 2000) and it was suggested to 
suppress tumour growth by increasing the apoptotic rate. Pyrimidine derivatives have 
always been considered to be the most popular targets for drug design and development. 
Murray and co-workers (Murray et al., 2002) reported a series of bicyclic pyridinium- 
substituted uracil and thymine analogues that have been designed for thymidine 
phosphorylase. Their efficacy was tested on E.coli TP: the 6-amino-5-substituted
derivatives have been shown to be potent inhibitors of TP, the most potent being 6- 
amino-5-bromouracil, with and IC50 of 1.1 mM. Brown and Bicknell (1998) reported the 
efficacy of 5-nitrouracil in TP inhibition; IC50 of 414 pM. Reigan (Reigan et al., 2005) 
described the design and development of a class of inhibitors that act as prodrugs and rely 
on the tumour environment (in particular the hypoxic conditions and high concentration
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of xanthine oxidase present in many tumours) for their conversion. One such example is 
the design of 5-halo-6’-[(2’-nitroimidazol-r-yl)methyl]uracil, reduced to 2’-amino 
analogues by xanthine and reported to be a potent inhibitor of TP (Reigan et al., 2005).
An interesting type of inhibition is that of the metabolite of TP, 2-deoxy-D-ribose by its 
enantiomer 2-deoxy-L-ribose. The latter has been shown to inhibit endothelial cell 
migration occurring as a response to 2-deoxy-D-ribose (Akiyama et al., 2004; Nakajima 
et al., 2004). The stimulation of other angiogenic molecules by 2-deoxy-D-ribose was 
also reduced in the presence of its enantiomer, indicating its potency in inhibiting this 
angiogenic mediator. Although 2-deoxy-L-ribose has been shown to reduce the 
angiogenic activity of TP, it does not seem to affect its enzymatic activity; this is of key 
importance as maintenance of nucleic acid homeostasis is crucial.
Most inhibitors that are currently designed and tested are prodrugs that require TP for 
their conversion. One such example is doxifluridine, an oral prodrug, which upon 
conversion from TP becomes 5-fluorouracil (5FU). This however is a rate-limiting drug 
as toxicity is accumulated in areas where TP is expressed; not only in tumours but in the 
gastrointestinal tract as well. A new drug, currently in clinical trials, capecitabine, was 
designed so as to pass through the gastrointestinal tract at its intact form and deliver the 
converted 5FU only to cancer cells (Miwa et al., 1998).
For a successful inhibitor, parameters such as the nature of the inhibitor, the size and the 
number of interactions with the enzyme have to be considered. In the present study hTP 
has been examined at its native state and in complex with a pyrimidine based analogue, 
5-iodouracil, 5IUR, which greatly resembles the chemotherapeutic agent 5-fluorouracil 
(Brown and Bicknell, 1998).
3.5 Pyrimidine nucleoside phosphorylases : an overview
The family of pyrimidine nucleoside phosphorylases consists of thymidine and uridine 
phosphorylases (see 3.1). The similarity of the substrates they recognise (Figure 3.6) as 
well as the reaction they catalyse would probably lead to the assumption that the two
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types of pyrimidine nucleoside phosphorylases are also similar in structure; primary to 
quaternary. Interestingly this is not the case: uridine phosphorylase differs greatly from 











Figure 3.6: Structure of uridine and thymidine, the two substrates catalysed by uridine 
nucleoside phosphorylase and thymidine nucleoside phosphorylase respectively.
3.5.1. Uridine nucleoside phosphorylase
Uridine phosphorylase (UP; Pugmire and Ealick, 2002) is an enzyme of key role in the 
pyrimidine salvage pathway: it catalyses the reversible phosphorolysis of uridine to uracil 
and ribose-1-phosphate. As previously described (see 3.1) two typical folds represent 
members of the nucleoside phosphorylase superfamily: a fold which is considered to be 
characteristic of PNPs and a different one, characteristic of PyNPs. Although functionally 
UP is a member of the PyNP superfamily, structurally it appears to differ greatly from the 
typical fold expected for members of this family. The fold it acquires is a single subunit 
a/p-fold (Figure 3.7).
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Figure 3.7: Cartoon representation of UP monomer from Escherichia coli (PDB ID 
1RXY; Caradoc-Davies etal., 2004). Uridine phosphorylase is a one-domain molecule (a 
single subunit), that acquires an a/p-fold.
The quaternary structure of the enzyme consists of trimers or hexamers. One such 
example is the structure of E.coli UP (Burling et al., 2003; Caradoc-Davies et al., 2004) 
which acquires a hexameric quaternary structure (Figure 3.8).
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Figure 3.8: Cartoon representation of the quaternary structure of UP from Escherichia 
coli (PDB ID 1RXY, Caradoc-Davies et al., 2004). The hexameric quaternary structure 
observed for UP (PyNP) is typically observed for members of the PNP superfamily.
Three binding sites have been identified in E.coli UP: a phosphate binding site, a ribose 
binding site and a uracil binding site. The phosphate binding site appears to consist of 
almost identical residues to that of E.coli PNP, probably due to the evolutionary 
relationship and conserved function of these enzymes. The ribose binding site consists of 
four key residues in both E.coli UP and E.coli PNP, suggesting that the same overall
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pattern of hydrogen bonding to ribose exists in both cases (Caradoc-Davies et al., 2004). 
Comparison of the sequence of UP from E.coli and human revealed that residues 
involved in ribose and uracil binding are conserved and probably involved in the same 
network of interactions as that of E.coli PNP. These findings suggest that UP and 
hexameric PNP diverged from a common ancestor (Pugmire and Ealick 2002), while the 
few differences observed between the two structures are probably the evolutionary event 
that separated UP from the ancestral form of hexameric PNPs.
Structural studies on native and complex forms of E.coli UP (Caradoc-Davies et al., 
2004) revealed that it displays induced fit upon substrate binding (specific for 
pyrimidines) and acquires a closed conformation, proposing thus a type of ‘domain 
movement’, essential for catalysis to occur. Regions that appear to be disordered in the 
native form of the enzyme, show significant improvement in the closed, bound state.
Although the sequence, structure and mechanism of E.coli UP was proposed to resemble 
greatly those of PNPs, the enzyme appears to be specific only for pyrimidines (Vita et al., 
1986). These findings present an interesting case of common ancestry, evolutionary 
divergence and structure-function relationships of enzymes with key roles in the 
nucleoside salvage pathway.
3.5.2. Thymidine nucleoside phosphorylase structures from Escherichia coli, Bacillus 
stearothermophillus and Human species.
A wealth of structural information about thymidine nucleoside phosphorylase has come 
from studies on E.coli and B. stearothermophillus TP. The structure of E.coli thymidine 
phosphorylase (EcTP), the first structure of TP to be determined, was first reported by 
Walter and co-workers in 1990 (Figure 3.9; Walter et al., 1990) at 2.8A resolution, with a 
sulphate ion bound on the phosphate binding site. The structure of Bacillus 
stearothermophillus PyNP (BsPyNP) was later reported by Pugmire and Ealick in 1998 
(Figure 3.9; Pugmire and Ealick, 1998) in complex with pseudouridine and phosphate. 
The structure of human thymidine phosphorylase (hTP; Figure 3.9) was first described by 
Norman and co-workers in 2004 (Norman et al., 2004) in complex with a small molecule
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inhibitor, TPI. Another complex of hTP was later determined by El Omari, where 
thymine was identified in the active site of the enzyme, although thymidine was present 
in the crystallisation conditions (El Omari et al., 2006). While E.coli and human TP have 
been described to be specific for 2-deoxy-ribosides, BsPyNP showed no such specificity.
The first thymidine phosphorylase to be structurally characterised, EcTP, was identified 
to consist of two domains, a small a-helical domain, composed of six helices and shown 
to be involved in interactions at the dimer interface. The larger mixed a/p domain was 
identified to consist of a central six-stranded mixed P-sheet, surrounded by two helices 
and a smaller, four-stranded antiparallel p-sheet, with no evident interactions with the 
central six-stranded mixed P-sheet (Figure 3.9).
Bacterial TP is smaller than its mammalian homologue: each monomer has a molecular 
weight of 45kDa, composing a homodimer of around 90kDa, while each monomer of 
mammalian TP has a molecular weight of around 50kDa, with a dimer molecular weight 
of around lOOkDa. On the sequence level bacterial TP shares ~41% sequence similarity 
with human TP (Walter et al., 1990; Brodsky et al., 1992). Structurally, bacterial TP 
resembles greatly its mammalian homologue: they have the characteristic PyNP fold of a 
small a and larger a/p domain, ‘held’ together by three polypeptide loops: LI, L2 and L3 
(Figure 3.9; Walter et al., 1990; Norman et al., 2004; El Omari et al., 2006). Structural 
characterisation of TP from bacterial sources initiated the design and development of 
drugs targeting these enzymes, while mechanisms of TP activity, proposed on the basis of 
structural findings, have ‘directed’ the design and development of drugs targeting its 
enzymatic activity and, subsequently, its angiogenic activity.
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EcTP BsPyNP
(Walter et al., 1990) (Pugmire and Ealick, 1998)
H IN G E
H IN G E i
hTP
(Norman etal., 2004)
Figure 3.9: Cartoon representation of the secondary structure of the three thymidine 
phosphorylases; EcTP, BsPyNP and hTP. Shown in cyan is the a domain and in grey is 
the mixed /(3 domain. Highlighted in pink are the three loop regions (LI, L2 and L3) and 
the hinge region (HINGE), proposed to allow for flexibility, necessary for domain 
movement upon occupation of the phosphate and substrate binding sites. In the structure 
of hTP (first described by Norman et al., 2004) the hinge region was proteolytically 
cleaved.
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3.5.3. Binding sites o f TP
The active site where the substrate (thymidine) binds is proposed to be located at the 
interface between the a domain and the mixed a/p domain (Figure 3.10; Walter et al., 
1990; Pugmire and Ealick, 1998). A number of charged residues form a network of 
interactions with molecules bound at the active site, stabilising them in the active site 
cleft (Walter et al., 1990; Pugmire and Ealick, 1998; Norman et al., 2004). Residues 
identified to interact with molecules bound at the active site of EcTP, BsPyNP and hTP 
appear to be conserved amongst species.
A phosphate binding site was identified to be located at the mixed a/p domain, access to 
which was proposed to be via the cavity between the two domains (Figure 3.10; Walter et 
al., 1990; Pugmire et al., 1998a; Pugmire and Ealick, 1998). The residues previously 
proposed to be essential for phosphate binding have also been identified in hTP, 
suggesting that these residues are conserved among species. A glycine-rich loop has been 
proposed to be involved in the binding of the phosphate ion. Similar glycine-rich loops 
have been identified in other nucleotide-binding proteins (Dreusicke and Schulz, 1986). 
Due to its high content in glycine residues it is considered to be very flexible and aid the 
movement of the two domains (Pugmire et al., 1998a). This glycine-rich loop region is 
conserved in all known TP structures, signifying its potential functional implication.
Two more ‘pockets’ were identified in the structure of BsPyNP: one potential metal ion 
(most probably Ca2+ or K*) binding site and one hydrophobic pocket. The hydrophobic 
pocket surrounds the 5’-position of the pyrimidine ring bound on the active site, as seen 
in this crystal structure (Pugmire and Ealick, 1998). The same hydrophobic pocket was 
later identified in hTP; in the structure of hTP-TPI this pocket appears to hold the 





Figure 3.10: Cartoon representation of the secondary structure of hTP. The two domains 
are colour-coded: a domain and mixed a/p domain The active site cleft, located at the 
interface between the two domains, is highlighted in pink whereas the phosphate binding 
site, located in the mixed a/p domain is highlighted in blue
3.5.4 Domain movement in PyNPs
Early work on EcTP revealed that the distance between the substrate binding site and the 
phosphate binding site was too large (8 A )  for the nucleophilic attack to occur (Pugmire et 
al., 1998a). Hence a type of domain movement was proposed to take place upon binding
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of substrates, where both a and a/p domains move as rigid bodies (Figure 3.11). The 
proposed sequence of events initiates with the binding of phosphate, which triggers the 
movement of the mixed a/p domain by 8°. This is followed by the binding of thymidine, 
which triggers a further domain movement, to a total of 21°, and leads to the fully closed 
(active) enzyme conformation (Pugmire and Ealick, 1998).
Three loop regions (LI, L2 and L3) ‘bridge’ the a and the mixed a/p domains. These 
three regions were proposed to confer flexibility for domain movement, which occurs 
upon occupation of the phosphate binding site and the active site. Another region of 
flexibility was proposed to be a seven residue loop (the hinge region) that extends across 
the active site cleft and appears to act as a ‘latch’ that forms a network of interactions 
with both domains and ‘covers’ the active site cleft (Pugmire and Ealick, 1998).
Figure 3.11: Schematic representation of the proposed movement of thymidine 
phosphorylase upon substrate binding. Thd represents thymidine, the natural substrate for 
thymidine phosphorylase. The three loops (LI, L2 and L3) are proposed to allow the rigid 
body movement that brings the two domains closer together for catalysis to occur. Shown 
in yellow is the mixed a/p domain and in light green is the a domain (Figure adapted 







Both structures of hTP complexes determined to date are in the closed conformation 
(1UOU, Norman et al., 2004; 2J0F, El Omari et a l, 2006). The absence however of 
phosphate in both complexes of hTP might indicate that occupation of the active site 
alone, without prior occupation of the phosphate binding site, suffices to induce the 
‘closed’ conformation of the enzyme (Norman et al., 2004; El Omari et al., 2006). All 
data currently available that support domain movement are based on structures of EcTP. 
Further structural data of an ‘open’ (unbound) form of hTP would provide valuable 
information on the two states of the enzyme and would indicate under which conditions 
domain movement is induced.
We have determined the structure of a complex of hTP with 5-iodouracil (5IUR), a small 
molecule inhibitor that greatly resembles the chemotherapeutic agent currently used, 
5FU. Further structural information for hTP and possible conformational changes 
between an unbound (inactive) and a bound (active) conformation was obtained from the 
crystal structure of native hTP. Structural alignment of the bound and unbound structures 
of hTP provides new insights about potential domain movement and necessity of 
substrate/phosphate binding for inducing the closed conformation. To elucidate the role 
of certain active site residues for the enzymatic activity of hTP, mutagenesis experiments 
and enzymatic activity assays were carried out. New findings implicate residues which 
appear to have no direct interaction with the molecules bound in the active site of the 
enzyme and reveal which residues are indispensable for enzymatic activity.
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A. Structural analysis
3.6 Materials and Methods
Crystals and data for hTP-5IUR complex and native hTP were obtained by Dr. 
Anastassios Papageorgiou. Crystals for hTP-5IUR and native hTP were grown with 
protein provided by Dr. Darell Sleep and Dr. Chris Finnis.
3.6.1 Crystallisation and X-ray data collection
Crystals for both native hTP and the hTP-5IUR complex were obtained by the hanging 
drop vapour diffusion method. Crystals of native hTP were grown in 0.1M sodium- 
acetate (pH 5.2), 25% PEG 4000 and 0.1M ammonium acetate and belonged to P2i space 
group. Crystals for the hTP-5IUR complex were obtained after overnight incubation of 
hTP with lOOmM 5IUR at 4°C prior to equilibration over a reservoir solution containing 
2.8-3.5 M sodium-formate (pH 8.7). The complex of hTP-5IUR crystallised in P2i2i2i 
space group. This condition is similar to that reported by Spraggon in the absence of any 
ligand (Spraggon et al., 1993).
Data for hTP were collected in Elettra Synchrotron light source (X=l A ; Trieste, Italy). 
Data for hTP-5IUR complex were collected in SRS Daresbury (7,=1.48 A ; UK) and 
EMBL DESY (A,=0.84; A  Hamburg, Germany) and the collected data sets were merged 
together. Data collection was carried out at cryogenic temperatures.
3.6.2 Structure determination and refinement
Phases for the determination of the two hTP crystal structures were obtained by 
molecular replacement method using the program MOLREP (Vagin and Teplyakov,
1997). The coordinates of human thymidine phosphorylase (PDB code 1UOU; Norman et 
al., 2004) were used as the search model for the hTP-5IUR complex. hTP-5IUR complex 
crystallised in P2j2i2i spacegroup with unit cell dimensions a=61.9, b=67.3 and 
c=212.3A. Matthew’s coefficient was calculated to be 2.3 A3/D and the Wilson B-factor 
was calculated to be 46.7A2. The structure of the complex was initially refined using CNS 
(Briinger et al., 1998). Refinement consisted of rigid body refinement (initial cycles of
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refinement) as the model came directly from molecular replacement. The CNS task file 
‘rigid.inp' was used to optimise the positions of the two monomers in the asymmetric 
unit. The result of rigid body refinement was a new coordinate file (rigid.pdb), which was 
used as input for simulated annealing that uses torsion angle dynamics to improve the 
model. The CNS task file ‘anneal.inp’ was used to perform simulated annealing 
refinement. A starting temperature of 1000K was initially used since the model was 
identical to the target molecule. A slowcool protocol, applied during simulated annealing, 
heated up the molecule to overcome all energy barriers and then slowly cooled it down to 
approach energy minima. Examination of the maps revealed two loop regions, where the 
main chain electron density was broken: residues 237 to 238 and 406 to 415. To improve 
the phases, density modification was carried out. Density modification at medium 
resolutions, with multiple copies of the molecule in the asymmetric unit, has been shown 
to improve phases by reducing model bias. It calculates phase probability distribution for 
the model and the experimental amplitudes. The variations in electron density in the 
asymmetric unit are used to calculate a mask, which defines the protein/solvent boundary, 
and an electron density map. Density modification also provides an output reflection file 
of the observed amplitudes and reconstituted amplitudes. Three CNS task files were used 
for this purpose: ‘model_phase.inp\ 'density modify.inp’ and ‘fourier map.inp’. The 
electron density map calculated using the phases from density modification revealed 
electron density for the two loop regions. Once gross errors were corrected for, a round of 
rigid body refinement and simulated annealing was carried out to correct any errors 
introduced during manual model building and to optimise the fit of the retraced region. 
The R-factors improved, indicating correct changes were being made to the model. 
Towards the final steps of refinement of the hTP-5IUR complex structure torsion angle 
molecular dynamics coupled with temperature during simulated annealing were used as it 
allowed for sampling of several conformations at higher temperatures, avoiding the 
trapping of structures in false minima. For this purpose Refmac was used to incorporate 
TLS (Winn et al., 2001) thermal refinement and each molecule within the asymmetric 
unit was defined as a TLS tensor group for the purpose of refinement. Refinement 
proceeded in 15 cycles with atomic residual isotropic B-factors set at 35A2, followed by 
10 cycles of individual atomic restrained refinement. Once refinement of the structure
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was completed, coordinates for 5-iodouracil were retrieved from the HIC-Up server. 
Water molecules were detected using the ‘waterpickinp’ input file from CNS (Briinger et 
al., 1998) and were examined manually, to ensure no peaks were mistakenly picked as 
water molecules. Water-pick was carried out after the introduction of the inhibitor so that 
waters would not falsely occupy the inhibitor density. Water refinement included a total 
of 20 steps of minimisation and B-factor refinement. The minimum distance allowed 
between water molecules and any atom was set to 2.6A, and the maximum distance was 
set to 4.0A. A total of 89 waters were detected for the dimer of hTP-5IUR complex. The 
structure was refined to a crystallographic R-factor ( R Cryst) of 23.9% and free R-factor 
(Rfree) of 29.6% (Table 3.1).
Native hTP crystallised in P2i spacegroup with unit cell dimensions of a= 101. 0, b=77.1, 
c=103.lA and a=90°, p=98° and y=90°. Matthew’s coefficient was calculated to be 1.8 
A3/D using the CCP4 interface and Wilson B-factor was calculated to be 31.6 A2. For the 
structure of native hTP the search model used was the previously solved structure ofhTP- 
5IUR complex. The structure was refined using CNS (as described for hTP-5IUR 
complex structure) to an Rcryst of 25.21% and an R ^ e  of 31.6% (Table 3.1; Briinger et al.,
1998). Although the resolution was lower in this case no ‘gaps’ were identified in the 
main chain density. Due to the low observation-to-parameter ratio, individual B-factor 
refinement proved to be problematic. The use of anisotropic-fixed-isotropic option in the 
‘bindividual.inp' file from CNS (Briinger et al., 1998) allowed the correction of 
individual B-factors. Detection of water molecules was carried out using the 
‘waterpickinp’ input file of CNS (Briinger et al., 1998). Water refinement included a 
total of 20 steps of minimisation and B-factor refinement. The minimum distance allowed 
between water molecules and any atom was set to 2.6A, and the maximum distance was 
set to 4.0A. A total of 50 water molecules were detected for the native hTP structure. 
Programs employed for structure analysis included Molprobity (Lovell et al., 2003), 
Procheck (Laskowski et al., 1993), HBPLUS (McDonald and Thornton, 1994) and 
CONTACT (CCP4).
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Table 3.1 : Statistics for data collection, processing and refinement
hTP-SIUR complex hTP
Spacegroup V2{1\2\ P2i
Unit Cell Dimensions (A ) a=61.9, b=67.3,c=212.3 a=101.0, b=77.1, c=103.1 
P=98°
Resolution Range (A ) 50-2.5 38.35-3.0
Total reflections measured 371493 85968
Unique reflections 31655 31746
measured
Rmergea(% ) 15.60 (36.7) 14.9 (38.6)
(outermost shell)
1/0(1) 4.5 (3.6) 4.9 (1.8)
Completeness (%) 97.6 (99.7) 89.9 (81.9)
Rcrys,b(% ) 25.1 24.8
RfreeC(% ) 31.0 31.4
R.m.s. deviation from ideality
In bond lengths (A ) 0.007 0.007
In bond angles (deg.) 1.3 1.4
Average B-factor (A 2)
Overall 41.2 30.4
* Rsymm = Xh2Zi[|/(h) ”  (/(h))|/Eh^ioi)]» where 7^) is the ith measurement and il^-) is the weighted mean of 
all measurements of 7(h)
bRcryst= h^lT  ^ “  Fc ft IT^F0, where Fa and Fc are the observed and calculated structure factor amplitudes 
o f reflection h.
cRfree is equal to RCTyst for a randomly selected 5% subset o f reflections not used in refinement.
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3.7 Results and discussion
3.7.1 Quality o f native hTP and KTP-5IUR complex structures
The crystal structure of hTP-5IUR complex was determined at 2.5A resolution with a 
crystallographic R-factor of 25.1% and an Rfree of 31%. Two copies of the hTP-5IUR 
complex were identified in each asymmetric unit, with one molecule of 5IUR bound in 
the active site of each hTP monomer and no phosphate ions present in the phosphate 
binding sites (Figure 3.12).
Of the two copies present in the asymmetric unit, the second was slightly disordered with 
weak electron density in some areas. Arg342 in chain B has been modeled as alanine due 
to lack of visible electron density beyond Cp atom. The final structure contains a total of 
89 water molecules and has 87.1% of the residues in the favourable regions of the 
Ramachandran plot (Figure 3.13; Ramachandran et al, 1963). The two hTP monomers 
dimerise at the N-terminal domain, as previously reported by Norman and co-workers 




Figure 3.12: Cartoon representation for the dimer of hTP-5IUR. Each monomer is 
coloured differently: monomer A is coloured in pink and monomer B is coloured in 
green. One copy of 5IUR is bound in the active site cleft of each of the monomers. 
Dimerisation occurs at the N-terminal a-helical domain, as previously reported for other 
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Residues m disallowed regions * 0 0.0*.
Figure 3.13: Ramachandran plot for the structure of hTP-5IUR complex. A total of 
87.1% of the residues are on the most favourable regions, while 12.9% of the residues are 
in the additional allowed regions of the Ramachandran plot. No residues are in the 
generously allowed or disallowed regions.
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The crystal structure of native hTP was determined at 3.0A resolution with an i^ cryst of 
25.21% and an Rfree of 31.6%. Four copies of hTP were identified in each asymmetric 
unit forming biological dimers with the symmetry related molecules (Figure 3.14).
Figure 3.14: Cartoon representation for the native structure of hTP. Four molecules were 
present in each asymmetric unit, forming two dimers. The two dimers are illustrated here: 
monomer A is coloured in cyan and monomer B in pink. The second dimer is that of 
monomer C, coloured in golden, and monomer D, coloured in green.
6 8
For the three of the four monomers of native hTP in the asymmetric unit electron density 
was observed for residues 34-479, while electron density for residues 32 and 33 was 
observed for one of the monomers. In this crystal structure the active site of the enzyme 
is not occupied and neither is the phosphate binding site. The final structure has a total of 
50 water molecules. Examination of the Ramachandran plot (Ramachandran et al., 1963; 







FjKI*»5 aia»s:&vour94 repots [A Ji.] 1180 79.9*.
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Figure 3.15: Ramachandran plot for the structure of native hTP. A total of 79.9% of the 
residues are on the most favourable regions, while 20.1% of the residues are in the 
additional allowed regions of the Ramachandran plot. No residues are in the generously 
allowed or disallowed regions.
The two different crystal forms observed for hTP-5IUR complex and native hTP appear 
to be the effect of crystal packing. The different crystallisation conditions under which 
hTP-5IUR and native hTP crystallised may have been the reason for the two different
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crystal forms and space groups. Hence, hTP-5IUR complex crystallised in P2i2i2i 
spacegroup and native hTP crystallised in P2i spacegroup. In order to identify possible 
structural differences between the two forms a structural alignment of the dimer (hTP- 
5IUR) and the tetramer (native hTP) was carried out. More specifically, structural 
alignment of Ca atoms of hTP-5IUR (dimer) against each of the dimers of the native 
crystal structure (tetramer) yields an rmsd of ~1.3A (SPDBV; Guex and Peitsch, 1997). 
The inter-molecular contacts observed in hTP dimer (P2i2j2i) revealed some noticeable 
differences to those observed in the two dimers of the native hTP tetramer (P2i). The 
total number of inter-molecular contacts identified for the dimer of hTP-5IUR is the same 
as those observed for one of the two dimers of native hTP, while the other dimer of native 
hTP tetramer has considerably less number of interactions at the interface. As no 
conformational changes can be detected for the two crystal structures, it is possible to 
assume that the differences observed are most likely due to crystal packing. The inter­
subunit contacts observed in our two structures are similar to those reported previously 
for hTP structures hTP-TPI, (Norman et al., 2004) and hTP-TDR (El Omari et al., 2006).
3.7.2 Overall hTP structure
As the resolution of both native hTP and hTP-5IUR complex structures is low, it would 
not allow for a great amount of detail to be observed. At this resolution however it is 
possible to obtain information about the overall structure and observe conformational 
changes, if any. Hence each of the two structures as well as the comparison of the two 
provided valuable information.
No secondary structure variations were observed for native hTP and the hTP-5IUR 
complex structures from the previously reported structures of hTP (Norman et al., 2004; 
El Omari et al., 2006). Each monomer of hTP consists of a total of 18 a-helices and 13 P 
strands, organised in two domains: an a  domain and a mixed a/p domain (Norman et al., 
2004). The a domain is composed of six helices (al-a4 extending from residue 36 to 97 
and a8-a9, extending from residues 193 to 223). The mixed a/p domain can be 
considered to have two sub-domains: the first is composed of a total of ten a-helices and 
six p-strands, organised in a central mixed p sheet (P1-P5, residues 115 to 272 and pl3,
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residues 473 to 477), which is surrounded by ten a-helices (a5-a7, residues 125 to 178 
and al0-al6 , residues 275 to 341). The second sub-domain of the mixed a/p domain 
consists of strands P6, P7, P9, pi 1 and P8, plO and pi 2, forming two small P-sheets. Two 
a-helices (al7  and al8, residues 394 to 456) separate the two small p-sheets, near the C- 
terminal domain of hTP. Flexibility for the two domains of hTP has been proposed to be 
conferred by three polypeptide loops: LI, which connects a4 to pi, L2, which connects 
P3 to a8 and L3, which connects a9 to P4 (Figure 3.16; Norman et al., 2004). A topology 
diagram illustrating the secondary structural elements of hTP is given below, Figure 3.16.
The N-terminal helices of the two monomers come together to form a coiled-coil 
interface and bury a total surface area of around 2010A2 upon dimerisation (Figure 3.12). 
Buried at the dimer interface are residues Gln35, Pro37, Ile40, Arg44, Asp45, Gln67, 
Gly68, Ala69, Gln70, Gly72, Ala73, Met76, Ala77, Arg79, Leu80, Ala201, Val204, 
Thr205, Ala206, Asp209, Glu403, Ser409 from both monomers, while residues Glu38, 
Arg41, Arg410, Ala411 and Gly412 are contributed only by monomer A and residues 
Ser65, Arg81, Ala406 and Arg408 from monomer B. Six potential hydrogen bonds and a 
hundred and sixty five van der Waals contacts are observed between the two monomers 
at the interface. Previous findings on EcTP (Walter et al., 1990) suggested that the dimer 
interface was held mainly by hydrophobic interactions.
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Figure 3.16: Topology diagram illustrating the secondary structure of hTP. The a helical 
is illustrated in light green, while helices which are part of the mixed a/p domain are 
illustrated in . The three polypeptide loops (LI, L2 and L3) and the hinge
regions are highlighted in pink. The role of these flexible regions and their implication in 
the function of hTP is discussed in 3.7.4. (Figure adapted from: Norman etal., 2004).
3.7.3 Inhibitor binding and interactions o f hTP with 5IUR.
The active site of hTP is located at the interface between the a and the mixed a/p domain, 
while the phosphate binding site is located below the active site cleft, in the mixed a/p 
domain (Walter et al., 1990). Identification of putative hydrogen bonds was carried out 
with the program HBPLUS (McDonald and Thornton, 1994) while identification of
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putative van der Waals interactions was carried out using the program CONTACT 
(CCP4). Complex formation results in a total of 747.4A2 surface area of each hTP 
monomer to be buried at the interface. The program ‘buriedjsurface.inp’ of CNS 
(Briinger et al., 1998) was used for the calculation of the buried surface. The residues that 
get buried upon complex formation were identified to be His 116, Seri 17, Thrll8, 
Leul48, Tyrl99, De214 and Ile218.
Previously proposed active site residues, conserved amongst species, are Hisl 16, Seri 17, 
Leul48, Arg202, Val208, Ile214, Lys221 and Val241. Putative hydrogen bonds that 
stabilise the binding of 5IUR at the active site of hTP are detected for Hisl 16, Arg202, 
Ser217 and Lys221 in the hTP-5IUR structure (Figure 3.17). Almost ‘opposite’ to Hisl 16 
in the active site cleft is Arg202, bonded via NH1 (3.0A) and NH2 (2.8A) to 04  of 5IUR. 
Ser217 OG appears to interact by means of hydrogen bonds to N3 (2.9A) of 5IUR. 
Lys221 NZ forms a potential hydrogen bond with 02 of IUR (2.5A). A close up view of 
the active site residues which form putative hydrogen bonds with 5 IUR is shown in 
Figure 3.17. The potential hydrogen bonds as identified by HBPLUS (McDonald and 
Thornton, 1994) are presented in Table 3.2.
Of the active site residues, only Thrl 18 appears to form a putative hydrogen bond with a 
water molecule. No phosphate ion was present in the phosphate binding site of hTP-5IUR 
complex but a water molecule was detected at that particular position.
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Figure 3.17: Close up of the active site residues forming putative hydrogen bonds with 
the bound 5IUR. Shown here are residues Hisl 16, Arg202, Ser217 and Lys221. 
Hydrogen bonds are illustrated in blue dashed lines. The map illustrated is a 2F0-FC 
electron density map, contoured at la  level.
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Table 3.2: Putative H-bonds for hTP-5IUR complex.
hTP Atom 
Chain_A
B-factor (A2) IUR 660 Y B-factor (A2) Distance 
D -A  (A)
Angle 
D -H -A  (°)
H isll6N E2 38.44 IURN1 45.56 3.0 -
H isll6N E2 38.44 IUR 02 41.57 3.1 128.5
Arg202 NH1 26.38 IUR 04 43.80 3.0 142.9
Arg202 NH2 23.93 IUR 04 43.80 2.9 147.6
Ser217 OG 31.15 IURN3 45.46 2.6 -
Lys221 NZ 42.00 IUR 02 41.57 2.5 152.2
hTP Atom B-factor (A2) IUR 661 Z B-factor (A2) Distance Angle D-
Chain_B D,mA (A) H -A
o
Arg202 NH1 18.97 IUR 04 41.65 2.9 161.9
Ser217 OG 26.98 IURN3 41.89 3.1 -
The upper limit for the donor-acceptor distance is 3.3A. Contacts involving a sulphur 
atom have an upper limit of 3.6A. The lower limit for the donor-acceptor angle is 120°. 
Bond angles are not given where the hydrogen position is ambiguous. The contact 
distances were calculated using the program HBPLUS (McDonald and Thornton, 1994).
Further stabilisation of 5IUR in the active site cleft of hTP is obtained by a network of 
electrostatic interactions. Residues identified to form this network of interactions include 
Hisl 16, Seri 17, Thrll8, Leul48, Tyrl99, Arg202, Ile214, Ser217, Ile218, Lys221 and 
Val241. van der Waals interactions between hTP and 5IUR are presented in Table 3.3, as 
detected by CONTACT (CCP4, 1994).
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Table 3.3: van der Waals contacts between hTP chains and 5IUR.
IUR 660 Y Atoms hTP Chain_A residues No. of contacts
IUR660 YN1 Hisl 16 1
IUR660YC2 His 116,Tyr 199,Ser217,Ile218,Lys221 5
IUR 660 Y 02 Hisll6,Lys221 2
IUR660YN3 Ile218 1
IU R660YC4 Leul 48,Ile214,Ser217,Ile218 4
IUR 660 Y 04 Arg202,ne214(8) 9
IUR660YC5 Leul48,Ile214 2
IUR 660 Y I Leul48,Thrl 18(2),ne214(2),Val241 6
IUR660YC6 Seri 17,Thrl 18®,Leul48 4
IUR 661 Z Atoms hTP Chain_B residues No. of contacts
IUR661 ZN1 Hisl 16 1
IUR661 Z C2 His 116,Tyr 199,Ile218,Lys221 4
IUR661 Z 02 Hisl 16,Tyrl99,Lys221 3
IUR661 ZN3 Ser217,Ile218 2
IUR661 Z C4 Leul 48,Ile214,Ser217,Ile218 4
IUR661 Z 04 Arg202(3),Ile214(8) 11
IUR661 Z C5 Leul48,Ile214 2
IUR661 Z I Leul48,Thrl 18(2),Ile214(2),Val241 6
IUR661ZC6 Leul48,Serll7,Thrll8(2) 4
The maximum allowed values of intermolecular distances are C-C, 4.lA;C-N, 3.8
A;C-0, 3.7 A ;0-0 , 3.3 A;0-N, 3.4 A; N-N, 3.4 A;C-S, 4.1 A;0-S, 3.7 A;N-S, 3.8 A;I-
C, 4.3 A;I-N, 3.9 A;I-0, 3.7 A. Superscript numbers in parentheses represent the
number of contacts made by the indicated residue. Contact distances were calculated
using the program CONTACT (CCP4, 1994).
Conservation of the active site residues is supported by previous work on EcTP where 
residues His85, Argl71, Seri86 and Lysl90 were identified to interact with the substrate
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bound at the active site (Walter et al., 1990; Pugmire et al., 1998a). The role of one of 
these residues, His85, has attracted a lot of interest, as it was proposed to be 
indispensable for the maintenance of the enzymatic activity of TP (Mendieta et al., 2004). 
Similarly the structure of BsPyNP indicated that residues interacting with the 
pseudouridine moiety bound at the active site, include Lysl87, Seri 83, Argl68, Tyrl65 
and His82 (Pugmire and Ealick, 1998). It is evident that these charged residues are 
forming a network of interactions, similar to that observed for the active site of hTP. The 
conservation of these residues amongst species is thus highlighting their significance in 
the catalytic activity of TP.
The binding of thymidine to the active site cleft of TP was described in detail by Walter 
and co-workers (Walter et al, 1990) based on structures including 5-iodouracil, thymine 
and thymidine (available on the Protein Data Bank is the structure of EcTP in complex 
with sulphate and thymine; PDB ID: 1TPT). A surface representation of the active site 
cavity of EcTP (Walter et al, 1990) where thymidine and phosphate were modeled, 
indicated a tyrosine residue (Y168 EcTP; Y199 hTP; Y165 BsPyNP) involved in 
interactions with the ribose moiety of thymidine. Similar interactions have not been 
described for the complexes of BsPyNP (Pugmire and Ealick, 1998) and hTP (Norman et 
al., 2004; El Omari et al, 2006). The lack of this particular interaction is most likely due 
to the size of the molecules bound in the active site of the BsPyNP and hTP complex 
structures; the smaller size of pseudouridine in BsPyNP (Pugmire and Ealick, 1998) and 
TPI and thymine in hTP (Norman et al, 2004; El Omari et al, 2006) probably does not 
allow for the total number of interactions to be observed.
Pugmire and Ealick first described the presence of a hydrophobic pocket within the active 
site cleft of the BsPyNP structure (Pugmire and Ealick, 1998). The residues described to 
compose this pocket in BsPyNP are Phe207, Vall74, Ilel80 and Leul 14 where they 
appeared to surround the 5’-position of the pyrimidine ring, bound in the active site of 
BsPyNP (Pugmire and Ealick, 1998). Norman and co-workers (Norman et al., 2004) later 
reported that the same hydrophobic pocket was identified in the structure of hTP-TPI 
complex. More specifically, residues Val208 and Ile214 of the a-domain and Leul 48 and
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Val241 of the mixed a/(3-domain were proposed to stabilise the chlorine atom of TPI in a 
manner similar to that previously seen for BsPyNP and pseudouridine. In the structure of 
hTP in complex with 5IUR the same hydrophobic pocket appears to ‘hold’ the iodine 
atom of 5IUR, in a manner similar to that previously proposed. A close up view of the 
active site, highlighting the hydrophobic pocket is presented below; Figure 3.18.
V241
Figure 3.18: Close up view of the active site cleft, rotated by 90°. Shown here are the 
active site residues previously described to interact via hydrogen bonding interactions 
with 5IUR. Highlighted in golden are the residues that form the hydrophobic pocket, 
residues Leul48, Val208, Ile214, Ile218 and Val241.
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Of the two a domain residues that are part of the hydrophobic pocket, Val208 is at a 
distance of 4.1 A and Ile214 is at a distance of 3.7 A from the iodine atom of 5IUR. Of the 
two a/p domain residues that form the hydrophobic pocket, Leu 148 is at a distance of 
3.9A and Val241 is at a distance of 4.2A from the iodine atom of 5IUR. Hisl 16, part of 
the active site cleft, interacts via its CE1 with 02 of 5IUR at a distance of 2.9A. The 
carbonyl of Thrl 18 is located at a distance of 3.6A from the iodine atom of 5IUR. It is 
evident that these residues, with the exception of Val241, which corresponds to Phe207 
in BsPyNP, are conserved amongst species. Hence apart from the hydrogen bond network 
which is essential for stabilisation, the hydrophobic pocket also appears to play a crucial 
role.
3.7.4 Domain movement and comparison o f bound and unbound hTP structures 
Of the two substrates that are required for catalysis by hTP, phosphate is considered to 
bind first, followed by the binding of the substrate, thymidine. Domain movement (once 
the active site is occupied) is considered to be essential in bringing the substrates into 
close proximity for the reaction to occur. Hence a theory of domain movement has been 
proposed for the members of the PyNP superfamily.
Structural studies on EcTP revealed that the distance between the substrate binding site 
and the phosphate binding site appears to be too large (8A) for reaction to occur (Pugmire 
et al., 1998a). Modeling of thymidine in the substrate binding site of EcTP indicated that 
upon substrate binding the cavity between the two domains is occupied and no 
accessibility is permitted to the phosphate binding site (Walter et al., 1990). Hence the 
two domains are proposed to come closer and reduce the distance between the two 
reactants. This movement is considered to shield the substrates from solvent access and 
trap the intermediates so that they are not released before completion of the reaction 
(Pugmire et al., 1998a). Reducing the solvent access has been proposed to be of key 
importance for the reaction to occur: if the aqueous environment during phosphorolysis is 
in vast excess over phosphate, hydrolysis may compete with phosphorolysis (Pugmire et 
al., 1998a).
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When the active site of the enzyme is not occupied, it is proposed to acquire an ‘open’, 
inactive conformation. Upon occupation of both active and phosphate binding sites, 
domain movement is considered to occur as a rigid body movement for both a and a/p 
domains. A total of 21° rotation was observed for the a/p domain with respect to the a 
domain in BsPyNP when compared to an ‘open’ conformation of EcTP (Pugmire and 
Ealick, 1998). Adding to this flexibility are three polypeptide loops, LI, L2 and L3 which 
are proposed to assist domain movement. Of the three loops, LI and L2 appear to 
undergo significant conformational changes when the ‘open’ and the ‘closed’ form of the 
enzyme were compared (Mendieta et al., 2004). Additional information by Pugmire and 
Ealick indicates that of the three loops, L2 plays the most important role in bridging the 
gap between the two domains, while LI and L3 are proposed to act as passive hinges 
between the two domains when movement occurs (Pugmire and Ealick, 1998). A key 
hydrogen bond, formed between the side-chain of Hisl 19 and the carbonyl oxygen of 
Gly208 has been proposed to form in the ‘closed’ conformation of the enzyme, when the 
two domains are in close proximity (Walter et al., 1990; Pugmire and Ealick, 1998). 
Another area of flexibility was proposed to be the hinge region (residues 364 to 371 in 
BsPyNP, corresponding to residues 405 to 415 in hTP) that extends across the active site 
cleft and appears to act as a ‘latch’ (Pugmire and Ealick, 1998).
The structure of EcTP lead to the identification of a glycine-rich loop, preceded by a p- 
strand (p2; Figure 3.16) and followed by an a-helix (a6; Figure 3.16), which was 
proposed to be involved in the binding of the phosphate ion. This feature has been 
identified in other nucleotide-binding proteins (Dreusicke and Schulz, 1986). Due to its 
high content in glycine residues it is considered to be very flexible and aid the movement 
of the two domains (Pugmire et al., 1998a). This glycine-rich loop region is conserved in 
all known TP structures, signifying its potential functional implication.
The two crystal structures of hTP reported to date, hTP-TPI (Norman et al, 2004) and 
hTP-thymine (El Omari et al., 2006) were both in the ‘closed’ (active) conformation 
(Norman et al., 2004; El Omari et al., 2006). Based on previous work (El Omari et al., 
2006) the findings of which suggested that the ‘closed’ form of the enzyme can be
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induced solely by occupation of the active site, it is possible to argue that binding of 
5IUR suffices to induce domain movement and lead to the ‘closed’ and hence active 
conformation of hTP.
More information about the proposed domain movement and its occurence in hTP was 
obtained by the native (unbound) structure of the enzyme. The crystal structure of 
unbound hTP provided some very controversial albeit interesting findings. Alignment of 
the Ca_chain of the two structures (native hTP and hTP-5IUR complex) indicates that 
they overall align well, with an rmsd of 0.7A over 446 Ca atoms (Figure 3.19). The good 
alignment of the two structures and the low rmsd are indicative of the lack of 
conformational differences. This is opposed to all previously proposed theories according 





Figure 3.19: Structural alignment of native hTP (in re?) and hTP in complex with 5IUR 
(in ). The two structures appear to align well with no areas of significant
differences. The secondary structure features superimpose well for the two structures 
indicating that there is no domain movement that would separate a bound (open) from an 
unbound (closed) conformation, as expected according to the proposed theory of domain 
movement.
Adding to this observation were the results from the examination of the previously 
proposed areas of flexibility, loops LI, L2 and L3 as well as the hinge region (Figure
3.20). Structural alignment of the bound and unbound hTP structures revealed that all 
flexible loops align well in the two structures, again indicating that no conformational 
change, in these regions, exists between the bound and the unbound states of the enzyme.
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The hinge region, also proposed to have a similar role, appears to have no major 
differences between the two structures; a small area at the beggining of this loop only 
appears to differ between the bound and unbound states of hTP (Figure 3.20). It is 
important however to note that this region of the loop is not located near the active site 
and hence such small difference would not be enough to explain the flexibility of the 
whole loop. The observed difference in the hinge region is most likely due to crystal 
packing. A structural alignment of bound and unbound hTP, highlighting the three 
polypeptide loops and the hinge region is presented in Figure 3.20.
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HINGE
Figure 3.20: Structural alignment of native hTP (in re>) and hTP in complex with 5IUR 
(in ), highlighting the three flexible polypetide loops LI, L2 and L3 (in green) and 
the hinge region (in magenta). It is evident that even in these areas of flexibility the two 
structures, bound and unbound hTP, align well.
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Previous work on EcTP and BsPyNP lead to the identification of a key feature of the 
‘closed’ enzyme conformation. A key hydrogen bond, formed between the side-chain of 
Hisl 19 and the carbonyl oxygen of Gly208 (in BsPyNP) has been proposed to form when 
phosphate binds to the phosphate binding site, leading to the ‘closed’ conformation of the 
enzyme (Walter et al., 1990; Pugmire and Ealick, 1998). The residues involved in this 
hydrogen bond, correspond to His 150 and Ala239 in hTP. Interestingly, an identical 
hydrogen bond was identified in both bound and unbound structures of hTP (Figure
3.21), possibly indicating that native hTP is also present in the closed conformation, 
eventhough no substrate or phosphate are present in the active site cleft. It is also possible 
that this hydrogen bond is not a key feature of only the closed (bound-active) state of the 
enzyme.
hTP-51 UR' 
co m p le x
Figure 3.21: Shown in this figure is the key hydrogen bond proposed to form in the 
bound (active) conformation of TP. This hydrogen bond was identified in the structures 
of both bound hTP (shown in pink) and in native hTP (shown in grey).
8 6
Another common feature of the two structures of hTP is the presence of a water molecule 
in the phosphate binding site (Figure 3.22). It is unlikely that solely the binding of water 
molecules would trigger the enzyme to acquire its half-closed conformation (proposed 8 ° 
rotation upon phosphate binding). It is likely that the proposed 8 ° rotation would be 
observed if phosphate (and not water) would bind at the phosphate binding site, as hTP is 
a potent phosphorylase and not a hydrolase. Hence, binding of phosphate could ‘activate’ 
the phosphorolytic activity of hTP and initiate the phosphorolytic reaction.
5IUR
URIDIN
H O S P
Figure 3.22 Shown here is a structural alignment (full length) of hTP-5IUR (in ire ) 
against BsPyNP (in magenta). In the structure of BsPyNP, a phosphate ion is present in 
the phosphate binding site. In the structure of hTP-5IUR a water molecule occupies the 
phosphate binding site.
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Rick and co-workers (Rick et al., 1999) performed quantum mechanical calculations 
using the structure of EcTP in order to elucidate the mechanism of the catalytic activity 
of the enzyme. A mechanism of catalysis, not based on the crystal geometry, suggests 
that the reaction occurs in two steps: once both phosphate and substrate are bound, there 
is a direct nucleophilic attack of the phosphate on the glycosidic bond, resulting in its 
cleavage. This is then followed by phosphorylation of the ribose ring, where the reaction 
is completed. There is limited information about product release although another 
conformational step would probably be required before that occurs (Rick et al., 1999).
Comparison of the two states of hTP (bound and unbound) revealed that presence of 
substrate or substrate analogues is not required for the enzyme to acquire the ‘closed’ 
conformation. Overall comparison reveals no conformational differences. It is quite likely 
that domain movement does not occur in hTP. It should be mentioned that hTP is larger 
to EcTP by 42 residues and to BsPyNP by 49 residues, a small difference which would 
not account for such a significant conformational change, as proposed to exist between a 
bound and an unbound state. It is possible however that the closed corformation observed 
for unbound hTP, is favoured by crystal packing, while different forms of the enzyme 
exist in solution. As no structure of transition states of the enzyme have been reported to 
date, it is not possible to state with confidence whether domain movement does or does 
not occur in hTP.
3.7.5 Comparison o f hTP with other known TP structures.
The homology between hTP, EcTP and BsPyNP was calculated to be -41% (Walter et 
al., 1990; Brodsky et al., 1992). Most of the a domain and part of the mixed a/p domain 
are conserved between the three PyNPs. High conservation can be observed especially 






•  •  •
Bs PyNP YTNGDIPD YQMSALAMAIYFRGMTEEETAALTMAMVQS GEMLDLSS -  - 1 RGVKVDM|tg
hTP WNGSAQGAQIGAMLMAI RLRGMDLEETSVLTQALAQSGQQLEWPEA-WRQQLVD^Bt G
e c t p  ir d n t is e g q ia a l a m t if f h d m t m p e r v s l t m a m r d s g t v l d w k s l h l n g p iv d ^ J tg
Bs PyNP g v g d t t t l v l g pl v a sv g v p v a k m sg r g | g h t g g t id k l e s v p g f h v e is k d e f ir l v n e
hTP GVGDKVSLVLAPAIiAACGCKVPMI SGRgI gHTGGTLDKLES IPGFNVIQSPEQMQVLLDQ
Ec t p  g v g d v t sl m l g pm v a a c g g y ip m isg r g | g h t g g t l d k l e s  i p g f d i f p d d n r f r e i i k d
•  •  •  •  •  •  •
Bs PyNP NGI A l  IGQTGDLT PAD KK J A L |D V T  AT|NS IP i Ma s B msI k IAAGADAIVLDVKTGAG
hTP AGCCIVGQSEQLVPADGI J aAMDVTAt I d S Lp J ta H l s I k LVEGLSALWDVKFGGA
Ec t p  v g v a iig q t s s l a p a d k r f | a t | d it a t | d s  i p J t a H la | k la eg ld a lv m d v k v g sg
Bs PyNP aI m kkldearrlarvm vd  ig k r v g r r tm a v i sd m sq p l g y a v g n a l e v k e a ie t l k g n g p
hTP aI fp n q e q a r e l a k t l v g v g a sl g l r v a a a l t a m d k pl g r c v g h a l e v e e a l l c m d g a g p
EcTP a§ m p t y e l s e a l a e a iv g v a n g a g v r t t a l l t d m n q v l a ss a g n a v e v r e a v q f l t g e y r
BsPyNP - h d l t e l c l t l g s h m v y l a e k a p s l d e a r r l l e e a ir s g a a ia a f k t f l a a q g g d a s w d
hTP -  PDLRDLVTTLGGA1LWLSGHAGTQAQGAARVAAALDDGSALGRFERMLAAQGVDPGLAR
EcTP NPRLFDVTMALCVEMLIS GKLAKDDAEARAKLQAVLDNGKAAEVFGRMVAAQKGPTDFVE
Bs PyNP DL--------------------DKLPKAAYTSTVTAAADGYVAEMAADDIGTAAMWLGAGRAKKEDVIDLA










(in the order high!
1 residues among 





BsPyNP K81 H82 S83 LI 14 Y165 R168 V174 1180 S183 1184 K187 F207
hTP K115 HI 16 S 117 L148 Y199 R202 V208 1214 S217 1218 K221 V241
EcTP K84 H85 S86 LI 17 Y168 R171 V177 1183 S186 1187 K190 F210
Figure 3.23: (A) Full length sequence alignment of hTP, EcTP and BsPyNP. Conserved residues 
amongst the three PyNPs marked (•) and highlighted in pink. Shown in cyan is one of the 
members of the hydrophobic pocket, Val241 in hTP which corresponds to F207 in BsPyNP and 
F210 in EcTP. (B) The table illustrates the conserved residues, in the order highlighted in the 
sequence alignment, with the respective numbering for each of the three PyNPs examined; hTP, 
EcTP and BsPyNP.
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Structural comparison of hTP, EcTP and BsPyNP gave an insight into the structural 
similarity of the three PyNPs. The overall structural pattern, typical for members of the 
PyNP superfamily is observed in the three enzymes. Structural alignments for all 
structures were calculated for the backbone C“ atoms, using the program SPDBV (Guex 
and Peitsch, 1997). Alignment of native hTP against EcTP-thymine complex (PDB ID: 
1TPT) yielded an rmsd of 1.5A (Figure 3.24), while alignment of hTP-5IUR complex 
against EcTP-thymine complex yielded an rmsd of 1.6 A . When the unbound structure of 
EcTP (PDB ID: 1AZY) was aligned against native hTP the rmsd obtained was 1.7A, 
equal to that obtained for its alignment against hTP-5IUR complex (Table 3.4; Figure 
3.24 to 3.26).
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Figure 3.24: Structural alignment of native hTP 
(in grey) against EcTP-thymine complex (in 
green). Differences between the aligned EcTP 
structures and hTP structures are mainly 
identified for the a helical domain, while the 
mixed a/|3 domain appears to have fewer 
differences amongst the aligned structures. 
Bound in the active site cleft of EcTP is thymine 
and in the phosphate binding site is a sulphate 
ion.
Structural alignment of hTP-5IUR complex (in 
range) against bound EcTP (in green). Again 
differences are mainly observed in the a helical 
domain.
Bound in the active site cleft of EcTP is thymine 
and in the phosphate binding site is a sulphate 
ion. Superposition of bound EcTP and hTP- 
5IUR structures reveals that the molecules bound 
in the active site cleft do not align perfectly. This 
could possibly be due to the a helical domains 
not aligning well for the two structures.
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Figure 3.25: Structural alignment of native 
hTP (in ) against unbound EcTP (in pink) 
Differences between the aligned structures are 
mainly observed in the a helical domain. The 
mixed a/(3 domain appears to align better and 
fewer differences on this domain can be 
identified amongst the aligned structures.
Structural alignment of hTP-5IUR complex (in 
orange) against unbound EcTP (in pink). 
Shown in the active site cleft of hTP is 5IUR. 
The a helical domain of EcTP appears to differ 
from that of hTP, as previously seen for the 
alignment hTP and EcTP structures.
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Structural alignment of native hTP against BsPyNP (PDB ID: 1BRW) yielded an rmsd of 
1.4A, same as that obtained for the structural alignment of hTP-5IUR against BsPyNP 
(1.4A; Figure 3.26). The results obtained for all structural alignments are given in Table 
3.4.
Table 3.4: Structural alignment results for the three PyNPs.
Structures Aligned Seq. Identity (%)
(Full length seq. 
alignment)
RMSD (A)
hTP-5IUR vs EcTP-thymine 1.6
Native hTP vs EcTP-thymine
38
1.5
hTP-5IUR vs EcTP 1.7
Native hTP vs EcTP 1.7
hTP-5IUR vs BsPyNP-uracil 1.4
Native hTP vs BsPyNP-uracil
40
1.4
Structural alignment of hTP, EcTP and BsPyNP were calculated for the backbone
Ca atoms only. The program used for structural alignment and rmsd calculation
was SPDBV (Guex and Peitsch, 1997).
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Figure 3.26: Structural alignment of 
native hTP (in grey) against BsPyNP 
(in cyan). The two structures appear to 
align well, with few only differences. 
Both a helical domain and the mixed 
a/p domain superimpose well 
indicating that the two structures have a 
few only differences. Shown in cyan in 
the active site cleft is uracil, present in 
the structure of BsPyNP. A phosphate 
ion, bound in the phosphate binding site 
can also be observed for the BsPyNP 
structure.
Structural alignment of hTP-5IUR 
complex (in >range) against BsPyNP 
(in cyan). Shown in the active site cleft 
is 5IUR of the hTP-5IUR complex, 
aligned with uracil, present in the 
structure of BsPyNP. Bound in the 
phosphate binding site is a phosphate 
ion, present in the structure of BsPyNP. 
The two molecules bound in the active 
site of hTP and BsPyNP appear to align 
well in contrast to the alignment of 




Structural analysis of the two forms of hTP, native and in complex with 5IUR have 
provided some new insights for the enzyme. The lack of detectable domain movement 
might signify that it does not actually occur in the case of hTP. It is possible that the 
‘closed’ state of the enzyme is favoured by crystal packing, and binding of phosphate or 
substrates is not required for the enzyme to acquire this particular conformation. Based 
on the findings from the two crystal structures of hTP, it is not possible to determine 
whether any intermediate stages exist during catalysis and what structural differences 
those might have with the bound and unbound states of hTP.
Comparison of bound and unbound hTP with previously determined structures of EcTP 
and BsPyNP revealed that although most of the a helical domain is conserved amongst 
the PyNPs in sequence level, structurally the mixed a/p domain aligns better. This could 
either be due to sequence differences (bacterial PyNPs are smaller to hTP) or due to the 
organisation of the domains in the environment of the crystal (crystal packing). It is 
however likely that the differences observed for bound and unbound EcTP are indicative 
of domain movement, which has not been identified yet in its human homologue.
It is likely that intermediate stages, for which structures have not been determined yet, 
will provide more information not only for the catalytic activity but for the 
conformational changes that might be essential for the reaction to occur. Identification of 
intermediate stages, both functional and structural, could be used for the design and 
development of new drugs: if intermediate stages are required for the completion of the 
hTP-catalysed reaction, drugs that target such intermediate stages could be designed. If 
however no domain movement is essential and the enzyme acquires the ‘closed’ 
conformation even when inactive, it is of key importance to design specific drugs that 
target the overexpression of hTP.
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B. Functional Analysis
3.8 Materials and Methods
Cloning and initial expression and purification work on native hTP was carried out by Dr. 
Stephen H. Prior.
3.8.1 Construction o f recombinant native human thymidine phosphorylase
The original cDNA for hTP was obtained from Mammalian Gene Collection (MGC) and 
was in pMCV-SPORT6 vector. Analysis of its sequence with SignalP revealed that hTP 
does not have a signal peptide. The coding DNA sequence, (residues 38 to 482) was 
amplified in the presence of 0.5M betaine (primers used are given in Table 3.5). The 
fragment was then digested by T4 polymerase in the presence of dTTP before being 
annealed into a predigested pYSBLIC1 vector (Bosnor et al., 2006) with BseRI (NEB) 
and then transformed into NovaBlue (Novagen) cells. The DNA was then extracted using 
the SV Wizard (Promega) and transformed into BL21(DE3)codon+ expression cells 
(Novagen), used to overcome codon bias, since hTP contains several rare codons as 
determined by Graphical Codon Usage Analyser (GCUA; Fuhrmann et al., 2004). Vector 
integrity was then analysed by sequencing (MWG Biotech).
3.8.2 Construction o f recombinant human thymidine phosphorylase mutants
3.8.2.1 Rationale for mutational work
Structural analyses on members of the PyNP superfamily lead to the identification of 
residues that are conserved among species. Conserved residues of particular interest are 
those involved in the binding and stabilisation of the substrate/inhibitor in the active site 
cleft. Using the structural information gained from the hTP-5IUR complex, point
pYSBLIC is a modified pET-28a vector where the thrombin cleavage site has been removed to 
allow for ligation independent cloning (LIC). A non-cleavable His-tag is annealed to the N-terminus of the 
expressed protein.
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mutations were designed for some of the active site residues; Lysll5, H isll6 , Tyrl99, 
Arg202, Ile214 and Ser217 (Figure 3.17, page75; Figure 3.18, page 79; Figure 3.27).
Figure 3.27: Active site of hTP where the residues under study (Lysll5, H isll6 , 
Tyrl99, Arg202, De214 and Ser217) are illustrated as ball-and-stick. Also shown in ball- 
and-stick is the inhibitor 5IUR, present in the hTP-5IUR complex.
Although Lysll5 does not form any hydrogen bonds with 5IUR in the hTP-5IUR 
complex structure, it appears to be conserved in all PyNPs (Figure 3 .18). Previous studies 
(Edwards 2006) have proposed a role for Lysl 15 in interacting with phosphate, and along 
with three other residues (Seri26, Serl44 and Seri 17) stabilising it in the phosphate 
binding site. Site-directed mutagenesis on Lysl 15, where it was mutated to glutamic acid,
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(Miyadera et al., 1995) resulted in abolishing the enzymatic and angiogenic activity of 
hTP. Hence, Lysl 15 appears to be essential for maintaining the enzymatic activity of hTP 
and further mutational work on this residue would ‘explain’ its significance in the 
phosphorolytic activity of hTP. Introducing thus a negative charge (mutant K115E) 
would indicate whether the positive charge is absolutely necessary at that particular 
position, while introducing a hydrophobic residue (mutation K115A) would indicate 
whether charge and size of Lysl 15 side chain are both essential for the enzymatic 
activity.
H isll6 is a residue of key importance in PyNPs: previous studies on the equivalent 
residue of EcTP (His85) by means of targeted molecular dynamics, suggested that this 
highly conserved residue is important for the catalytic mechanism of TP (Mendieta et al., 
2004). The role attributed to H isll6 (His85 in EcTP) has also been discussed and 
confirmed by Rick and co-workers, based on findings from experiments of quantum 
mechanical calculations (Rick et al., 1999). More recently, Norman and co-workers 
(Norman et al., 2004) proposed the participation of H isll6  in a proton shuttling 
mechanism in hTP, where Asp 114, Glu225 and Lys222 form a triad delivering a proton 
to His 116, which then interacts with TPI, as seen in the hTP-TPI complex structure 
(Figure 3.17; Norman et al., 2004). In order to understand the significance of H isll6 
towards the enzymatic activity of hTP, mutations to phenylalanine and lysine were 
introduced. H116F mutant retains the ring side chain of histidine but loses the charged 
groups, while HI 16K retains the positive charge but loses the ring structure.
In contrast to other PyNPs, hTP possesses only one tyrosine residue in the whole amino 
acid sequence of the enzyme. The tyrosine residue in hTP is located at the active site cleft 
and is involved in electrostatic interactions with 5IUR (Figure 3.18; 3.7.3, Table 3.3). 
The role of this residue is yet unclear, although it has been suggested that modification of 
this residue might interfere with substrate binding or catalysis (Finnis et al., 1993). 
Walter and co-workers (Walter et al, 1990) have shown that a tyrosine residue (Tyrl68 
in EcTP) is implicated in hydrogen bonding interactions with thymidine, as seen from a 
Connolly surface diagram. Hence, point mutations were also carried out on Tyrl99 (hTP)
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in order to substantiate its role in the catalytic mechanism of hTP. Mutation to 
phenylalanine retains the aromatic character of tyrosine, losing only the hydroxyl group. 
Mutation to leucine introduces a bulky, hydrophobic side chain, while mutation to alanine 
removes both charge and size of the side chain, completely changing the environment 
previously present around that particular amino acid.
Involved in the network of interactions that stabilise 5IUR in the active site cleft are 
residues Arg202 and Ser217 (Figure 3.17). The two residues have been previously 
described to interact with molecules bound in the active site of hTP, such as TPI and 
thymine (Norman et al., 2004; El Omari et al., 2006). The significance of Arg202 for the 
enzymatic activity of hTP has been studied by mutational work where Arg202 was 
mutated to glutamate. Results indicated abolishing of both angiogenic and enzymatic 
activity of hTP (Miyadera et al., 1995). It is not however clear if mutation to glutamate 
(and introduction of a negative charge at this position) causes this effect or if Arg202 is 
absolutely essential for enzymatic activity. For this purpose R202E, which introduces a 
negative charge and R202S, which removes the lengthy side chain and the basic character 
of arginine at that position, were examined. On the other hand, nothing has been reported 
to date for Ser217, and its significance for the enzymatic activity of hTP. Hence, 
mutation S217G would indicate whether the hydroxyl group of serine at that particular 
position is essential. These mutations would provide a better understanding of the 
significance and role of Arg202 and Ser217 in the catalytic activity of hTP.
Apart from the residues that interact via hydrogen bonds with 5IUR, a hydrophobic 
pocket appears to ‘hold’ the iodine atom (Figure 3.18). This has been previously 
described for hTP-TPI complex (Norman et al., 2004), where the inhibitor bound in the 
active site cleft had a chlorine atom, stabilised in the same pocket. Mutational work on 
members of the hydrophobic pocket has only been reported for L148R, where biological 
work indicated complete loss of the enzymatic and angiogenic activity of hTP (Miyadera 
et al., 1995). Mutational work on another residue of the hydrophobic pocket, Ile214, 
would thus indicate whether the hydrophobic pocket is a significant component of the 
active site cleft, essential for stabilising bound molecules so as for hTP to be
99
enzymatically active. Mutant I214A completely removes the bulky side chain of leucine 
and would be indicative of whether the size of the leucine side chain is essential in that 
particular position, for retaining van den Waals interactions, as part of the hydrophobic 
pocket.
3.8.2.2 Materials and methods
Primers for the desired mutations (K115E, K115A, H116F, H116K, H116A, Y199A, 
Y199L, Y199F, Y199K, R202E, R202S, S217G and I214A) were designed with Primer 
X (Lapid, 2003) and were ordered from Invitrogen (Table 3.5). The coding sequence of 
native hTP (already present in pYSBLIC2; Bosnor et al., 2006) was used as a template for 
PCR amplification in the presence of the primers for the desired mutation (forward and 
reverse; Table 3.5) and 0.5M betaine. The polymerase chain reaction (PCR) was 
performed using KOD polymerase (Novagen) and the Boehringer Expand™ PCR 
system. The protocol used for all PCR reactions is the following: 94°C for 2min, 18 
cycles of 94°C for 30sec (melting) followed by 55°C for 30sec (annealing) and 68°C for 
8min (extension), 68°C for 7min and storage at 4°C. The PCR product was visualised on 
a 0.1% agarose gel and was then digested with lpl of Dpnl (Promega) at 37°C for lhr to 
remove any non-mutated plasmids. The resulting DNA was transformed in 
BL21(DE3)codon+ expression cells by heat shock and was plated out onto LB agar plates 
supplemented with 50pg/ml kanamycin and 50pg/ml chloramphenicol. Transformants 
were incubated overnight at 37°C. Single colonies were then selected from the 
transformation plates and used to inoculate 10ml of LB supplemented with 50pg/ml 
kanamycin and 50pg/ml chloramphenicol, allowed to incubate overnight at 37°C. 
Plasmid DNA was extracted using the mini-prep wizard (SV Wizard, Promega) and 
successful insertion of mutations was confirmed with T7 forward and reverse sequencing 
(MWG Biotech).
2 pYSBLIC is a modified pET-28a vector where the thrombin cleavage site has been removed to
allow for ligation independent cloning (LIC). A non-cleavable His-tag is annealed to the N-terminus of the 
expressed protein.
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Y199F 5'- GAC GGA ATC GTA TTT GCA GCC AGA -3'
5'- ATC TCT GGC TGC AAA TAG GAT TCC GTC -3'
Y199A 5'- GAC GGA ATC CTA GCG GCA GCC AGA -3'
5'- ATC TCT GGC TGC CGC TAG GAT TCC GTC -3'
Y199L 5'- GAC GGA ATC CTA CTG GCA GCC AGA -3'
5’- ATC TCT GGC TGC CAG TAG GAT TCC GTC -3'
H116F 5’- AG CTT GTC AC AAG TTT TCC ACA GGG GGT G -3'
5’- ACC CCC TGT GGA AAA CTT GTC CAC AAG CTG -3'
H116K 5'- CAG CTT GTC AC AAG AAA TCC ACA GGG GGT G -3* 
5’- ACC CCC TGT GGA TTT CTT GTC CAC AAG CTG -3’
K115E 5’- CAG CAG CTT GTG GAC GAA CAT TCC ACA GGG GG -3' 
5'- CCC TGT GGA ATG TTC CTC CAC AAG CTG CTG -3'
K115A 5'- CAG CAG CTT GTG GAC GCG CAT TCC ACA GGG GG -3' 
5’- CCC TGT GGA ATG CGC CTC CAC AAG CTG CTG -3'
R202E 5'- ATC CTA TAT GCA GCC GAA GAT GTG ACA GCC ACC -3’ 
5'- TGG CTG TCA CAT CTT CGG CTG CAT ATA GGA -3'
R202S 5’- ATC CTA TAT GCA GCC AGC GAT GTG ACA GCC ACC -3' 
5'- TGG CTG TCA CAT CGC CGG CTG CAT ATA GGA -3'
I214A 5'- CTG CCA CTC GCG ACA GCC TCC ATT CTC AGT AAG -3' 
5'- GAG AAT GGA GGC TGT CGC GAG TGG CAG GC -3'
S217G 5'- CCA CTC ATC ACA GCC GGC ATT CTC AGT AAG AAA -3' 
5'- TTC TTA CTG AGA ATG CCG GCT GTG ATG AGT GGC -3'
H116A 5'- AG CTT GTC AC AAG GCG TCC ACA GGG GGT G -3'
5'- ACC CCC TGT GGA CGC CTT GTC CAC AAG CTG -3'
Y199K 5’- GAC GGA ATC CTA AAA GCA GCC AGA -3'
5'- ATC TCT GGC TGC TTT TAG GAT TCC GTC -3'
The altered nucleotides for the incorporation of each mutation are underlined. The two mutations
shown in italics (HI 16A and Y199K) were unsuccessful.
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3.8.3 Expression o f native hTP and hTP mutants
Cells harbouring the recombinant plasmid of native hTP were used to inoculate overnight 
cultures of LB/TB (Sambrook et al., 1989) media, supplemented with kanamycin 
(34pg/ml) and chloramphenicol (50pg/ml). Initial trials for the expression of native hTP 
were carried out in 2L culture flasks of TB media supplemented with K2HPO4 and 
KH2PO4 salts and chloramphenicol (50mg/ml) and kanamycin (34mg/ml). Cultures were 
incubated at 37°C for approximately 4hrs before the cell density at O.D.600 reached 0.6- 
0.8, at which point protein expression was induced by the addition of ImM isopropyl P- 
D-thiogalactoside (IPTG-Bioline). Cells were incubated three hours post-induction and 
then harvested by centrifugation at 7,000rpm for lOmin. Cell pellets were stored at -20°C 
until further use. Due to the low yield however, optimisation of the expression was 
necessary. For this purpose large-scale expression of the enzyme in a fermentor (Bioflo 
3000-New Brunswick Scientific) was carried out (details for preparing and connecting 
the fermentor are given in Appendix I). Conditions such as temperature, pH and agitation 
were controlled during fermentation. Two temperatures were tested for optimal hTP 
expression: 37°C and 30°C. Cell density was monitored and when the O.D.6oo reached 
0.6-0.8, protein expression was induced by the addition of ImM isopropyl p-D- 
thiogalactoside (IPTG, Bioline). To identify the optimal incubation time after induction 
cultures were monitored over a period of 24hrs, at which point cell death was easily 
identified. Cells were harvested by centrifugation at 7,000rpm for lOmin.
Cells harbouring the recombinant plasmid of mutants were used to inoculate overnight 
cultures of LB/TB (Sambrook et al., 1989) media, supplemented with kanamycin 
(34pg/ml) and chloramphenicol (50pg/ml). Protein expression for the mutants was 
carried out in 2L culture flasks. When cell density at O.D.600 reached 0.6-0.8, protein 
expression was induced by the addition of ImM isopropyl P-D-thiogalactoside (IPTG- 
Bioline). Cells were incubated three hours post-induction and then harvested by 
centrifugation at 7,000rpm for lOmin. Cell pellets were stored at -20°C until further use.
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3.8.4 Cell lysis o f native hTP and hTP mutants.
Cells were initially resuspended in lysis buffer containing 20mM Na-citrate pH5.7, 
lOOmM NaCl and one tablet Compl@te EDTA-free protease inhibitor (one tablet per 
25ml of solution, as recommended by the supplier; Roche). Lysozyme (SIGMA) was 
initially added to this suspension which was further incubated at 4°C for 15min. Addition 
of lysozyme however appeared to reduce protein viability and was removed in further 
cell lysis steps. Two types of cell lysis were tested: French press and sonication, using an 
MSE Soniprep 150 sonicator with 20sec pulses. The lysed cells were subjected to 
centrifugation at 24,000 rpm for lhr at 4°C and the cell lysate was filtered using sterile 
0.45pm filter units (Millipore).
3.8.5 Protein purification o f native hTP and hTP mutants
The filtered cell lysate (native or mutant hTP) was loaded onto a 5ml Ni2+ His-select 
column (Sigma) previously equilibrated with buffer A (20mM Na-citrate pH5.7, lOOmM 
NaCl, one tablet Compl@te EDTA-free protease inhibitor; one tablet per 25ml of 
solution, as recommended by the supplier; Roche). Sample was loaded and the column 
was washed with buffer A. Protein was eluted using an imidazole gradient (0-250mM 
Imidazole) by mixing buffers A and B (buffer B: 20mM Na-citrate pH5.7, lOOmM NaCl, 
one tablet Compl@te EDTA-free protease inhibitor, 250mM Imidazole). Fractions were 
analysed on a 15% SDS-PAGE and those containing significant amounts of hTP were 
pooled.
Further purification was carried out by size exclusion chromatography using a Superdex 
200 column (GE Healthcare) pre-equilibrated with buffer C (20mM Na-citrate pH5.7, 
lOOmM NaCl). A protocol for multiple injections (5ml -  5runs) was set-up in order to 
facilitate the purification procedure. Sample loading was carried out at a flow rate of 
0.5mg/ml and the column was washed with 1.1 column volumes of buffer C, for the 
completion of each run (each run consisted of 1ml sample injection). Eluates were 
analysed on a 15% SDS-PAGE to check purity of the protein.
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3.8.6 Protein concentration and quantitation
Fractions containing pure protein were pooled together and concentrated. Concentration 
of the protein sample was performed using Amicon Ultra-15 (30KD cut-off; Millipore). 
Concentration was carried out in 5min cycles of centrifugation at 4,000g. The initial pool 
of ~ 1 0 ml was concentrated down to ~lml, at which point the concentration of flow 
through and supernatant (flow through -  impurities, supernatant -  purified protein) was 
assayed, using the BCA assay method (standard BCA Assay, Pierce). Absorbance was 
measured at 562nm. Usually no additional concentration cycles were required. Analysis 
of the concentrated protein samples was performed by SDS-PAGE.
An additional step, carried out only for native hTP was that of trichloroacetic acid 
precipitation (TCA precipitation). TCA is a potent dehydrator, and as such it removes 
water that is normally found in the protein. As a result the protein aggregates and 
subsequent analysis with SDS-PAGE allows the easy identification of proteins. This is 
particularly useful as it allows for even a low amount of protein (such as impurities) to be 
detected in a protein sample. 20% TCA was added to an equal volume of the protein 
sample to be examined and the sample was incubated for 30min on ice. Centrifugation 
for 15min at 4°C resulted in the formation of a pellet containing the precipitated proteins. 
The supernatant was discarded and -300pi of cold acetone were added to the pellet. 
Centrifugation for 5min at 4°C and subsequent removal of the supernatant were followed 
by drying of the pellet for 10-20min. The pellet was resuspended in SDS-PAGE loading 
dye and analysis was carried out by SDS-PAGE.
3.8.7 Identifying hTP -  Western blot analysis
hTP was expressed as a fusion protein with a His-tag on its N-terminal domain. This 
property was used for Western blot analysis. Protein and marker samples were initially 
analysed by SDS-PAGE. In order to make the protein sample accessible to antibody 
detection, it was transferred from the gel to a membrane, made of Polyvinylidene 
Difluoride (PVDF). Protein binding on the membrane is based on hydrophobic and 
charged interactions between the membrane and protein. The effectiveness of transfer of
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the protein samples from the gel to the membrane was checked by staining the membrane 
with Ponceau S dye.
To avoid non-specific binding the membrane was washed in a dilute solution of non-fat 
dry milk, containing 0.1% of Tween 20 detergent (blocking). After blocking, the primary 
antibody, (mouse anti-his antibody) at a final concentration of 1 :2 , 0 0 0  was incubated 
with the membrane overnight, under gentle agitation.
The membrane was rinsed to remove unbound primary antibody and incubated with the 
secondary antibody (rabbit anti-mouse anti-his antibody) at a final concentration of 
1:1,000. The secondary antibody was linked to horseradish peroxidase in conjunction 
with a chemiluminescent agent. This allowed for the detection of the product as it 
produced luminescence, in proportion to the amount of protein. Incubation with 
secondary antibody was carried over an hour, in dark. A photographic film was then 
placed against the membrane, and exposure to the light from the reaction created an 
image of the antibodies bound to the blot.
3.8.8 Reversed phase chromatography and Mass Spectrometry
Purification steps for hTP did not normally include reversed phase chromatography. This 
was a step necessary for sample preparation for Mass spectrometry. Purified protein was 
diluted to 3mg/ml (total sample volume of 1ml) prior to being loaded on the reversed 
phase column. A gradient was set up from 30 to 80% buffer B (acetonitrile) and eluted 
fractions were collected over a total period of lhr. Fractions containing the protein were 
pooled together and freeze-dried prior to lyophilisation. A pool sample was also run on 
SDS-PAGE to check for any protein degradation.
Mass spectrometry was carried out on hTP in order to confirm the protein and whether 
any impurities or protein degradation was present in solution. Initial experiments were 
carried out using the method of ElectroSpray Ionisation -  Time of Flight Mass 
spectroscopy (ESI-TOF MS), using a microTOF electrospray (Bruker Daltonik GmbH, 
Bremen, Germany). This was coupled to a syringe pump for the introduction of sample at 
4pl/min. The protein sample was in buffer consisting of 20mM Na-citrate and lOOmM
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NaCl and the protein concentration used was 1 mg/ml. Data was acquired over 5min and 
averaged to obtain the spectrum recorded. The nebulising gas used was nitrogen, applied 
at a pressure of 0.4 bar. The drying gas was also nitrogen, supplied at a flow rate of 4 
1/min and a temperature of 200°C. The ion mode that was used for this experiment was 
positive ion mode. Data acquired was processed via Compass OpenAccess 1.2 Software 
(Bruker Daltonik GmbH, Bremen, Germany). Further experiments using ESI-TOF were 
set up for protein sample in HPLC grade water, with and without formic acid. Spectra 
obtained from this method indicated that the use of a different mass spectrometry method 
might prove to be more suitable for this protein sample. Hence Matrix Assisted Laser 
Disorption/ Ionisation -  Time of Flight (MALDI-TOF) was then carried out.
MALDI analyses were performed on the Voyager (Applied Biosystems) 
MALDI-TOF mass spectrometer with linear and reflectron analysers. Solutions of protein 
sample (protein concentration of 1 mg/ml in HPLC grade water) and matrix were mixed 
and 0.5-1 pi was pipetted onto a sample plate. The sample spot was dried, allowing the 
crystallisation of the mixture and then irradiated with a pulsed nitrogen laser (wavelength 
of 337nm at 20hZ). The matrix was ablated from the plate while the sample was 
simultaneously desorbed and ionised. Following ionisation, the sample was accelerated 
into a flight tube (typically 2 0 kV).
3.8.9 hTP affinity for heparin
A lml heparin column (SIGMA) was used to test the affinity of hTP for heparin. The 
column was initially equilibrated with buffer A (20mM Na-citrate and lOOmM NaCl at 
pH 7). A total of 11ml of 1 mg/ml protein sample was loaded onto the pre-equilibrated 
heparin affinity column, at a flow rate of 0.5ml/min. The same buffer was used for 
washing the column prior to elution. Elution was carried out using buffer B (2M NaCl). 
Eluted fractions were collected and analysed on a 15% SDS-PAGE.
3.8.10 Crystallisation trials for native hTP and hTP mutants
For crystallisation of native hTP and hTP mutants the Hampton structure screens I and II 
(Hampton Research) were performed, using the hanging drop vapour diffusion method.
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The protein concentration used initially was 7mg/ml and incubation was carried out at 
16°C. Initial hits obtained from the structure screens were further optimised. 
Crystallisation under oil as well as incubation with additives was carried out as part of the 
optimisation trials. Techniques such as micro-seeding and streak seeding were employed 
to improve the quality of the crystals obtained, as well as cross-linking, using 
glutaraldehyde. A 0.1% of glutaraldehyde was added to the mother liquor and drops were 
monitored over a period of three hours. Dehydration experiments where the drop was 
exposed to air for 5 to 20sec were also carried out.
3.8.11 Enzymatic activity assays
The enzymatic activity of native hTP and hTP mutants was assayed by the 
spectophotometric method, a variation of the method firstly descried by Friedkin and 
Roberts in 1954 (Friedkin and Roberts, 1954; Yoshimura et al., 1990), which takes 
advantage of the absorbance difference between thymidine and thymine at 300nm. The 
reaction solution for the enzymatic activity assays, required several steps of optimisation, 
as hTP was quite unstable in several of the previously used conditions. Optimised 
reaction conditions contained 0.1M MES pH 5.5 as the buffer of the reaction, 0.1M 
KH2PO4 PH 5.5 as a source of phosphate, essential for the phosphorolytic activity of hTP 
and thymidine, the substrate of the reaction in a total reaction volume of lOOpl. The pH 
of MES and KH2PO4 was adjusted to 5.5, based on previous experiments which examined 
the pH profile of recombinant hTP in phosphorolysis reactions and indicated that hTP 
phosphorolytic activity is most optimum at pH 5.0-6.0 (Finnis et al., 1993). The 
substrate, thymidine, was ordered from Sigma and was diluted with HPLC grade water to 
prepare the stock solution, from which varying substrate concentrations (IOOjiM to 
lOmM) were used to identify the optimum range for the reactions. Purified native hTP of 
various concentrations (2 ng/ml to lpg/ml) was used in assays in order to identify the 
lowest enzyme concentration that could be used without jeopardising the validity of the 
results. The most optimum enzyme concentration was found to be 2ng/pl, which is 
equivalent to 40nM, as the molecular weight of hTP is ~50kDa. All experiments, for 
native hTP and hTP mutants were therefore carried out using the same enzyme 
concentration for consistency purposes. All reactions were prepared in triplicates in order
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to ensure the validity of the results and all experiments were carried out in duplicates in 
order to ensure the accuracy of the results obtained. Reactions were incubated at 37°C 
and stopped by the addition of 900pl of 0.2M NaOH. Blanks were also prepared and 
treated in the same way as the reaction samples; all blanks included the reaction mixture, 
lacking only the enzyme, in order to ensure that the only readings would correspond to 
thymine produced by the phosphorolytic reaction of hTP. The absorbance was measured 
at 300nm, where the difference in the extinction coefficient between thymine and 
thymidine is 3400M'1cm'1 (Spinazzola et al., 2002). The extinction coefficient is required 
for the conversion of the absorbance readings to concentration (Beer’s Law: A=e*c*l). 
These values were then used for the calculation of the initial velocity (Vo) taking into 
consideration the time points at which each sample was collected and the reaction was 
stopped. The initial velocities were then used as the input for further analysis using the 
GraFit Erithacus software (Erithacus software; Leatherbarrow, 2001), where addition of 
the Michaelis-Menten equation and of the protein concentration allows the calculation of 
Km, Vjnax and standard error values. values obtained by this analysis were then used 
to calculate kcat using the formula kcaf=Vmax/E, where E is the molarity of the enzyme. 
(Enzyme kinetics theory is provided in Appendix II).
The enzymatic activity assay was also used to measure the inhibition potency of 
5iodouracil. 5IUR (see 3.7) was crystallised with hTP as a mimic of 5FU, a currently 
used chemotherapeutic agent, with the added advantage that it is devoid of the fluorine 
atom. As discussed above, 5FU can cause a cumulative effect of toxicity, which with 
5IUR would be significantly reduced, given that 5IUR would also be an effective 
inhibitor of hTP. 5IUR was purchased from Sigma and was dissolved in NaOH. A stock 
concentration of lOmM was prepared, of which varying concentrations (0.005, 0.01, 0.05, 
0.1, 0.15 and 0.2mM) were tested for its efficacy in inhibiting hTP. The reaction assays 
were prepared as those previously described for native hTP and hTP mutants, with the 
addition of inhibitor. Inhibitor was also added in all the blanks, which were only devoid 
of enzyme, in order to blank for any of the substances that could give background 
absorbance. As previously described, reactions were incubated at 37°C and stopped by 
the addition of 0.2M NaOH. Absorbance readings were converted to concentration, using
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the extinction coefficient of thymine. Once the initial velocity was calculated for the 
reactions that contained inhibitor, results were used for generating Dixon plots. Dixon 
plots (Dixon, 1953) are an efficient way of determining the type of inhibition, as well as 
the Kj for the inhibitor.
3.8.12 Modeling o f mutants on the hTP-5IUR crystal structure
In order to identify the effect that the mutations might have on the active site 
environment of hTP all point mutations were modeled in the hTP-5IUR structure. 
Mutations were introduced using Coot (Emsley et al., 2004) and models were locally 
refined to ensure that the mutated structure was devoid of steric hindrances. To have a 
directly comparable result, the structure of hTP-5IUR was also taken through the same 
treatment prior to analysis. Analysis was performed by calculation of the number of van 
der Waals contacts using the program CONTACT by CCP4 (CCP4, 1994) for each 
mutated residue. The effect of the mutations on the hydrogen bond network was 
estimated by the calculation of hydrogen bonds for each of the mutated active site 
residues, using the program HBPLUS (McDonald et al., 1994).
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3.9 Results and discussion
3.9.1 Construction o f hTP mutants
Successful incorporation of the mutations was confirmed by DNA sequencing for each of 
the mutants. Although the same protocol was used for all mutations, HI 16A and Y199K 
were not successfully amplified. Analysis of the PCR product revealed no DNA for these 
two samples, in contrast to the results obtained for all other mutations. Optimisation of 
the conditions used for PCR was carried out without any success for HI 16A and Y199K 
(Table 3.5).
3.9.2 Expression and purification o f native hTP and hTP mutants
Although an initial protocol for expression and purification of native hTP was available, 
the yield obtained was low and optimisation of the initial conditions was required. Auto­
induction media (expression is induced automatically in late log-phase growth due to the 
depletion of carbon sources) were tested for hTP expression, producing however an even 
lower yield of protein to that obtained in TB media. Large scale production of native hTP 
was finally achieved using the BioFlo fermentor vessel (see Appendix I).
As no protocol was available for this type of expression, expression trials were set-up 
where conditions such as temperature, pH, dissolved oxygen (supplied to the vessel 
during bacterial cultures), as well as post-induction incubation time were tested. Addition 
of antifoam to bacterial cultures was tested as it reduces the formation of foam produced 
during fermentation. This however can prove to be inhibitory for cell growth when added 
in excess, so optimisation of this step was also necessary.
Optimum conditions for native hTP expression were temperature of 30°C and pH of 6.5. 
The agitation of the cell culture was optimum when set in-loop with the dissolved oxygen 
(DO). More specifically, when DO value dropped below a user-specified value (35.0) the 
agitation increased (minimum of 50rpm, maximum of 300rpm), to allow for more oxygen 
to be supplied to the vessel. Using a loop mode for DO and agitation allowed the 
‘automated’ control of the oxygen supplied and no manual input was required for this 
parameter (see Appendix I). The bacterial cell growth reached a ’plateau’ three hours
110
after induction, while further incubation appeared to result to cell death. The use of 
antifoam was limited to pi amounts of 10% antifoam solution (SIGMA). In order to 
reduce the formation of foam, media were prepared in such amounts as for the impellers 
to be submerged in liquid (approximately 3.5L of media). Large-scale expression using 
the optimum conditions for hTP yielded approximately 700pl of pure protein 
(concentration of ~9mg/ml), as opposed to 200pl of protein (concentration 6-7mg/ml) 
typically obtained by 2L flask cultures.
Expression of hTP mutants was less problematic. The use of the initial expression 
protocol indicated that only a few modifications were required before the yield was 
satisfactory. Expression for all mutants was carried out in TB media, supplied with 
glycerol, KH2PO4 and K2HPO4 salts and chloramphenicol (50mg/ml) and kanamycin 
(34mg/ml). Bacterial cultures were incubated at 37°C and monitored for cell growth in 
order to induce expression by the addition of ImM IPTG. Although all mutations were 
only point mutations, they appeared to express better than native hTP (this might be due 
to the loss and/or reduction of the enzymatic activity of hTP mutants when compared to 
that of the native enzyme; see 3.9.8). For this reason the use of a ‘more controlled’ 
environment, using a fermentor vessel, was not required.
Purification was carried out using the same protocol for native hTP and all hTP mutants. 
The cell pellet obtained was lysed using sonication, although cell lysis using French 
press, was also tested. Sonication proved to be more efficient as French press yielded 
very dense cell lysate which was not easily handled in the following steps of purification. 
The first step of purification, using an affinity chromatography column, allowed the 
separation of hTP from several other contaminants which were present in the cell lysate. 
Once most of the impurities were removed, the eluate of the affinity chromatography step 
was centrifuged, in order to remove any dust or particles, and was then loaded onto a size 
exclusion chromatography column. Separation according to size was favourable for hTP 
as most of the contaminants that remained in the sample were of different molecular 
weight. The two steps used in the purification process of native hTP and hTP mutants 
were enough to remove any impurities present in the cell lysate. SDS-PAGE analysis for
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each step of the purification procedure confirmed the presence of protein and the removal 
of impurities present in the initial sample (Figure 3.28).










Figure 3.28: A. Expression and purification of native hTP. Lanes 1 and 2 contain 
expression samples, pre and post induction respectively. Lanes 4 to 6 contain fractions 
after the first purification step (affinity column). Lanes 7 and 8 contain samples after the 
second purification step, where the protein is pure and all impurities have been removed. 
Lanes 3 and 10 contain protein markers (low molecular weight marker, SIGMA; in kDa 
range).
3.9.3 Protein concentration and quantitation
Protein concentration presents a risk as it is possible for the protein sample to bind the 
membrane used. In order to limit this risk the membranes used for concentration were 
washed with buffer, same as that which contained the protein sample (20mM Na-citrate 
pH5.7 and lOOmM NaCl). The use of 30kDa molecular weight cut-off filters allowed 
further removal of contaminants (if present) of smaller molecular weight from the eluate 





Figure 3.29: Figure A illustrates the SDS-PAGE analysis of native hTP, purified and 
concentrated. Lane 1 contains the marker (low molecular weight marker, SIGMA; in kDa 
range) and lane 2 contains the protein sample. Figure B illustrates the SDS-PAGE 
analysis of purified and concentrated mutants of hTP. Lane 1 -  marker (low molecular 
weight marker, SIGMA; in kDa range), lane 2 -  mutant K115E, lane 3 -  mutant K115A, 
lane 4 -  mutant K115A (different purification sample), lane 5 -  mutant HI 16F, lane 6 -  
mutant H116K, lane 7 -  mutant Y199A, lane 8 -  mutant Y199L and lane 9 -  mutant 
Y199F.
In order to ensure that no impurities were present in the protein sample an additional step 
was carried out after the completion of protein concentration. This involved the 
precipitation of ~20pl of the concentrated sample with TCA This was only carried out 
for native hTP, in order to get an understanding of how accurate the results obtained from 
SDS-PAGE were. A standard TCA precipitation protocol was carried out and the protein 
samples were analysed by SDS-PAGE. If any remaining impurities were present in the 
protein sample, they would show up clearly after TCA precipitation. The results obtained
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from this step indicated that a significant amount of hTP was present in the sample tested 







Figure 3.30: SDS-PAGE analysis of native hTP after TCA precipitation. Lane 1 contains 
the marker (low molecular weight marker, SIGMA; in kDa range) and lane 2 contains the 
protein sample after TCA precipitation. It is evident that only hTP is present in the 
sample. No impurities or degradation products are detected.
The protein concentration was calculated after the concentration steps, using the BCA 
method. Initial methods for the calculation of the concentration of native hTP included 
the BSA method and the UV reading of the protein sample at a wavelength of 280nm. 
The results however obtained from both these methods did not agree with the observation 
made based on the concentrated samples which were analysed with SDS-PAGE: very low 
concentrations were calculated (using both BSA and UV methods) for the protein sample 
which was in contrast to the bright, single bands observed on the SDS-PAGE for hTP. 
The use of BCA method was chosen based on its agreement with the results observed on 
the SDS-PAGE for the concentrated samples. The concentration of native hTP was 
calculated to be ~8.8mg/ml and that of mutants ranged from 7.5mg/ml to ~20mg/ml.
114
3.9.4 Identifying hTP -  Western blot analysis
Western blot analysis was performed to confirm expression and purification of hTP since 
the only alternative identification tool was SDS-PAGE analysis. The presence of a 
histidine tail on the N-terminal domain of the protein made the western blot analysis 
easier. A sample of pure, native hTP, as assessed by SDS-PAGE analysis, was used for 
western blot. Development of the photographic film allowed the detection of a single 
band in the correct molecular weight for hTP. This confirmed the results obtained by 
SDS-PAGE analysis (Figure 3.31).
Figure 331: Western blot analysis for hTP. Lane 1 contains the marker (low molecular 
weight marker, SIGMA; in kDa range) and lane 2 contains the protein sample. It is 
evident from the Western blot analysis that hTP is present in the sample. (The bands 
marked for the marker on lane 1 are an approximation of the actual marker bands as seen 
on the SDS-PAGE).
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3.9.5 Mass Spectrometry and Reversed phase chromatography
ESI-TOF experiments were carried out for native hTP in 20mM Na-citrate pH 5.7 and 
lOOmM NaCl. The spectrum obtained from this experiment did not resemble that 
expected typically for a sample of pure protein. Instead of an ‘envelope’ spectrum, with 
peak at the correct molecular weight, the spectrum obtained indicated either protein 
degradation or the presence of several proteins (impurities) in the sample tested, since 
several peaks of different molecular weights were detected. In order to identify why this 
is happening and whether the buffer in which the protein sample is affects the spectrum 
obtained, a series of ESI-TOF experiments were carried out.
Initially a sample of BSA was used as standard and was tested in HPLC grade water, 
where the spectrum obtained was that of pure protein at the correct molecular weight. 
Introduction of formic acid in the solution prior to ESI-TOF analysis provided extra 
charge and improved the signal. BSA was then resuspended in 20mM Na-citrate pH 5.7 
and lOOmM NaCl, the buffer in which hTP was first examined. The results obtained were 
dramatically different. More specifically, the spectrum obtained clearly indicated that the 
buffer ‘masks’ the readings as the ‘envelope’ previously observed was now absent. 
Addition of formic acid to the solution did not improve the spectrum obtained.
This indicated that the buffer in which hTP was stable was probably not suitable for this 
type of analysis. Buffer exchange would probably assist in exchanging the buffer with 
HPLC grade water but due to the sensitivity of the protein, a different method was 
chosen. Reversed phase chromatography, which takes advantage of the hydrophobic 
interactions made between the protein sample and the gel bed of the column, was not 
normally used for hTP purification. It was however an alternative way to remove the 
buffer from the protein sample and exchange it with HPLC grade water. Hence, the eluate 
collected from reversed phase chromatography was dissolved in HPLC grade water and 
the sample was analysed by SDS-PAGE, which indicated that the protein sample was 
pure although a small amount of degradation had occurred during this step. The 
concentration of the protein sample in water was calculated to be 13.5mg/ml (Figure 
3.32).
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Figure 332: SDS-PAGE analysis of hTP, concentrated after elution from reversed phase 
chromatography. Lane 1 contains the marker (Low molecular weight marker, SIGMA; in 
kDa range) with the molecular weights corresponding to each band. Lane 2 contains the 
sample, where it is clear that hTP is present and concentrated. A few background bands 
also observed on lane 2 are probably degradation products of hTP.
Once the buffer was removed, hTP samples in HPLC grade water were again used for 
ESI-TOF experiments. The spectrum obtained was that of an ‘envelope’ although the 
molecular weight which was calculated from this spectrum did not correspond to hTP. 
More than one peaks were identified and several were of lower molecular weights. As the 
SDS-PAGE analysis did not show any impurities in the protein sample, this was 
indicative of protein degradation.
It is possible that the instability of the sample was not allowing for a good spectrum to be 
obtained with the method of ESI-TOF and degradation was occurring. For this purpose a 
second type of mass-spectrometry was tested for hTP: MALDI-TOF. This is considered 
to be the method of choice for protein samples as it is a soft ionisation technique, used for 
samples which tend to be fragile and fragment when ionised by more conventional 
ionisation methods. It is similar to electrospray ionisation although it causes much fewer 
multiply charged ions. In addition, MALDI-TOF uses a matrix to protect the protein 
samples from being destroyed by the direct laser beam (used for ionisation) and to 
facilitate vaporisation and ionisation.
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The protein sample for MALDI-TOF experiments was prepared only in an aqueous 
solution as the buffer previously proved to ‘mask’ the signal. The spectrum obtained from 
this method resembled that of ESI-TOF: more than one peaks were detected and the 
molecular weight corresponding to those peaks was probably that of hTP degradation 
products. It was thus evident that the protein sample was not stable enough for use with 
either of the two mass spectrometry methods. It is not however clear what was causing 
the degradation of hTP and what could be done to make the protein sample stable enough 
for use in such experiments. Purification trials of hTP which included a reversed phase 
chromatography step indicated that the protein does not recover after lyophilisation. It is 
thus possible that a part of the protein is still in its intact form even in aqueous solution 
while most of it degrades to smaller fractions, as those observed in the spectra from both 
ESI-TOF and MALDI-TOF.
3.9.6 hTP affinity for heparin
Many angiogenic molecules have been reported to interact with heparin. The binding of 
heparin to many of the angiogenic growth factors, such as the vascular endothelial growth 
factor (VEGF; Ishihara et al., 2003) and the fibroblast growth factor 2 (FGF-2; Ferrara et 
al., 2003) has been reported to occur through their heparin binding domains. Angiogenin 
also binds heparin via its heparin binding site, of which key component is a cluster of 
three arginine residues (Soncin et al., 1997). A similar cluster of arginine residues can be 
observed in the mixed a/p domain of hTP. Residues 279, 303, 369, 430, 433 and 464 
appear to form a ‘patch’ of basic charge which would be likely to compose a heparin 
binding site. In order to identify whether hTP has affinity for heparin the experiment 
described in 3.8.9 was carried out. The protein sample loaded on the heparin affinity 
column would bind to heparin on the gel bed and only be removed upon elution with 
NaCl. This however was not the case as detected by SDS-PAGE analysis of samples 
collected from all steps of the process (Figure 3.33). The protein sample loaded to the 










Figure 3.33: SDS-PAGE analysis of the samples loaded and eluted of the heparin affinity 
column. Lane 1 contains the marker (Low range molecular weight marker, SIGMA; in 
kDa range). Lane 2 contains the sample loaded on the heparin column, lane 3 contains the 
sample which was collected while washing the column and finally lane 4 contains the 
elution sample.
The results showed that the entire protein sample loaded on the column was washed off, 
during the washing step. This indicated that hTP did not bind to the gel bed and probably 
requires further experimental investigation.
3.9.7 Crystallisation trials for native hTP and hTP mutants
3.9.7.1 Native hTP
Crystals of native hTP were previously obtained in 0.1 M sodium-acetate (pH 5.2), 25% 
PEG 4000 and 0.1M ammonium acetate, while crystals for hTP-5IUR complex were 
obtained in 2.8-3.5M sodium-formate. Hence the first step was to check whether these 
conditions would be reproducible using a new ‘batch’ of hTP. The concentration of the 
protein sample used for crystallisation experiments was measured by BCA (PIERCE) to 
be ~7.7mg/ml. The condition that has previously yielded crystals of native hTP did not 
produce any, while that of hTP-5IUR complex produced overlapping two-dimensional 
plates (Figure 3.34).
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Figure 3.34: Crystals of native hTP obtained in 2.8M sodium formate. The crystals look 
like overlapping plates, small in size and with no clear edges.
The crystals appeared after ~70hrs incubation at 16°C. It was thus assumed that 
nucleation occurs quickly and in order to produce larger, single crystals, the nucleation 
process should be slowed-down. For that reason a series of additives and precipitants 
were tested in addition to screening concentrations of Na-formate (Table 3.7). All the 
additives and precipitants were tested separately on the initial condition (and the 
concentration screen) as well as in combinations in an effort to obtain single, good 
quality crystals. Unfortunately all conditions yielded the same type of overlapping plates 
(sometimes of better quality) which however could not be used for X-ray diffraction data 
collection.
Another commonly used method for controlling nucleation is the crystallisation under oil. 
For this technique 200|il of 1:1 paraffin : silicon oil (Qiagen) were added to the reservoir 
solution (Table 3.6. The ratio of protein: reservoir solution was 1:1 and the drops were 
incubated at 16°C. Unfortunately this technique did not yield any crystals.
To improve crystal quality, seeding experiments were performed. Spontaneous nucleation 
(without seeds present) requires a high degree of supersaturation and can sometimes lead 
to aggregation. When seeds are provided, more molecules can associate with them and 
that can lead to a ‘proper’, single crystal. Two types of seeding experiments were carried
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out for optimising this condition: streak-seeding and micro-seeding. Streak-seeding 
(during which a whisker is used to touch an already formed crystal and then seeds are 
transferred to pre-equilibrated drops) was carried out on drops which had been pre­
equilibrated with protein sample for lhr and for 24 hrs. The ratio of protein to reservoir 
solution used for equilibration of the drops was from 0.5:1, 1:1, 1:2, 1:3 to 1:4 and all 
drops were incubated at 16°C. Micro-seeding (during which a crystal is dissolved in 
mother liquor and then used to provide seeds for a new drop) was carried out on drops 
which were also pre-equilibrated with protein sample, at the same ratios as those used for 
streak-seeding. Both techniques were not successful: streak-seeding produced the same 
type of crystals as those initially observed (overlapping, two-dimensional plates) while 
micro-seeding did not yield any crystals.
Table 3.6: Crystallisation trials for native hTP
Condition Additives and precipitants
2.8-3.5MNa-Formate Ethylene glycol, Glycerol, MPD, Jeffamine 600, Spermine,
PEG 400, 4K, 8K, 10K, Imidazole, DMSO, (NH^SCU, 
Na-citrate, Na-acetate, LiCh, MgCl2 , CdCl2 , CaCh
Techniques
Crystallisation under oil 
1:1 paraffin : silicon oil
Streak seeding 
Micro-seeding
During these optimisation trials, structure screens I and II (Hampton Research) were also 
set up in order to identify new possible ‘hit’ conditions. Two conditions that produced 
crystals were: 1) 2% Dioxane, 01.M Bicine pH 9.0 and 10% PEG 20K and 2) 0.4M 
ammonium dihydrogen phosphate. The first condition produced small but good quality 
rectangular crystals. These crystals were very fragile and not reproducible. The second 
condition produced very thin needle crystals (Figure 3.35).
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Figure 3.35: Crystals of native hTP grown in 
0.4M ammonium dihydrogen phosphate and 
incubated at 16°C.
This condition was screened for concentrations of 0.2M to 0.5M ammonium dihydrogen 
phosphate and a pH range of 4.0 to 6.0. The most optimum concentration was found to be 
0.4M while the most optimum pH was found to be 4.0. Further optimisation of this 
condition included the use of additives, precipitants and alcohols. All crystals produced 
resembled those obtained by the initial condition: very thin, needle crystals (Figure 3.36).
Figure 336: Needle crystals of native hTP obtained in 0.4M ammonium dihydrogen 
phosphate, pH 4.0, incubated at 16°C.
The exposure of these needle crystals to the X-ray beam revealed that they diffracted very 
poorly, to ~9A. To improve crystal quality, experiments such as cross-linking (using 
glutaraldehyde) and dehydration were carried out. The use of glutaraldehyde did not
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destroy the crystals, which even after three hours incubation maintained their original 
shape and size. The cross-linked crystals diffracted better, to ~ 6 A  which however 
required further optimisation. Dehydration experiments did not significantly affect the 
crystal morphology or the diffraction pattern obtained. Experiments of the same condition 
were aiso set up for incubation at 4°C, without any success.
The use of ammonium dihydrogen phosphate in combination with sodium formate 
(200mM and 300mM) initially appeared to cause phase separation. The drop morphology 
changed however after incubation at 16°C for approximately nine months and rock -  like 
crystals appeared in the drop (Figure 3.37).
Figure 337: Crystals of native hTP grown in ammonium dihydrogen phosphate and 
sodium formate, which appeared after nine months incubation at 16°C.
These crystals however were grown under a film, and when tested under the X-ray beam 
proved to be very fragile and did not diffract.
3.9.7.2 Crystallisation trials for hTP mutants
Of all hTP mutants expressed and purified some presented greater ‘structural’ interest 
than others. For this reason crystallisation trials for hTP mutants started off from specific 
mutations rather than all of them. In order to cover all residues mutated, one 
‘representative’ was chosen. Mutants K115E, H116F and H116K, Y199A and Y199F
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were the mutations taken to crystallisation trials. All mutants were concentrated to 
~8mg/ml and the drops were all set at a ratio of 1:1, protein to reservoir solution.
The first conditions to be tested for all mutants were those which provided crystals for 
native hTP. hTP mutants however did not crystallise in any of these conditions. In order 
to obtain initial hits which would be further optimised, structure screens I and II 
(Hampton Research) were carried out. Mutants H116F, H116K and Y199F formed 
clusters of needle crystals (Figure 3.38) in 0.1M CdCl2, 0.1M Na-acetate at pH 4.6 and 
30% PEG 400.
Figure 3.38: Cluster of needle crystals for 
mutant HI 16F in 0.1M CdCl20.1M Na-acetate at 
pH 4.6 and 30% PEG 400. Drops were incubated 
at 16°C.
Similar clusters of needles were obtained for 
H116K and Y116F.
A screen of chloride salts and PEG was set up to optimise the initial condition (Table 
3 .7). This screen yielded crystals of similar quality to those initially obtained, while some 
of the conditions did not produce any crystals.
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Table 3.7: Crystallisation trials for mutants H116F, H116K and Y116F
Condition Additives and precipitants
0.1M CdCl2 CdCl2, CsCl, LiCl, MgCl2, MnCl2, KC1, ZnCl2, FeCl3,
0.1M Na-acetate pH 4.6 CoCl2, NiCl2, CuCl2, CaCl2, PEG 2K, MPD, Glycerol
30% PEG 400
Mutants K115E and Y199A formed crystals under completely different conditions. Initial 
hits (crystalloids) were obtained in 0.1 M Sodium acetate, 0.1M Tris HC1 pH 8.5 and 30% 
PEG 4K (structure screen II, Hampton Research). This condition was further optimised 
by screening around the concentration of PEG and sodium acetate. Additives and 
precipitants were also tested (Table 3.8). The drops were incubated at 16°C and the ratio 
of protein to reservoir was 1:1. Additives were separately tested on the initial hit as well 
as in combinations, in order to identify a condition which would yield good quality 
diffracting crystals of the mutants. A different buffer around the same pH range was also 
tested in order to check whether it was the pH or the buffer composition which was 
essential for crystal formation.
Table 3.8: Crystallisation trials for mutants K115E and Y116A 
Condition Additives and precipitants
0.1M Sodium acetate CdCl2, CsCl, LiCl, MgCl2, MnCl2, KC1, ZnCl2, FeCl3,
0.1M Tris HC1 pH 8.5 CoCl2, PEG 400, PEG 2K, MPD, Glycerol, Jeffamine
30% PEG 4K 600, Ethylene glycol, Dioxane, (NH4)2S0 4
Buffer
O.IMNa-HEPES pH 7.5
Optimisation of the original condition yielded either amorphous spherulites (Y199A), or 
clusters of needles of very poor quality (K115E; Figure 3.39) in 0.1M Sodium acetate,
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0.1M Tris HC1 pH 8.5, 40% PEG 4K and 0.1M Sodium acetate, 0.1M Tris HC1 pH 8.5, 
30% PEG 4K and 1 OOmM (NH^SO*
Figure 3.39: Amorphous spherulites and clusters of needles around a cloth fiber were 
initially obtained for mutants K115E and Y199A.
Further optimisation of this condition and substitution of Tris HC1 pH 8.5 by Na-HEPES 
at pH 7.5 resulted in crystal formation. Crystals were observed for both K115E and 




Figure 3.40: Crystals obtained for mutants K115E and Y199A in 0.1 M Na-HEPES 
pH 7.5, 0.2M CdCl2,28% PEG 400 and 30% MPD, after incubation at 16°C.
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The crystals were exposed to the X-ray beam but no diffraction was obtained. All hTP 
crystals, native and mutants, proved to be extremely fragile and were destroyed very 
quickly when exposed to the X-ray beam.
In an effort to further optimise the conditions obtained for all hTP mutants, an OptiSalt 
screen (Qiagen) was performed. Crystals obtained by two conditions of the screen (0.1M 
Na-acetate pH 4.6, 0.6M Na-fluoride and 0.1M Tris HC1 pH 8.5, 0.6M Na-fluoride) 
turned out to be salt crystals.
Protein for mutants R202E, R202S, S217G and I214A was produced much later than that 
of the previous mutations on K115, HI 16 and Y199. For this reason, crystallisation 
experiments on R202, S217 and 1214 mutants are not described.
3.9.8 Enzymatic activity assays and correlation with hTP mutant models 
The phosphorolytic activity of hTP was assessed by enzymatic activity assays, as 
described above (Chapter III, 3.8.11). Analysis of the results obtained from the assays 
indicated that native hTP (His-tag on the N-terminal domain) was active, with a kcat of 
8.2s'1 (Table 3.9), comparable to that reported previously by Finnis, where kcat = 9.4s'1 for 
recombinant native hTP (no His-tag on the N-terminal domain; Finnis et al., 1993). The 
profile of the phosphorolytic reaction catalysed by native hTP is given by the plot of 
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Figure 3.41: Phosphorolytic reaction catalysed by native hTP. The plot of velocity V 
against substrate concentration [S] here illustrates the profile of the reaction. Shown in 
light blue is the double reciprocal plot (Lineweaver-Burk plot) of \IV against 1/[S],
Of all hTP mutants (total of eleven point mutations; K115E, K115A, H116K, H116F, 
Y199A, Y199L, Y199F, R202E, R202S, S217Gand I214A) only four retained some of 
the enzymatic activity of hTP. Km, Vmax and kcat for hTP and for each of the mutants are 
given in Table 3.9. Two hTP mutants, K115E and R202S, previously reported by 
Miyadera and co-workers (Miyadera et al., 1995) were repeated to confirm the previous 
results and to provide a standard for the rest of the mutations carried out.
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kcat ( s ')
Native hTP 0.35 19.7 8.2
(0.01) (2)
K115E - - -
K115A 0.42 16.4 6.8
(0.04) (0.9)
H116F - - -
H116K - - -
Y199A - - -
Y199L 3.14 10.6 4.4
(1.0) (2)
Y199F 2.1 8.4 3.5
(0.6) (1)
R202E - - -
R202S - - -
I214A 0.74 12.53 5.2
(0.03) (0.3)
S217G - - -
No product formation (thymine) could be detected for mutant K115E, signifying that the 
mutation had lead to complete loss of enzymatic activity. This result is in agreement with 
previous work by Miyadera and co-workers (Miyadera et al., 1995), where mutant 
K115E had no enzymatic and angiogenic activity. On the other hand, mutant K115A 
reduced the enzymatic activity of hTP by about 1.2 fold. Vmax for K115A (16.4pM/min; 
Table 3.9; profile for phosphorolytic reaction of K115A is shown in Figure 3.42) is 
slightly lower than that of the native enzyme, indicating that this mutation has a mild 
effect on the enzymatic activity of hTP. Interestingly, the van der Waals contacts for 
K115E appear to be more than those for K115A. Lysl 15 in native hTP is involved in 21
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van der Waals contacts, which are reduced to twelve in K115A, but increased to twenty 
nine in K115E (Table 3.10). Although there is an increase in the number of interactions 
for K115E as opposed to Lysll5 of native hTP, it is very likely that introduction of 
negative charge at this position does not facilitate the binding of phosphate due to charge 
repulsion, thus rendering the enzyme inactive. Mutant K115A loses the positive charge of 
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Figure 3.42: Phosphorolytic reaction catalysed by hTP mutant K115A The plot of 
velocity V against substrate concentration [S] illustrates the profile of the reaction. Shown 
in light blue is the double reciprocal plot (Lineweaver-Burk plot) of 1/V against 1/[S]. It 
is evident that K115 A reduces the velocity of the reaction, without however completely 
abolishing it.
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Table 3.10: Hydrogen bond and van der Waals interactions for native hTP and hTP
mutants.




















Shown in this table are the van der Waals contacts and the hydrogen bonds for hTP-5IUR 
and each of the mutations, van der Waals interactions have been calculated for each 
individual residue both in hTP-5IUR and mutants. Also shown here, are the hydrogen 
bond interactions for each individual residue.
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The significance of H isll6  has been discussed previously, on E.coli thymidine 
phosphorylase (Rick et al., 1999) and in hTP (Norman et al., 2004), although mutational 
work on this residue has not been reported so far. Enzymatic activity assays carried out 
on two H isll6  mutants (H116F and H116K) indicate that both mutations have a severe 
effect on hTP, as they completely abolish the enzymatic activity (Table 3.9). Analysis of 
intramolecular interactions in these mutants showed a decrease in the number of 
hydrogen bonds as opposed to native hTP; from 2 (native) to 1 (HI 16K and HI 16F). van 
der Waals interactions increased in mutant H116F, while in H116K these interactions 
were reduced slightly (Table 3.10). Since both H isll6  mutations completely abolish the 
enzymatic activity of hTP, it is possible that both the basic charge and the ring structure 
of histidine at this position are an absolute requirement and that H isll6 is an absolutely 
crucial residue for the catalytic activity of hTP. Structural studies of the two Hisll6 
mutants would possibly reveal whether the binding of substrate in the active site is 
hindered when Hisl 16 is mutated.
Tyrl99, whose role is yet unclear, appears to affect the catalytic activity of hTP. 
Mutations on Tyrl99 provided some interesting information on its role and significance 
for the catalytic activity of hTP. Among the three tyrosine mutations, Y199L and Y199F 
reduced the catalytic activity of hTP, while Y199A completely abolished it (Table 3.9). 
Mutant Y199L catalyses the reaction at a much slower rate than native hTP (Fmax Y199L 
10.6pM/min; Table 3.9; Figure 3.43) while its catalytic efficacy is almost half of that 
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Figure 3.43: Phosphorolytic reaction catalysed by hTP mutant Y199L. The plot of 
velocity V against substrate concentration [S] illustrates the profile of the reaction. Shown 
in light blue is the double reciprocal plot (Lineweaver-Burk plot) of XIV against 1/[S]. 
Mutant Y199L was shown to reduce the rate of the phosphorolytic reaction and the 
catalytic efficacy (Table 3.9).
Mutant Y199F reduced the rate of the reaction even more than mutant Y199L (Vmax Yi99f 
8.4pM/min; Table 3.9; Figure 3.44) as well as the catalytic efficacy (reduced to 3.5s*1 for 
Y199F). The difference between the results obtained by the two Tyrl99 mutants are 
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Figure 3.44: Phosphorolytic reaction catalysed by hTP mutant Y199F. The plot of 
velocity V against substrate concentration [S] illustrates the profile of the reaction. Shown 
in light blue is the double reciprocal plot (Lineweaver-Burk plot) of \/V  against 1/[S]. 
Mutant Y199F significantly reduced the rate of the phosphorolytic reaction and the 
catalytic efficacy (Table 3.9).
Analysis of the models generated for Y199F, Y199L and Y199A shows a reduction in the 
number of putative interactions (Table 3.10). More specifically, hydrogen bonds are 
reduced for all mutants, while van der Waals interactions are almost halved in mutant 
Y199A, reduced in mutant Y199L and retained in mutant Y199F, the latter being a rather 
conservative mutation as it retains the ring structure of the residue albeit the loss of the 
hydroxyl group. Examining the environment surrounding Tyrl99 in the hTP-5IUR 
complex shows that the ring structure is essential for a number of intramolecular contacts 
in order to maintain the integrity of the active site, van der Waals interactions of Tyr 
residue include those with Leu 148 which is a part of the hydrophobic pocket holding the 
iodine atom of 5IUR in place (or chlorine atom of TPI in 1UOU; Norman et al., 2004). 
Leul48 in turn interacts with Val208, also part of the same hydrophobic pocket. Mutation 
of Tyrl99 to Phe retains these interactions, thereby retaining the enzymatic activity of 
hTP. It is very likely that both size and hydrophobicity of the residue at this position is
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essential for maintaining the structural integrity of the active site. Any change otherwise 
disfavours the normal function of hTP. It is thus evident that Tyrl99 is indeed involved in 
the enzymatic activity of hTP.
Another mutation which completely abolished the enzymatic activity of hTP was the one 
targeting residue Arg202. Arg202 is involved in the hydrogen bonding network that 
stabilises 5IUR in the active site cleft, as seen in the hTP-5IUR complex structure (Figure 
3.18). Site-directed mutagenesis carried out previously on Arg202, (R202S by Miyadera 
et al., 1995) resulted in abolishing the enzymatic and angiogenic activity of hTP. Our 
findings are in agreement with previous work; both Arg202 mutants (R202E and R202S) 
completely abolish the enzymatic activity of hTP (Table 3.9). Models of the two Arg202 
mutants indicate a significant reduction both in hydrogen bonds and van der Waals 
interactions. In native hTP, Arg202 is involved in three hydrogen bonds and a total of 
twenty nine van der Waals interactions. Mutant R202E shows a reduction in van der 
Waals contacts to twenty two, while no hydrogen bonds could be detected for the 
mutated residue. Mutant R202S shows an even more drastic reduction in the number of 
van der Waals interactions, reduced to only fifteen (Table 3.10). In contrast to R202E, 
R202S retains one of the three hydrogen bonds, observed in the native hTP (Table 3.10).
Ser217 is also part of the active site cleft and has been shown to be involved in stabilising 
the molecules bound in the active site of the enzyme via hydrogen bonds (Figure 3.18; 
hTP-5IUR complex structure; Norman et al., 2004). No mutational work has so far been 
reported for Ser217 and hence no information was available on its significance for the 
enzymatic activity. In the present study, Ser217 was mutated to glycine and the mutant 
was assayed for detection of enzymatic activity. No thymine production could however 
be detected, indicating that the mutation had abolished the enzymatic activity (Table 3.9). 
Analysis of the intramolecular contacts of S217G indicated a significant reduction in the 
number of van der Waals interactions and a loss of one hydrogen bond, as opposed to 
native hTP (Table 3.10). This hydrogen bond, involving the hydroxyl group of Ser 
contributes to the stabilisation of the bound molecule in the active site cleft, and appears 
to be essential for maintaining the enzymatic activity of hTP.
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Site-directed mutagenesis on Leul48 (Miyadera et al., 1995), part of the hydrophobic 
pocket of hTP (Figure 3.19), indicated its significance for the enzymatic activity of hTP, 
as the mutation completely abolished both the phosphorolytic and angiogenic activity of 
the enzyme. Mutation of Ile214, another member of the hydrophobic pocket, showed 
reduction but not loss of the enzymatic activity. More specifically, mutant I214A reduced 
the rate of the phosphorolytic reaction, (PmaXi2 i4A 12.5pM/min; Table 3.9), as well as the 
catalytic efficacy of hTP (&cat= 5.2s'1; Table 3.9). Analysis of the network of interactions 
for native Ile214 and I214A indicates a significant reduction in the number of van der 
Waals contacts while hydrogen bond interactions are retained (Table 3.10). Although the 
reduction in intramolecular interactions is significant, mutant I214A does not abolish the 
enzymatic activity of hTP, probably due to the retaining of the hydrophobic character of 
lie by Ala. The reduction, on the other hand, of the catalytic efficacy is most likely due to 
the loss of the ‘bulkier’ side chain of lie to Ala.
A summary of the results obtained by the enzymatic activity assays for native hTP and 






Figure 3.45: Phosphorolytic reaction catalysed by native hTP and hTP mutants. The plot 
of velocity V against substrate concentration [S] illustrates the profile of the reaction. 
Mutants K115A, Y199L, Y199F and I214A maintain some of the enzymatic activity of 
hTP, while mutants K115E, HI 16K, HI 16F, Y199A, R202E, R202S and S217G abolish 
the catalytic activity of the enzyme.
The catalytic efficacy of native hTP and hTP mutants, as determined by the enzymatic 
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Figure 3.46: Catalytic efficacy of native hTP and hTP mutants. Mutations K115A, 
1214 A, Y199F and Y199L reduce the enzymatic activity of hTP, with the first two having 
less of an effect on the catalytic potency of the enzyme. Mutants K115E, HI 16K, HI 16F, 
Y199A, R202E, R202S and S217G completely abolish the catalytic activity of the 
enzyme, as also seen from Figure 3.41.
The results of the enzymatic activity assays illustrate the significance and indispensability 
of certain residues to the catalytic activity of hTP. It is evident that Hisl 16, Arg202 and 
Ser217 are absolutely essential for the enzymatic activity. It is important to note that hTP 
was rendered inactive when mutations on residues which are involved in hydrogen 
bonding interactions with the molecules bound in the active site of the enzyme were 
introduced.
Lysll5 affects the enzymatic activity mostly due to its interactions with phosphate, 
essential for the phosphorolytic reaction. Mutagenesis on Tyrl99 affects but not always 
abolishes the enzymatic activity of hTP. It is likely that certain features surrounding the 
active site cleft can be conserved, by conservative mutations, which affect without 
abolishing the activity of the enzyme. It is thus possible to suggest that it is not only the 
active site residues which are essential for the binding of the substrate, but the
hydrophobic pocket and the phosphate-binding site residues, which collectively retain the 
catalytic activity of hTP.
3.9.9 Significance o f phosphate binding in hTP activity
As one of the substrates for the phosphorolytic reaction catalysed by hTP, phosphate is 
required for the catalysis that yields thymine and 2dDR-lP. The role of phosphate in the 
reaction catalysed by hTP has been previously discussed by Birck and Schramm (Birck 
and Schramm, 2004) where enzymatic activity assays which omitted phosphate, resulted 
in a very low rate of reaction, resembling that of an inactive enzyme. The detection of 
some activity was probably the result of the hTP ‘acting’ as a hydrolase, as which 
however the enzyme does not seem to be very efficient. The role of phosphate became 
however a bit unclear, as in a recent structure where hTP was crystallised with thymidine, 
the product thymine was present in the active site of the molecule as seen in the crystal 
structure, without phosphate being included in the crystallisation conditions (PDB code 
2J0F; El Omari et al., 2006). This raises questions about the necessity of phosphate for 
the catalysis of the reaction. One crystal structure where phosphate was present in the 
phosphate binding site was that of BsPyNP (Pugmire and Ealick, 1998). Crystal structure 
of BsPyNP (PDB ID 1BRW; Pugmire and Ealick, 1998) was aligned against those of 
hTP-TDR (PDB code: 2J0F; El Omari et al., 2006) and hTP-5IUR. This alignment 
reveals a water molecule at the phosphate binding site, in both the hTP structures. It is 
possible that this water molecule mediated the nucleophilic attack on the sugar moiety of 
thymidine just as phosphate would have if it were present, in the case of hTP-TDR. The 
sole possible source of phosphate in hTP-TDR complex which could mediate the 
catalysis, would be from the culture media, assuming phosphate was present and was not 
removed in subsequent purification steps. In such an instance, phosphate could mediate 
the reaction and subsequently leave the phosphate-binding site.
In order to understand the necessity of phosphate for catalysis an enzymatic activity assay 
was carried out for native hTP, this time omitting the phosphate source, KH2PO4 . If 
phosphate is an absolute requirement for the reaction to occur then no product (thymine) 
should be detected. On the other hand, if water can mediate the reaction and hTP is a
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potent hydrolase, then thymine would still be detected, even in the absence of phosphate. 
This would also be the case if phosphate is already present from the expression media.
Results from the enzymatic activity assay confirmed the previous work which suggested 
hTP is not a potent hydrolase. More specifically, very low enzymatic activity was 
detected when the phosphate source was removed, resembling an almost inactive enzyme 
(Km, Vmax and kcat values were too low to be determined). This result suggests that the 
hydrolytic activity of hTP is very low especially when compared to the phosphorolytic 
activity of the enzyme. Since phosphate is required for the reaction to occur it is not 
likely that water molecules seen in the phosphate binding site would mediate an effective 
hydrolytic reaction. It is thus evident that phosphate is an absolute requirement for the 
reaction catalysed by hTP and upon the removal of phosphate, the enzyme becomes 
inactive.
3.9.10 Is 5IUR a potent hTP inhibitor?
In the present structure of hTP-5IUR complex, the small size of the inhibitor as well as its 
similarity to 5FUR (currently used chemotherapeutic agent) make it an attractive target 
for drug design. Kinetic studies carried out by Razzell and Casshyap (1964) have shown 
a 61% inhibition of thymidine arsenolysis when 0.64mM of 5IUR was used (Razzell and 
Casshyap, 1964). In order to determine the type of inhibition and the potency of 5IUR in 
inhibiting hTP, enzymatic activity assays, including 5IUR, were carried out. The 
substrate concentrations used for this assay were (0.2mM, 0.6mM and 1.2mM), while 
inhibitor concentrations used were 0.005, 0.01, 0.05, 0.1, 0.15 and 0.2mM. The inhibition 
of phosphorolysis was measured by the reduction in the reaction rate. To determine the 
type of inhibition and the Kj for 5IUR Dixon plots were used (Appendix II; Dixon, 1953). 
Results for 1 /V and [S]/V were plotted against the inhibitor concentration, for the 
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Figure 3.47: Plot for 1/V against the inhibitor concentration, [I]; the concentration of 
5IUR. The three substrate concentrations used for these measurements are 0.2mM, 
0.6mM and l.OmM. The three substrate concentrations ‘meet’ just above the x-axis, 
which is indicative of competitive inhibition.
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Figure 3.48: Plot of [S]/V against the inhibitor concentration, [I], The measurements at 
three substrate concentrations produce parallel lines, which is indicative of competitive 
inhibition.
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According to the published method of Butterworth (Butterworth, 1972) where Dixon 
plots are presented as way to study enzyme inhibition, the plots of 1/V (Figure 3.47) and 
[S]/V (Figure 3.48) were generated. In competitive inhibition, the substrate 
concentrations in a plot of 1/V against [I] should intersect above the x-axis, for the 
different substrate concentrations, while in the plot of [S]/V against [I] substrate 
concentrations should be parallel. The results from the inhibition assay for 5IUR are in 
agreement with this type of inhibition and it is thus possible to say that 5IUR is a 
competitive hTP inhibitor. Due to its similarity to the product of the phosphorolytic 
reaction catalysed by hTP, 5IUR would be expected to ‘compete’ with the substrate for 
the active site of the enzyme.
Dixon plots are an efficient way for determining the inhibition efficiency, Kj. In 
competitive inhibition Kj can be determined from the plot of 1/V against [I]. According to 
the results obtained for 1/V against [I], K ,  is 0.48mM. This K j  is ‘low’ for a competitive 
inhibitor, but it is in agreement with previous results as reported by Razzell and Casshyap 
(Razzell and Casshyap, 1964), where only 61% inhibition of hTP arsenolysis was 
achieved when 0.64mM of 5IUR were used. Hence, although a competitive inhibitor, 
5IUR is not a very efficient hTP inhibitor. It is possible however that modification on 
5IUR would increase its efficacy, which along with the lack of a toxicity group (such as 
the fluorine atom in 5FU) would probably make it an interesting drug target.
3.9.11 Conclusion and future work
Thymidine phosphorylase is an enzyme responsible for the reversible phosphorolysis of 
thymidine to thymine and 2-deoxy-D-ribose-l-phosphate. The catalytic activity of TP, 
essential for providing pyrimidine nucleotides for DNA repair and replication, has been 
shown to be indispensable for the angiogenic activity of the enzyme. The role of hTP in 
angiogenesis (physiological and pathological) has attracted a lot of interest for the 
enzyme. In physiological angiogenesis, its role as the ‘supplier’ of pyrimidine nucleotides 
is essential for the salvage pathway and for maintaining the nucleic acid homeostasis. 
Several pathological conditions have also been linked to hTP: detection of the enzyme in 
primary tumours is a risk factor as it has been associated with tumour invasiveness and
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metastasis. hTP has also been found to overexpress in conditions such as rheumatoid 
arthritis, ulcers, irritable bowel disease and psoriatic lesions, making it thus a primary 
target for design and development of new drugs. As the angiogenic activity of hTP is 
dependent on its enzymatic activity, it is essential to target the enzymatic activity in order 
to inhibit its role in angiogenesis. Inhibitors of hTP can act as anti-angiogenic agents, 
significantly reducing tumour growth by disrupting the thymidine salvage pathway, 
angiogenesis or metastasis (Esteban-Gamboa et al., 2000; Kita et al., 2001). Several 
inhibitors have been designed for hTP and have mostly been tested in kinetic studies. The 
most potent inhibitor of hTP reported to date is TPI (IC50 value of 35nM), proposed to 
suppress tumour growth by increasing the apoptotic rate. Currently used as a 
chemotherapeutic agent target the activity of hTP is 5FU, administered as an oral 
prodrug, doxifluridine, which however is a rate-limiting drug as toxicity is accumulated 
not only in tumour areas but in the gastrointestinal tract as well. A new drug, currently in 
clinical trials, capecitabine, was designed so as for the prodrug to pass through the 
gastrointestinal tract at its intact form and deliver the converted 5FU to cancer cells only 
(Miwa et al., 1998).
Structural information has greatly enhanced the understanding of the structure and 
function of the members of the PyNP superfamily. The first structures to be reported 
were those of EcTP (Walter et al., 1990) and BsPyNP (Pugmire and Ealick, 1998), 
followed by their human homologue. Information gained from structural and 
computational studies on EcTP revealed two states of the enzyme: a bound-closed 
conformation and an unbound-open conformation. Analysis of the reported structures of 
TP from different species, indicates conservation in several characteristics, but also raises 
questions about some of the proposed mechanistic details employed for the catalytic 
activity of TP.
Two crystal structures of hTP have been reported to date: a complex of hTP-TPI, a small 
molecule inhibitor (PDB ID 1UOU; Norman et al., 2004) and a complex of hTP-TDR, 
the product of the phosphorolytic reaction catalysed by hTP, thymine (PDB ID 2J0F; El 
Omari et al., 2006). Both structures are complexes and provide information solely about
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one ‘state’ of the enzyme, in which it is in complex with another molecule. To understand 
the mechanistic details that drive the catalytic activity of hTP, more information, 
structural (e.g. bound and unbound forms of the enzyme) and functional (significance of 
active site residues) are required. The two structures of hTP, native and in complex with 
5IUR, reported here, provide new insights and raise new questions about the structural 
and functional understanding of the enzyme.
The crystal structure of hTP-5IUR and the analysis of the network of interactions holding 
the small molecule inhibitor in the active site cleft, showed similarities with previously 
reported hTP complexes (Normal et al., 2004; El Omari et al., 2006). The active site 
residues previously identified were also detected to form the same network of interactions 
with 5IUR (Figure 3.18). This was however expected, as several residues that form the 
active site cleft are conserved among species, as seen from structures of EcTP (Walter et 
al., 1990) and BsPyNP (Pugmire and Ealick, 1998). It is however possible that other 
residues, are also involved in stabilising the substrate thymidine in the active site cleft of 
the enzyme, which however have not been described to date as all molecules in complex 
with hTP reported so far are smaller in size.
Alignment of bound (hTP-5IUR) and unbound (native hTP) hTP structures, indicated a 
lack of ‘domain movement’, previously proposed for members of the PyNP superfamily. 
Domain movement was proposed to be essential in bringing the substrates closer 
together, for catalysis to occur. Based on our findings however, domain movement was 
not detected for the enzyme, which might indicate that it does not actually occur in the 
case of hTP (Figure 3.21). On the other hand, it is possible that the ‘closed’ state of the 
enzyme, observed in both bound and unbound hTP structures reported here, is favoured 
by crystal packing, and binding of phosphate or substrates is not required for the enzyme 
to acquire this particular conformation. It would not thus be accurate to state with 
confidence whether domain movement occurs in hTP or whether it is essential for 
catalysis, as structural information for possible intermediate stages have not been 
reported to date. Identification of intermediate stages, both functional and structural, 
could be used for drug design and development. It would be possible to design drugs that
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target specifically the intermediate stages of the phosphorolytic reaction catalysed by 
hTP, so as to ensure the enzyme is not inhibited in its inactive form. This would be 
particularly useful as inhibition of physiological hTP activity can lead to several 
pathological conditions.
The potency of the inhibitors currently developed and tested against hTP has been 
previously discussed by Birck and Schramm (Birck and Schramm, 2004). Kinetic isotope 
effect measurements were used for the determination of the transition states of the 
reaction catalysed by hTP. Research on the transition states, using computational 
methods, has also been carried out by two different research groups (Cole et al., 2003; 
Mendieta et al., 2004). Computational methods yielded similar results: they identified an 
SNl-type reaction for hTP, which involves the formation of a carbocation intermediate 
preceding the subsequent nucleophilic attack. In this type of reaction, the overall reaction 
rate depends on the concentration of the reactant only. A different type of reaction 
mechanism was however identified by the kinetic isotope effect measurements (Birck and 
Schramm, 2004). Experimental results indicated that hTP undergoes an S^-type 
reaction, which involves the direct displacement of a leaving group (2-deoxy-D-ribose) 
from the nucleophile (phosphate). This type of reaction mechanism does not involve the 
formation of a carbocation intermediate and is dependent on the concentration of the 
nucleophile as well as the concentration of the substrate. If this is in fact the reaction 
mechanism used in the phosphorolytic reaction which hTP catalyses, it is the first case of 
an SN2-type reaction for the family of A-ribosyl transferases. It is evident that inhibitors 
which were designed to ‘block’ an Sul-type reaction will not be as efficient in the 
inhibition of the S^-type reaction seen in hTP. Hence, it is possible that new small 
molecule inhibitors, aiming at the inhibition of an SN2-type reaction would be more 
efficient than the currently designed and tested compounds. Hence, compounds designed 
to efficiently inhibit hTP should be substrate analogues, with reduced toxicity and 
specific for the reaction type employed by the enzyme. It is not yet possible to predict 
whether reaction type and domain movement are related. Structures of transition states of 
the enzyme would provide more information and would aid in the understanding of both 
mechanistic details and conformational changes that might occur during catalysis.
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In order to understand the mechanistic details of hTP it is essential to elucidate the role 
and significance of the active site residues. Previous work carried out by Miyadera et al. 
indicated that residues Lysll5, Arg202 and Leul48 were indispensable for the enzyme, 
as mutagenesis abolished both enzymatic and angiogenic activity of hTP. The role of 
H isll6  (His85 in EcTP) was previously discussed by Rick et al. but mutagenesis work 
involving this residue was not reported to date. In order thus to understand the role of 
active site residues and their significance for the enzymatic activity, mutagenesis was 
carried out on Lysll5, H isll6, Tyrl99, Arg202, Ile214 and Ser217. With the exception 
of Ile214, which is part of the hydrophobic pocket, the rest of the residues examined are 
all involved in stabilising 5IUR in the active site cleft by means of hydrogen bonds. 
Introduction of point mutations to hTP, expression and purification of all mutants were 
followed by enzymatic activity assays in order to determine their effect in the 
phosphorolytic efficacy of hTP.
Lysll5, was previously proposed to stabilise phosphate in the phosphate binding site 
along with residues Seri26, Serl44 and Seri 17 (Edwards, 2006). Enzymatic activity 
assay results indicated that Lysll5 modulates the enzymatic activity of hTP via its 
interactions with phosphate, which is one of the required substrates for catalysis. It is 
evident that the positive charge at that particular position is the required environment for 
efficient phosphate binding, which in turn allows for the phosphorolysis to occur. 
Introduction of a negative charge changes the environment of the phosphate-binding site 
and yields the enzyme inactive.
The highly conserved H isll6  renders the enzyme completely inactive when mutated, 
indicating its significance for the catalytic activity of hTP. The role previously attributed 
to Hisl 16 in hTP (Norman et al, 2004) as part of a proton shuttling mechanism could not 
be established with the results obtained from mutants H116F and H116K. Mutational 
work however introducing glutamic acid at position 116 would indicate whether Hisl 16 
is in fact involved in a proton shuttling mechanism or whether it is simply involved in 
hydrogen bonding interactions in the active site cleft.
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Mutations on Arg202 and Ser217, both of which interact directly with bound molecules 
at the active site of the enzyme, adversely affect the catalytic efficacy of hTP, as 
previously seen for Hisl 16. This is indicative of the significance of the network of 
interactions in which these residues are involved, for efficient binding and catalysis by 
hTP. In contrast to these mutations, mutagenesis on Ile214, which is part of the 
hydrophobic pocket of hTP, reduces the enzymatic activity without completely 
abolishing it. It is thus evident from the results obtained that alteration of the environment 
around the active site, hydrophobic pocket and phosphate-binding site affects and in 
some cases completely abolishes the enzymatic activity of hTP.
Tyrl99, whose role was so far unclear, was identified to modulate the enzymatic activity 
of hTP, according to the mutation introduced at that particular position. The results 
obtained, indicate that the ring structure is essential at that position as mutation of Tyr to 
Ala completely abolished the enzymatic activity. Mutants Y199F and Y199L retained 
some of the enzymatic activity, which was however reduced when compared to native 
hTP.
The role of phosphate in the enzymatic reaction catalysed by hTP was shown to be 
indispensable. Enzymatic activity assay results, where phosphate was not included, 
resembled an inactive enzyme. The rate of reaction and catalytic efficacy were too low to 
be determined, indicating the significance of phosphate for the phosphorolytic reaction 
catalysed by hTP.
The insights gained from this functional work will provide a platform for further 
structural and functional studies, which would contribute towards a better understanding 
of the mechanistic action of hTP. Experiments such as fluorescence resonance energy 
transfer (FRET; Lakowicz, 1999), which allow the monitoring of protein-protein or 
protein-ligand interactions, would be useful in understanding the details of the reactions 
catalysed by hTP. Further mutagenesis work, including double and triple mutants of the 
active site cleft, phosphate-binding site and hydrophobic pocket, would further confirm 
the role of certain residues in the catalytic activity of hTP. Mutagenesis on the glycine-
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rich loop, previously suggested to be involved in phosphate-binding (Walter et al., 1990) 
would indicate whether this is in fact a conserved and essential feature of members of the 
PyNP superfamily. Mutants could also be subjected to circular dichroism, which allows 
the identification of the secondary structure characteristics. Although unlikely, it is 
possible that certain mutations affect the enzyme in such a way that the folding of the 
protein does not occur properly. Biological assays, such as cell proliferation assays, could 
be used to further confirm the effect of hTP mutants. More specifically, as the angiogenic 
activity of hTP depends on the enzymatic activity, mutants which abolish the latter would 
be expected to abolish the angiogenic activity as well.
The determination of crystal structures of hTP in complex with thymidine, hTP mutants 
and hTP in transition states would provide a wealth of information, essential for 
understanding the enzyme and its mechanistic details. Results from these studies, coupled 
with isothermal titration calorimetry (ITC; O’Brien et al., 2000) would allow the design 
and development of more specific drugs, targeting the enzymatic activity of hTP. The 
implication of hTP in several pathological conditions and the drawbacks it causes in 
treatment of several of these cases make it a primary target for research, which aims not 
only at inhibiting its activity but in modulating it, especially in cases where it appears to 
overexpress. Its role in the nucleic acid homeostasis makes hTP an essential enzyme for 
the living organism which however needs to be controlled in order to maintain a 
physiological environment rather than a pathological condition.
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Chapter -  IV -
Modeling studies on Tissue Inhibitor 
of Metalloproteinase (TIMP) 
from Drosophila melanogaster
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4.1 Introduction  to the extracellu lar m atrix
Cellular differentiation occurring in the early stages of embryogenesis, results in the 
formation of four major types of cells: muscle cells, epithelial cells, connective cells and 
neuronal cells. Each of these cell types is organised in a tissue (muscle, epithelial, 
connective and nervous tissue respectively), which consists of cells and the surrounding 
matrix, known as the extracellular matrix (ECM). ECM is mainly composed of fibrous 
elements, such as collagen and elastin, link proteins, such as laminin and fibronectin and 
glycosaminoglycans (Figure 4.1). It also contains several minerals and fluids such as 














Figure 4.1: The extracellular matrix (ECM). (A) Illustration of connective tissue, where a 
variety of cells and ECM components, among which the fibroblasts, which secrete 
extracellular matrix. (B) A low-power electron micrograph of cells surrounded by 
extracellular matrix. The ECM supports and holds tissues and organs together providing 
thus an essential means for maintaining a balanced environment for cell-cell and cell- 
matrix interactions.(Figures adapted from: Alberts etal., 1994).'
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The structural details and function of ECM differ for different tissues and organs and 
although produced by the cells, ECM has been shown to influence cell behaviour. 
Turnover of ECM is therefore a crucial process for the control of cellular behaviour. It is 
essential in morphogenesis and tissue remodelling which occur during normal 
physiological conditions, such as embryonic development, wound healing and 
angiogenesis (Nagase and Woessner, 1999; Lund et al., 1999). Misregulation of ECM 
components turnover, either by lack of degradation or excessive degradation, is linked to 
a series of pathological conditions (see Chapter II -  Introduction to angiogenesis) 
(Halpert et al., 1996; Konttinen et al., 1999; Nelson et al., 2000).
Modulation of cell-matrix interactions occurs through the action of proteolytic systems. 
Enzymes involved in these proteolytic systems regulate cell proliferation, differentiation 
and cell death. A number of proteinases are involved in the regulation of cell-matrix 
composition, the principal being the matrix-degrading proteinases known as Matrix 
Metalloproteinases (MMPs) or matrixins and the members of the family called a 
disintegrin and a metalloproteinase (ADAM; Nagase and Woessner, 1999; Brew et al., 
2000; Nagase and Brew, 2002). The role of these molecules is highly controlled under 
physiological conditions as disruption can lead to atherosclerosis, rheumatoid arthritis 
and cancer invasion and metastasis. Regulation of MMP activity is achieved by a plasma 
protein, a-2 macroglobulin in the fluid phase and by endogenous inhibitors of MMPs, the 
tissue inhibitors of metalloproteinases (TIMPs) in the tissue phase (Nagase and Brew, 
2002). The latter group of inhibitors have attracted a lot of interest due to their potential 
use in therapeutics. TIMPs from several organisms have been studied to date and 
conserved characteristics among species have been identified, indicating potential 
evolutionary relationships. The study of one member of the TIMP family, Drosophila 
melanogaster TIMP (dTIMP) is the aim of this research. Analyses (sequence and 
structural) which provide information about its similarities and differences with its 
homologues from vertebrates and invertebrates are the means used to understand the 
evolutionary relationship among TIMPs.
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4.2 Matrix metalloproteinases -  MMPs
MMPs are multidomain proteins, actively involved in the remodeling of ECM; enzymes 
of this family can process almost every component of the extracellular matrix (Vu and 
Werb, 2000; Egeblad and Werb 2002; Puente et al., 2003). A total of 24 genetically 
distinct MMPs have been identified in humans, while the total number of MMPs has 
risen to 33 (MEROPS database; Rawlings et al., 2006; http://merops.sanger.ac.uk/). 
MMPs were initially categorised according to their substrate specificity, into 
collagenases, matrilysins, gelatinases, stromelysins, membrane-associated and others, 
while later a numerical classification was employed as the number of MMPs and the 
substrates they catalyse increased (Gross and Lapiere, 1962; Park et al., 2000; Uria and 
Lopez-Otin, 2000). They are zinc-dependent endopeptidases and belong to a large family 
of proteinases, namely the Metzincin superfamily. Active members of this family are 
zinc-dependent and share the motif: HEXXHXXGXXH and a methionine turn (Met-tum; 
Bode et al., 1993; Wei et al., 2003). The domain organisation is conserved not only 
among different MMPs but among different species as well.
Conserved MMP domains include a signal peptide, the amino-terminal propeptide 
domain, the catalytic domain, the hinge region and the hemopexin-like domain at the 
carboxy-terminal (Figure 4.2; Massova et al., 1998; Brew et al., 2000). The signal 
peptide is required to direct secretion from the cell. The propeptide domain consists of 
around 90 amino acids, including a conserved cysteine. This cysteine residue has been 
shown to be involved in MMP regulation: it interacts with a zinc ion, present in the 
catalytic domain and keeps the MMPs in an inactive form, known as zymogen (Massova 
et al., 1998). Removal of the propetide domain results in an active MMP form. The 
catalytic domain contains two zinc ions, one of which is essential for structural integrity, 
while the other is required for catalytic activity. Two to three calcium ions are also 
present in MMPs and have a role in the enzymatic activity and overall stability of the 
enzyme (Massova et al., 1998). A linker or hinge region (of variable lengths) bridges the 
catalytic domain with the hemopexin domain at the carboxy-terminal of MMPs. The 
hemopexin-like domain is a highly conserved P-propeller structure. It has been shown to 
be involved in recognition, both for the binding of MMPs to their substrates as well as to
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Figure 4.2: Domain organisation of MMPs. The conserved domains include the 
propeptide domain, the catalytic domain, the hinge region and the hemopexin-like 
domain. These domains are conserved not only among different types of MMPs, but 
among different species as well.
Additional domains, such as fibronectin-like repeats and hydrophobic repeats in the C- 
terminal domain have been identified in some of the members of the MMP family, 
increasing their structural diversity (Llano etal., 2000).
Research on MMPs has resulted in the structural characterisation of individual domains 
as well as of the full-length protein. A full-length structure of porcine MMP-1 was 
determined at 2.5 A resolution by X-ray crystallography (PDB ID 1FBL; Li et al., 1995). 
This structure illustrates the conserved domains, propeptide, catalytic domain, linker and 
hemopexin domain. Bound in the catalytic domain are two zinc ions (required for 
catalytic activity and structural integrity) and two calcium ions (required for the overall 
stability of the enzyme), while in the centre of the hemopexin four-bladed p-propeller 




Figure 43: Crystal structure of porcine MMP-1 determined at 2.5 A resolution (PDB ID : 
1FBL; Li et al, 1995). Shown here are the catalytic domain, the hinge region 
(highlighted in cyan) and the hemopexin domain. Bound in the catalytic domain are two 
zinc ions (shown in orange) and three calcium ions (shown in blue). Bound in the centre 
of the hemopexin domain is a calcium ion (shown in blue).
As the main enzymes that catalyse the turnover of the extracellular matrix, MMPs are 
involved in physiological processes such as embryonic development, wound healing, 
angiogenesis and apoptosis (Werb, 1997; Murphy and Gavrilovic, 1999; Yu and 
Stamenkovic, 2000), as well as in pathological processes such as arthritis, atherosclerosis 
and tumour invasion and metastasis (Williamson et al., 1990; Parks and Mecham, 1998).
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Their implication in pathological processes has been extensively studied and has been 
directly associated with loss or imperfections in control of MMP activity (Stemlicht and 
Werb, 2001). Regulation of MMP activity is thus of utmost importance for the 
maintenance of a physiological environment and for avoidance of tissue destruction. 
Three major ways are employed for the regulation of MMP activity: restrained release of 
MMPs, secretion of MMPs in an inactive form (zymogen), or inhibition of MMP activity 
by a2-macroglobulin and by endogenous inhibitors, TIMPs. MMPs are normally secreted 
in an inactive form. Dismption of the bond between cysteines and zinc, which keeps 
MMPs in the inactive form, (known as the cysteine-switch) results in a partially active 
intermediate form of the enzyme, which is rendered completely active upon cleavage of 
the propetide domain, by autocatalysis (Van Wart and Birkedal-Hansen, 1990). Once 
activated MMPs can be regulated by inhibitors such as a2-macroglobulin in the fluid 
phase or by TIMPs in the tissue phase. TIMPs form tight 1:1 non-covalent complexes 
with MMPs inhibiting in this way their endopeptidase activity.
4.3 Tissue Inhibitors of Matrix Metalloproteinases -  TIMPs
TIMPs are endogenous proteins that regulate MMP activity either directly by inhibiting 
their action or indirectly by modulating zymogen activation (Brew et al., 2000; Wei et 
al., 2003). TIMPs have been shown to be selectively expressed by spongiotrophoblastic 
cells, which separate the labyrinthine zone from the zone of giant cells. A border is 
formed in this way between foetal and maternal tissues (Henriet et al., 1999). Some 
TIMPs have the ability to associate with the pericellular environment, as seen from the 
binding of TIMP-2 to cell surface MT1-MMP (membrane-type 1 MMP) which acts as a 
'receptor' for proMMP-2 (progelatinase A) (Murphy and Knauper, 1997; Nagase, 1998). 
In mammals and higher organisms mature TIMPs are two-domain molecules organised in 
a single chain of around 180 amino acid residues (Williamson et al., 1990).
TIMPs serve numerous biological functions, such as connective tissue re-modelling, cell 
growth promotion, matrix binding, induction of apoptosis as well as inhibition of active 
MMPs and pro-MMP activation. TIMPs stoichiometrically bind to MMPs to the ratio of
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1:1 and irreversibly inactivate them. These enzymes are slow, tight-binding inhibitors and 
the TIMP-MMP complex is one of the tightest complexes known, with dissociation 
constant in the nanomolar range (Murphy and Willenbrock, 1995). Although some 
TIMPs have been shown to inhibit more than one MMP, there is generally specificity and 
selectivity in MMP inhibition by TIMPs.
TIMPs have also been shown to inhibit in vitro some members of the ADAM (a 
disintegrin and a metalloproteinase) family. Members of this family are multidomain 
proteins that consist of an N-terminal propeptide domain, a metalloproteinase domain, a 
disintegrin-like domain, a transmembrane domain and a cytoplasmic domain. They also 
contain the HEXXHXXGXXH motif for zinc binding in the catalytic domain (Black and 
White, 1998). One example of ADAM inhibition by TIMP is seen in Drosophila 
melanogaster (Hynes and Zhao, 2000), where seven ADAMs and ADAMTSs (TS -  
thrombospondin motif) genes have been identified. JTIMP is thought to be involved in 
the regulation of all or most of these metalloproteinases. Interaction of fiTTIMP with the 
ADAMs is thought to be mediated by the binding of dTIMP to the metalloproteinase 
domain of ADAMs. The inhibitory interactions have been shown to be of the 
subnanomolar range (Kashiwagi et al., 2001).
TIMP structure is conserved among species: all TIMPs have a 23-29 amino acid residue 
leader sequence that is cleaved to produce the mature TIMP protein (Pohar et al., 1999). 
A characteristic feature of TIMPs is the twelve cysteines, all of which are involved in 
disulphide bonds (Figure 4.4). Two of these cysteines are present in the very beginning of 
the N-terminal domain and form the C-x-C motif, which is characteristic of all mature 
TIMPs. The first cysteine is of major importance, as it coordinates the catalytic zinc of 
the MMP that each TIMP inhibits. Mammalian TIMPs have an N-terminal domain of 
about 125 amino acid residues and a smaller C-terminal domain of about 65 amino acid 
residues. Each domain is stabilised by three disulphide bonds (Figure 4.5). Of the two 
domains, the N-terminal domain of TIMPs has been shown to be solely responsible for 
their inhibitory activity (Williamson et al., 1990). The role of the C-terminal domain is
156
not yet clear, but it is thought to assist in the orientation of the inhibitory end when 
binding to the MMPs (Langton et al., 1998).
Figure 4.4: Characteristic motif of mature TIMPs, where the leader peptide has been 
cleaved. Shown here are the twelve cysteines, conserved in vertebrates and all involved 
in disulphide bonds (Figure adapted from: Prosite; Hulo et al, 2006).
The N-terminal domain of both vertebrate and invertebrate TIMPs contains an 
oligosaccharide/oligonucleotide binding fold, and thus falls in the OB-fold category 
(Williamson et al., 1994; Gomis-Ruth et al., 1997; Tuuttila et al., 1998). It consists of a 
five-stranded P-barrel, with a Greek key topology, and two a-helices; it is relatively rigid 
and shows almost no movement on binding to MMPs. Characteristic of TIMPs is also the 
presence of an AB loop in the N-terminal domain (Figure 4.5; PDB ID 1UEA; Gomis- 
Ruth et al., 1997). No functional significance has been assigned to the AB loop although 
it seems to differ in length and arrangement in different TIMPs. One such example is the 
more extended AB loop of human TIMP2 in contrast to human TIMP1. Although human 
TIMP2 has been shown to form stronger complexes than human TIMP1, it has not been 





Figure 4.5: Structure of human TIMP1 (PDB ID: 1UEA; Gomis-Ruth et al., 1997). 
Shown in ball-and-stick are the disulphide bonds, conserved in TIMPs; three in the N- 
terminal domain and three in the C-terminal domain. Also labelled are the OB fold and 
the AB loop, characteristic features of TIMPs.
To date, four genetically distinct TIMPs have been cloned and characterised in humans 
(TIMP1 to TIMP4), with crystal structures available for TIMP1 and TIMP2. The number 
of TIMPs differs amongst species with most mammals having either two or four TIMPs, 
while most invertebrates seem to have a single TIMP copy (e.g. Drosophila 
melanogaster). Some nematodes also have a single TIMP (e.g. Necator Americanus), 
while others have more TIMP alleles (e.g. Hydra vulgaris TIMP 1-2 and Ascaris 
lumbricoides TIMP 1 -5).
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4.3.1 TIMP from Drosophila melanogaster - i/TIMP
TIMPs from different species have been studied, mainly those from human and bovine. A 
TIMP that has recently attracted interest is the TIMP from Drosophila melanogaster 
(dTIMP), which seems to have some unique features, while retaining the basic 
characteristics of TIMPs. Only one TIMP copy is present in Drosophila melanogaster 
and is responsible for the inhibition of the two MMPs (D/wMMPl and DmMMP2) as well 
as for the control of the activity of seven ADAMs also present in Drosophila. Mutational 
studies where dTIMP was knocked-out, resulted in inflated wings, bloated gut and death 
(Godenschwege et al., 2000). This is most likely the result of unregulated MMP and 
ADAM activity, as </TIMP is the sole enzyme responsible for their regulation.
dTIMP is a single protein sequence, consisting of 210 amino acids, 12 of which are 
cysteines involved in disulphide bonds. The full-length molecule greatly resembles its 
mammalian homologue: the C-terminal region is tightly packed against the N-terminal 
OB-fold. The characteristic motif of C-x-C in the N-terminal domain of mature TIMPs is 
also present in dTIMP, after a leader sequence of 27 amino acids. Interestingly, cTTIMP 
appears to lack two cysteines from the N-terminal domain, having thus two, instead of 
three disulphide bonds in the N-terminal domain. In contrast to its mammalian 
homologues, dTIMP has two extra cysteines in the C-terminal domain, having thus an 
extra disulphide bond (four disulphide bonds in the C-terminal domain of dTIMP; Figure 
4.8; Brew et al., 2000). The inhibitory activity of fiTTIMP appears to originate from the N- 
terminal domain, a characteristic that is conserved among TIMPs (Wei et al., 2003). The 
functional importance of the C-terminal domain (consists of around 65 amino acids) is 
not yet clear, as its removal did not appear to affect the inhibitory activity of dTIMP, as 
seen from experiments where JNTIMP was tested for its inhibitory activity against 
human MMPs, DraMMPs and human TACE (tumour necrosis factor-a-converting 
enzyme). Experimental results revealed that cfTIMP is a potent inhibitor of MMPs (from 
human and Drosophila melanogaster) as well as of TACE (human and Drosophila 
melanogaster) (Wei et al., 2003). Conservation of the N-terminal inhibitory activity in 
the absence of one disulphide bond might indicate that the third disulphide bond observed 
in mammalian TIMPs is an evolutionary acquisition rather than a conserved TIMP
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feature. Wei and co-workers (Wei et al., 2003), suggested that c/TIMP is most similar to 
mammalian TIMP3, suggesting that the latter is more closely related to the ancestral 
TIMP gene than the rest of mammalian TIMP classes. Hence, according to these findings, 
TIMPs classes 1, 2 and 4 are more recent and have probably diverged through gene 
duplication or mutational changes (Wei et al., 2003). Brew and co-workers (Brew et al., 
2000), proposed that TIMP1 has undergone the lowest rate of evolutionary change, 
making it the most proximal to the ancestral TIMP, from which the rest of the human 
TIMPs originated (Brew et al., 2000). It is evident that the findings of the two groups are 
not in agreement, indicating that further research in cTTIMP and its proximity to one of 
the human TIMPs would be required, in order to understand the ancestry and 
evolutionary relationship among TIMPs.
In order to obtain more information about ancestry and understand the evolutionary 
relationship of TIMPs, multiple sequence alignments and phylogenetic tree analyses were 
carried out. The structures, where available, and models (created for TIMPs whose 
structure has not been reported yet) were aligned and the root mean square deviation was 
calculated, as an indication of similarity or divergence. For that purpose, TIMP sequences 
from vertebrates as well as invertebrates were used in this study; all sequences used, are 
provided and discussed later in ‘Results and Discussion’ section (Table 4.2).
4.4 Bioinformatic analysis
Protein structure prediction is a widely used method that employs bioinformatic tools and 
aims at the determination of the three-dimensional structure of proteins, from their amino 
acid sequence only (primary structure). There are two types of protein structure 
prediction: Ab initio protein modeling and homology modeling. The first method aims at 
determining the three dimensional structure of a protein based on physical properties. 
This method involves algorithms like Rosetta and Monte Carlo, while Ramachandran plot 
can also be used for ab initio modeling. Ab initio protein modeling can be considered to 
consist of two steps: the generation of a scoring (energy) function that distinguishes 
between native or native-like structures, and a search method to explore the
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conformational space, which is an energy function that should account for all interactions 
between all pairs of atoms in the polypeptide chain.
Homology modeling for protein structure prediction aims at determining the structure of 
a protein based on previously determined three-dimensional structures of homologous 
proteins. This method is based on the evolutionary conservation of the fold of a protein. 
A sequence alignment of the protein of interest with homologous proteins, whose three- 
dimensional structures are available, is the first step employed by this method, so as to 
find the closest match that will be used as a template. Hence, it is a more accurate method 
for protein structure prediction than ab initio modeling, but requires that structures of 
homologous proteins are available. Homology modeling was the method used for 
generating a model for dTIMP, as structures of homologous proteins are available. 
Bioinformatic structure prediction can be considered to consist of eight stages: literature 
search, sequence search, motif search, sequence alignment, secondary structure 
prediction, tertiary structure prediction, model refinement and finally validation of the 
















Literature search is fundamental for structure prediction, as it provides information about 
the protein of interest, the structure and function of homologous proteins and any 
previous efforts for predicting the structure of the protein of interest. The pubmed 
database (http://www.ncbi.nlm.nih.gov/) allows for an extensive search on literature with 
links on the national center for biotechnology information, the national library of 
medicine and the national institutes of health. It is essential however to be critical on the 
information retrieved as literature may contain errors or the protein of interest might not 
be a typical member of well-characterised families. Hence an extensive literature search 
should be the first step in understanding the characteristics of the protein of interest and 
identifying homologues that can be used in further steps of the protein structure 
prediction.
4.4.2 Sequence search
Sequence search is an essential step in identifying protein sequences ‘related’ to the 
sequence of the protein of interest, that have been previously characterised and can be 
used as templates for building the model of the query. A tool that is most commonly used 
for sequence search is BLAST (Altschul et al., 1990), a web-based program accessible 
via NCBI. BLAST (Altschul et al., 1990) searches for local, ungapped alignments, which 
might prove to be a disadvantage, as low sequence similarity does not necessarily mean 
low structural similarity. Another web-based program which is frequently used for 
sequence search is FASTA (Pearson, 1990; Pearson and Lipman, 1998). This is a more 
sensitive web-based program that looks for small regions of similarity between the query 
and other known protein sequences. This type of search yields a list of sequences that are 
‘good matches’ for the query and are presented in descending order. Apart from the 
retrieved sequences, each program provides a list of parameters including the length of 
the retrieved sequences, the similarity with the query sequence and the expectation value. 
The expectation value (also known as the E value) represents the average amount one 
expects something to re-occur in the database where it was originally searched. Hence, 
the lower the E value, the more significant the score and the better the indication of the 
proximity of the sequences retrieved by the database. More information on the protein of
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interest can be obtained via the analysis of its amino acid sequence in the Protparam 
service (Gasteiger et al., 2005), available in the Expert Protein Analysis System server 
(www.expasy.org). Such an analysis can provide information on the molecular weight, 
the isoelectric point (pi), the extinction coefficient and the instability index of the protein 
of interest, which can prove to be very helpful in subsequent experimental steps.
4.4.3 Domain search
Domain search refers to the search for short, tightly defined patterns of polypeptide 
sequences that might be indicative of protein function. It produces a list of known 
domains, families and sites which are associated with protein function that have been 
identified in the query sequence. The most commonly used tool for motif search is 
Prosite (Hulo et al., 2006). Prosite allows the identification of possible domains and 
characteristic features (such as conserved disulphide bonds) according to the amino acid 
sequence of the protein of interest and provides literature documentation available on the 
identified characteristics. Hence, findings obtained from Prosite provide information for 
the protein of interest, by examination of members of the same family, both in structural 
and functional level. A web-based server which allows the prediction of domains based 
on the deposited sequence of the protein of interest is Meta -  DP (Meta Domain 
Prediction), which has the advantage to be coupled to different prediction servers. This 
allows the prediction of domains in the query sequence, even if no information for a 
homologue to the query protein is available (Saini and Fischer, 2005).
4.4.4 Sequence alignment
Preliminary sequence alignments are provided by BLAST, which aligns each of the 
results retrieved against the query. Multiple sequence alignments allow the simultaneous 
alignment of more than one sequence. Commonly used alignment programs are ClustalW 
(Thompson et al,. 1994) and Tcoffee (Notredame et al., 2000; Poirot et al., 2003). This is 
advantageous in that it highlights conserved residues, which in turn might prove to be 
significant for the structure and function of the protein of interest. Conserved regions 
identified in this way can be used for more sensitive analyses, using either a domain
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search or a PSI-BLAST (Altschul et al., 1997) search, which provides additional 
information on profiles identified in the deposited sequences.
4.4.5 Secondary structure prediction
Secondary structure prediction is the identification of secondary structure elements, 
which in turn can provide information on the topology of the protein of interest. Several 
web-based servers are available for the prediction of the secondary structure of a protein, 
where the amino acid sequence of the query is submitted and the results are usually 
mailed back to the user. Such programs use either sequence alignments or available PDB 
files in order to identify similarities between the query sequence and a protein (usually 
homologous) which has been already characterised. PHD is one such web-based program 
with an accuracy of around 71.4% for proteins which have at least one known homologue 
(Rost et al., 1994). Another web-based server for protein secondary structure prediction 
is JPRED, which was developed by the University of Dundee and has an accuracy of 
around 76.4% (Cuff et al., 1998). PROF is software for protein secondary structure 
prediction which can be accessed online, or downloaded for private use. It was developed 
from the University of Aberystwyth and requires PSI-BLAST and ClustalW in order to 
operate (Thompson et al., 1994). A commonly used web-based server for protein 
secondary structure prediction is PSIPRED, using a PSI-BLAST output as its input file 
(Jones, 1999). This server is advantageous in that it allows the prediction of protein 
secondary structure, the transmembrane topology (if applicable) and the fold recognition, 
based on the amino acid sequence. SAM-T99 uses Hidden Markov Models (HMM), a 
statistical method which uses available PDB structures in order to predict the secondary 
structure of the deposited query sequence (Karplus et al., 1999). SSpro is another web- 
based server which uses homology analysis for the prediction of protein secondary 
structure (Cheng et al., 2005). An extensive list of available programs for protein 
secondary structure prediction is available on the Meta-Predict Protein server (Eyrich and 
Rost, 2003), which also provides a model of the query sequence, if requested, and on a 
web-page developed by the University of York for analysis and modeling of proteins 
(http://www.ysbl.york.ac.Uk/~tom/structure.html#2D-prediction). Considering all the 
information that can be retrieved by such analyses, it is possible to say that secondary
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structure prediction gives a “first image” of the tertiary structure and the overall folding 
of the query protein. Further information about the tertiary structure and a prediction of 
the structure of the protein of interest, can be obtained by tertiary structure prediction.
4.4.6 Tertiary structure prediction
Tertiary structure prediction refers to the modeling of the query protein, using all the data 
collected in previous steps. The most commonly used program for molecular modeling is 
the SWISS-MODEL server (Schwede et al., 2003), an automated comparative modeling 
server. SWISS-MODEL (Schwede et al., 2003) hides all the technical details and yields a 
three-dimensional model of the query. The choices in SWISS-MODEL (Schwede et al.,
2003) include the first approach mode, where the query sequence is deposited and the 
structure is predicted using known structures as templates. The input can also be a 
sequence alignment (alignment interface) where the user can choose the best match to the 
query and use it as a template. Finally, project (optimise) mode allows the deposition of 
the sequence and the superimposed structures to be used as templates. A three- 
dimensional model of the query is then built according to the structures chosen as 
templates. Meta-protein predict (MPP; Eyrich and Rost, 2003) is a web-based server for 
the creation of a three-dimensional model, based on the amino acid sequence of the 
protein of interest. MPP allows access to other web-based servers which provide 
information on the secondary structure prediction of the protein of interest.
Once a model for the protein of interest has been generated, it is usually a good idea to 
check the structural features of proteins that belong to the same ‘class’. Two web-based 
servers which are commonly used for retrieving information on proteins according to 
their ‘class’ are the structural classification of proteins -  SCOP (Murzin et al., 1995) and 
the classification according to class, architecture, topology and homologous superfamily 
-  CATH (Orengo et al., 1997) databases, which provide information on the classification 
of protein patterns. Both can be accessed via TOPS (Michalopoulos et al., 2004), one of 
the most commonly used topology databases. TOPS (Michalopoulos et al., 2004) 
produces a first estimation of the pattern and topology of the protein of interest as well as 
a cartoon representation of the organisation of the domains in query protein. The division
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of the primary structure into secondary structure elements can be then compared to the 
protein secondary structure prediction outputs and the model generated for the protein of 
interest.
4.4.7 Model refinement
Once the three-dimensional model of the protein of interest is built, refinement is 
essential, in order to ensure the model is meaningful, informative and devoid of any steric 
hindrances. Model refinement refers to the use of physico-chemical modeling methods 
for the correction of mistakes in the model. Most common errors in modeled structures 
involve distorted geometry (bond angles and bond lengths) and overlapping atoms, which 
can be corrected during model refinement. Input files from CNS (Briinger et al., 1998) 
can be used for refining the model, by removing the crystal card from the input files, 
which then allows the use of the coordinate file and set parameters for refining. Most 
commonly used steps for model refinement include energy minimisation and molecular 
dynamics. After the model is refined, it should also be checked manually, in one of the 
graphics programs, such as ‘O’ (Jones et al., 1991) and ‘Coot’ (Emsley and Cowtan,
2004).
4.4.8 Model validation
As with structure validation, model validation is the fine-tuning step, where small errors 
are corrected, using the same methods that are used for three dimensional structures 
before their deposition to the protein data bank (PDB; Berman et al., 2000). PROCHECK 
(Laskowski et al., 1993) is the most commonly used program for validating protein 
structures and models. Once a model has been refined and validated, it can be deposited 
to SWISS MODEL repository, a database of models, currently counting 1,341,793 
deposited models.
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4.5 Results and discussion
Literature search in pubmed provided background information on dTIMP, its proposed 
characteristics and features. Once sufficient information was obtained, the next step was 
to retrieve the amino acid sequence and analyse it. The amino acid sequence of fiTTIMP 
was retrieved from the expasy website, with primary accession number Q9VH14. cTTIMP 
consists of 210 amino acids, while the mature protein, starting with the C-x-C motif, 
consists of 183 amino acids. Mature dTIMP has a molecular weight of ~21kDa and a 
theoretical pi of 9.6. According to its instability index (II), calculated by Protparam, 
based on the amino acid sequence, *fTIMP can be classified as unstable, with an II value 
of 55.5 (Gasteiger et al., 2005). A search against the PDB, using BLAST as a tool, 
yielded a series of matches, with the best ‘hits’ ranked first in the results list (best ‘hits’ 
for tfTIMP are provided in Table 4.1).
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Table 4.1: BLAST search against the Protein Data Bank.
Results from the BLAST search Expectation Value
2E2D -  Flexibility and variability of TIMP binding: X-ray 5e
structure of the complex between collagenase-3/MMP-13 and
TIMP-2 (Maskos et al., 2007)
Homo sapiens and Bos Taurus
1BUV -  Crystal structure of MT1 -MMP-TIMP-2 complex 5e*10
(Femandez-Catalan et al., 1998)
Homo sapiens and Bos taurus
1U EA- MMP-3/TIMP-1 complex (Bode et a l, 1997) 2e'8
Homo sapiens
2TMP -  N-terminal domain of tissue inhibitor of metalloproteinase 6e'7
N-TIMP2 (Muskett et a l , 1998)
Homo sapiens
2JOT -  Crystal structure of the catalytic domain of MMP1 in 3e'6
complex with the inhibitory domain of TIMP 1. (Iyer et al., 2007)
Homo sapiens
Note: The sequences with the highest expectation value are given in this table. Not all 
results of complexes of MMPs with TIMP2 are provided, as the expectation values were 
all in the same range (e‘10).
Results obtained include structures that have been determined by NMR and/or X-ray 
crystallography. The best ‘hit’ obtained was the structure of the complex of MMP13- 
TIMP2 (PDB ID 2E2D; Maskos et al., 2007), with an expectation value of 5e'10. Several 
hits with an expectation value of e '10 were retrieved for complexes including /zTIMP2.
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A Prosite analysis of cTTIMP (Hulo et al., 2006) revealed a netrin module (NTR module), 
which is typically found in the C-terminal domains of netrins, as well as in the N-terminal 
domains of TIMPs. A typical feature of the NTR module are six cysteines, (conserved in 
proteins that contain this particular module), which most probably form disulphide bonds, 
just as observed in TIMPs. Domain analysis using the Meta-DP server (Saini and Fischer,
2005) also indicated an NTR domain in the amino acid sequence of cfTIMP, just as 
previously obtained by Prosite (Hulo et al., 2006).
Based on the best ‘hits’ obtained from BLAST, TIMPs from vertebrate and invertebrate 
sources were selected for the following steps of the bioinformatics analysis and modeling 
process. Selected TIMPs are provided below, in Table 4.2.
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Table 4.2: TIMPs included in the analysis and building of the dTIMP model.




Drosophila TIMP 210 Q9VH14
TIMPs from vertebrates
Homo sapiens Human TIMP1 207 P01033
TIMP2 220 P I6035
TIMP3 211 P35625
TIMP4 224 Q99727








Scyliorhinus torazame Cloudy catshark TIMP3 214 Q9W6B4
Xenopus laevis African clawed TIMP3 214 073746
frog
TIMPs from invertebrates
Pristionchus pacificus TIMP 136 -
Necator americanus Strongylida TIMP 140 -
Hydra TIMP1 TIMP1 201 -
Hydra TIMP2 TIMP2 201 -
Sources of TIMPs used in multiple sequence alignments. The mammalian sequences
have been retrieved from the expasy website while nematode sequences were provided 
by our collaborators in Florida (Dr. Keith Brew, Florida Atlantic University).
TIMPs from homo sapiens, mus musculus and rattus norvegicus were selected as 
representatives of mammalian TIMPs which consist of four TIMP classes. Scyliorhius 
torazame and Xenopus laevis were also selected for the group of vertebrate TIMPs to be 
compared to dTIMP. As dTIMP is expected to represent a more ancestral TIMP form, 
invertebrate TIMPs were also included in the analysis. Invertebrate TIMPs examined, 
include Pristionchus pacificus, which is a free-living bacterivore nematode and Necator
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americanus which is a type of hookworm that severely affects humans, leading to severe 
blood loss, cardiac and pulmonary complications. Also used in this analysis was Hydra, 
one of the most well known members of the hydrozoan species. Comparative analysis of 
TIMP representatives from vertebrate and invertebrate species against </TIMP would 
provide information about their proximity and probable evolutionary relationship. Using 
all the results from secondary structure prediction, the available structures and homology 
models, tertiary structure prediction tools were employed to generate a model for dTIMP 
(Figure 4.7). The model generated was energy minimised (using CNS; Brunger et al., 
1998) and validated in order to ensure it was devoid of any steric hindrances.
A B  L O O P
O B  F O L D
Figure 4.7: Model generated for ifTIMP. Shown in ball-and-stick are the disulphide 
bonds, conserved in all TIMPs. The organisation of disulphide bonds in </TIMP differs 
from its mammalian homologues. Instead of three disulphide bonds in each domain, 
</TIMP has one less in the N-terminal domain, ‘compensated’ by an extra bond in the C- 
terminal domain. Also labeled are the OB fold and the AB loop, characteristic features of 
all TIMPs.
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The homology model generated for dTIMP resembles its mammalian homologues. The 
N-terminal domain contains an OB fold and an AB loop, just as seen from the three 
dimensional structures for ATIMP1 and ATIMP2. The C-terminal domain appears to be 
less ordered, with several loops connecting the secondary structural elements of this 
domain. Whilst six disulphide bonds are observed in cTTIMP their organisation and 
dispersal between the domains is different.
To identify the proximity or distance in structural/model level the root mean square 
deviation was calculated for all aligned structures and models. Due to differences in 
TIMPs from different sources, two groups have been created and analysed against 
(/TIMP: dTIMP against vertebrate TIMPs and fiTTIMP against invertebrate TIMPs. Two 
insect TIMPs have also been studied and analysed against cTTIMP.
4.5.1 dTIMP against vertebrate TIMPs
The amino acid sequence of tfTIMP was aligned against its vertebrate homologues, using 
a multiple sequence alignment tool, in T-coffee, a web-based server (Notredame et al., 
2000; Poirot et al., 2003; Figure 4.8). The alignment obtained was then used as an input 
for Boxshade, a web-based server that identifies conserved regions on multiple sequences 
alignments and colours them accordingly (Figure 4.8).
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Figure 4.8: Full length sequence alignment of </TIMP against vertebrate TIMPs. Conserved
and equivalent residues are highlighted here using Boxshade. </TIMP only shares a few of the
conserved residues of vertebrate TIMPs, most importantly the conserved cysteines. Multiple
sequence alignment was generated using the T-coffee server (Notredame et al., 2000; Poirot
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et al., 2003).
Several areas of black background, as seen in the sequence alignment, are shared among 
vertebrate TIMPs, indicating conserved residues. The overall sequence homology of the 
sequences aligned was 51.3%. Although the percentile sequence homology is high, 
cTTIMP does not share most of the conserved regions of vertebrate TIMPs, as seen from 
the Boxshade colouring of the multiple sequence alignment.
Phylogenetic tree analysis was performed to identify which class of vertebrate TIMPs is 
most proximal to the ancestral TIMP form, represented by ifTIMP. The tool employed for 
generating the phylogenetic tree, in the form of a phylogram, was the Genebee server 
(Brodsky et al, 1992), a web-based tool for multiple sequence alignments and 
phylogenetic tree generation (Figure 4.9).
dTIMP 














Figure 4.9: Phylogenetic tree analysis of dTIMP and vertebrate TIMPs. As the most 
ancestral TIMP form, dTIMP forms the root of this tree while vertebrate TIMPs occupy 
subsequent branches. Most proximal to dTIMP appears to be ATIMPl while the class of 
TIMP3 appears to be more distant to dTIMP.
As seen in Figure 4.9, dTIMP does not “cluster” with any of the vertebrate TIMPs and as 
representative of the most ancestral form dTIMP is the root of the phylogenetic tree. It 
has been previously suggested that /*TIMP1 has undergone the lowest rate of 
evolutionary change, and is thus the most proximal of all TIMPs to the ancestral form
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(Brew et al., 2000). This is in agreement with the results obtained from the phylogenetic 
tree analysis: /zTIMPl appears to be closer to ifflMP than any other vertebrate TIMPs, as 
they both appear to form the root of the tree. This in not however the case for the other 
vertebrate TIMP 1 members; mouse TIMP1 and rat TIMP1 appear to occur later, 
‘branching o ff from /zTIMPl. ATIMP2 is the next class of TIMPs most proximal to 
</TIMP as it occurs directly after /iTIMPl. Following are ATIMP3 and /zTIMP4, which 
occupy ‘later’ branches in the phylogenetic tree, indicating thus that they probably 
evolved later. Of all vertebrate TIMPs used in this analysis, /zTIMPs appear to be most 
proximal to dTIMP, rather than TIMPs from mouse (wTIMPs) and rat (rTIMPs).
In order to identify the proximity or distance of the vertebrate TIMPs to dTIMP, 
structures (where available) and homology models, were aligned and rmsd calculation 
was used as measure of proximity or distance (Table 4.3; the better the structures align 
the lower the rmsd). As mentioned above there are limited structures of TIMPs available, 
so for vertebrate TIMPs with no structure reported, homology models were produced and 
aligned against dTIMP. All models generated were energy minimised using CNS 
(Brunger et al., 1998) in order to be consistent and compare meaningful models.
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Table 4.3: Structural comparison of dTIMP against vertebrate TIMPs.
Structures/models aligned RMSD
(A)














RMSD is calculated for backbone (Ca) only using the program SPDBV (Guex and Peitsch, 
1997).
Vertebrate TIMPs shared an overall sequence homology of 51.3% with dTIMP. 
Structural alignment of different TIMP classes against dTIMP shows little variation, as 
seen from the rmsd. Alignment of vertebrate TIMP1 class against dTIMP yielded an rmsd 
in the range of 1.6A, indicating the differences among the structures and homology 
models that were aligned, although the homology percentage of this vertebrate class 
against dTIMP was 54.4%. It is thus evident that sequence homology and phylogenetic
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proximity cannot be used as a ‘representation’ or ‘indication’ of possible structural 
similarity.
Vertebrate TIMP2 class has much higher sequence homology to dTIMP, in the range of 
62%, indicating its proximity to cTTIMP, in the sequence level. Structures and models of 
this vertebrate class yielded an rmsd in the range of 1.4-1.5A when aligned against 
dTIMP. This rmsd range is not significantly lower than that obtained for vertebrate 
TIMP1 against dTIMP, even though the sequence homology is significantly high.
Similar are the findings from the alignment of members of the vertebrate TIMP3 class 
(including X. laevis and S. torazame) against cTTIMP: sequence homology is even higher in 
this case, reaching the range of 72%. Structural alignment of vertebrate TIMP3 against 
fiTTIMP yields an rmsd in the range of 1.4A, slightly lower than those obtained 
previously, but not significantly different.
Sequence homology of vertebrate TIMP4 against dTIMP is in the range of 64%, around 
the same range as that of vertebrate TIMP2. Structural similarity, as expressed by rmsd, 
for vertebrate TIMP2 against dTIMP is in the range of 1.5A, again in the same range as 
that observed for members of the vertebrate TIMP2 class.
Based on these findings, it is possible to say that, although closer in the phylogenetic tree, 
TIMP1 is not most proximal to gHTMP in sequence level. This appears to be vertebrate 
TIMP3, with a very high sequence homology percent, which is not however supported by 
the phylogenetic tree findings. This is rather interesting as sequence homology would be 
expected to agree with phylogenetic proximity. It is not thus yet clear whether vertebrate 
TIMP1 or TIMP3 is the most proximal vertebrate class to </TIMP. Vertebrate TIMP 2 and 
TIMP4 on the other hand appear to be around the same ranges, both in sequence 
homology and structural similarity against </TIMP. It should be mentioned that as models 
were used for the structural alignment, further crystallographic studies need to be carried 
out in order to authenticate the results of the present study.
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4.5.2 dTIMP against invertebrate TIMPs
TIMPs have also been identified in invertebrates with no structures reported to date. 
Some invertebrates have a single TIMP copy while others have more TIMP alleles (e.g 
Ascaris). Invertebrate TIMPs are considered to represent the more ancestral TIMP form, 
from which possibly the rest of TIMPs originated. In order to understand thus the 
proximity of fiflTMP to invertebrate TIMPs, and identify the rooting TIMPs and the 
evolutionary relationship that links the members of this group, sequence alignments, 
phylogenetic tree analysis and structural alignment were carried out for dTIMP against 
the homology models generated for invertebrate TIMPs.
Sequence alignment of dTIMP against invertebrate TIMPs yielded a homology of 23%. 
Interestingly, invertebrates “lack” the equivalent of the vertebrate TIMP C-terminal 
domain (Figure 4.10). In contrast however to other invertebrates, the two TIMP alleles 
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Figure 4.10: Sequence alignment of dTIMP against invertebrate TIMPs. Invertebrate 
TIMPs, with the exception of the two TIMP alleles from hydra, appear to Tack’ the 
equivalent to the vertebrate C-terminal domain.
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To identify whether the lack of the C-terminal domain from invertebrate TIMPs is the 
sole reason for this low sequence homology, sequence alignment was carried out as 
previously, with one difference: C-terminal domains of dTIMP and the two hydra TIMPs 
were deleted and their N-terminal domains were aligned against the invertebrate TIMPs 
(Figure 4.11). This yielded a sequence homology of 30%, slightly only higher than that 
obtained previously. It is however possible to suggest that the C-terminal domain in 
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Figure 4.11: Sequence alignment of N-</TIMP and N-/zy<iraTIMPl and N-hydraTlM?2 
against invertebrate TIMPs. It is evident that even when the C-terminal is removed from 
dTIMP and the two hydra TIMPs, the sequence similarity with the invertebrate TIMPs is 
low.
Multiple sequence alignments of both sets of sequences (with and without the C-terminal 
domains in dTIMP and hydra TIMPs) indicated several differences of the sequences 
examined. In both cases most regions of the sequences are not conserved for dTIMP and 
invertebrate TIMPs, with the exception of the two hydra TIMPs. Due to the similarities 
observed for dTIMP and hydra TIMPs, the sequence homology was calculated for these 
sequences only, and was found to be around 49%. This is significantly higher than the 
homology percent obtained for the comparison of dTIMP against all invertebrate TIMPs. 
This finding indicates the proximity of dTIMP to hydra TIMPs rather than invertebrates
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TIMPs, as a whole. This proximity of the three TIMPs would thus be expected to be 
evident from the phylogenetic tree analysis as well.
Both sets of sequences examined, (full-length sequences and same set of sequences, after 
removing the C-terminal domain from tfTIMP and hydra TIMPs) yielded the same 
clusters in the phylogenetic tree (hence the phylogenetic tree of the second set of 
sequences is not included). The root of the tree is formed by dTIMP and P.pacificus. 
Hydra TIMP1 ‘branches off from fiTTIMP, while hydra TIMP2 appears to occur later. 
N. americanus seems to ‘branch o ff from P.pacificus indicating the proximity of these 
two invertebrate TIMPs and their difference from hydra TIMPs and cTTIMP (Figure 
4.12). Hence, as expected from the sequence homology and multiple sequence alignment, 







Figure 4.12: Phylogenetic tree analysis of cTTIMP against invertebrate TIMPs. The root
of the phylogenetic tree is generated by dTIMP and P.pacificus while the rest of the 
invertebrate TIMPs occupy later branches.
As no structures have been reported for invertebrate TIMPs, homology models were 
generated and aligned against the model generated for *fTIMP. The results obtained from 
the alignment of the models are provided in Table 4.4.
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dTIMP-Necator americanus TIMP 1.3
dY\MP—Pristionchus pacificus TIMP 1.4
RMSD is calculated for backbone (C“) only using the program SPDBV (Guex and Peitsch,
1997).
From all homology models of invertebrates aligned against (/TIMP, N. americanus 
aligned better against </TIMP, with an rmsd of 1.3A, followed by P.pacificus with an 
rmsd of -1.4A. Hydra TIMP1 and TIMP2 -shown to be most proximal to dTIMP from 
the phylogenetic tree analysis and the sequence homology- yielded rmsd of 1.4A and 
1.5A respectively. It is highly likely that the results obtained for the alignments of *fTIMP 
against invertebrate TIMPs are not sufficiently accurate, as the latter group of TIMPs 
consists of only one domain, which probably aligns well against the N-terminal domain 
of dTIMP, as this domain is considered to be conserved and bare the conserved inhibitory 
activity of TIMPs. In contrast, the two hydra TIMPs, which are two-domain proteins 
probably have a higher rmsd against <fTIMP due to differences in both N and C-terminal 
domains of the homology models.
4.5.3 dTIMP against insect TIMPs
Two putative TIMPs have been more recently identified in insects Anopheles gambiae 
and Aedes aegypti. The genome of Anopheles gambiae, the principal vector of malaria in 
Africa, was sequenced in 2002 (Holt et al., 2002). On chromosome 2R, a locus (locus tag 
ENSANGG00000012010; primary accession number A0NG61) has been identified to be 
similar to tissue inhibitor of metalloproteinase from Drosophila melanogaster (t/TIMP). 
This is a 216 amino acid sequence in length, similar to the usual TIMP length that ranges
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from 180 to 210 amino acid residues. The conserved C-X-C motif at the N-terminal 
domain of mature TIMPs is also present in this protein, preceded by a leader sequence of 
28 amino acid residues. Preliminary analysis on this sequence lead to the identification of 
an NTR domain, characteristic of TIMPs, and thus allowed its classification as TIMP1. 
Genome sequencing of Aedes aegypti, a tropical mosquito that is frequently used as a 
host for dengue fever and yellow fever viruses, (Nene et al., 2007) lead to the 
identification of a 213 amino acid protein, with the characteristic C-x-C motif on the N- 
terminal domain. Preliminary analysis on this protein revealed the presence of an NTR 
domain, and was classified as a putative TIMP3. In order to identify the proximity of the 
two insect TIMPs to dTIMP, as well as to vertebrate and invertebrate TIMPs, an analysis 
of all TIMPs was carried out.
Sequence alignment of the three insect TIMPs, AgTIMP, A^TIMP and dTIMP and 
calculation of their sequence homology, reveals that they share an overall homology of 
55% with several conserved regions, as seen from the output of boxshade (Figure 4.13). 
Hence, it is possible to say that although the classification of the two insect proteins as 
TIMPs is preliminary, the high sequence homology to dTIMP and the conserved areas as 
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Figure 4.13: Boxshade output for the sequence alignment of the three insect TIMPs: 
/f.tfTIMP, dTIMP and AgTIMP. Several regions appear to be conserved among the three 
insect TIMPs. Shown in black background are the conserved amino acid residues, shown
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in grey are the equivalent amino acid residues and in white background are residues 
which are different in the three insect TIMPs.
Analysis of insect TIMPs against vertebrate TIMPs yielded a homology of 43%, while 
the homology against invertebrate TIMPs was only 28%, which is within the same range 
as the percentage homology obtained for full-length dTIMP against invertebrate TIMPs. 
It is important however to remember that invertebrate TIMPs are lacking the vertebrate 
C-terminal domain and are thus much smaller. In order to evaluate the proximity of 
TIMPs from different species, a phylogenetic tree analysis of all TIMPs used in this study 






















Figure 4.14: Phylogenetic tree analysis of insect TIMPs against vertebrate and 
invertebrate homologues. The root of the phylogenetic tree is formed by invertebrate 
TIMPs, from which the rest of TIMPs originated.
As seen in the phylogenetic tree analysis (Figure 4.14) the most ancestral TIMP forms are 
those present in invertebrates, and insects, as well as their human TIMP1 homologue. 
These are followed by the rest of the vertebrate TIMP homologues: of the four classes of
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vertebrate TIMPs, TIMP2, TIMP3 and finally TIMP4. It is hence possible to suggest, 
based on these findings, that invertebrate TIMPs represent the most ancestral TIMP form, 
from which the insect and vertebrate TIMPs originated. Conservation of disulphide bonds 
and the characteristic C-x-C motif in the N-terminal domain of all TIMPs verifies their 
common ancestry and their evolutional proximity.
Phylogeny provides information on evolutionary history, showing how organisms are 
related (rather than providing evidence for evolution as such). All organisms examined in 
this study are eukaryotes and belong to the animal kingdom (metazoa). Most ancestral of 
all is hydra belonging to the phylum cnidaria. Nematodes are the next in line, followed 
by cTTIMP and finally the vertebrates. Hydra TIMPs, seen as rooting sequences in the 
phylogenetic trees, provide valuable information on the evolutionary relationship of 
TIMPs.
A closer look at the amino acid sequence of TIMPs from different species reveals a detail 
of key significance. Invertebrate TIMPs, as one-domain molecules, contain a total of six 
cysteines, probably all involved in disulphide bonds. It is however not possible to 
extrapolate that to vertebrates TIMPs, which have an extra domain. Hence, it would be 
‘incorrect’ to include invertebrate TIMPs in the following type of comparison, as due to 
the lack of one domain, all assumptions made would be inaccurate. Insect TIMPs present 
an interesting discrepancy: AaTIMP and AgTIMP contain a total of fourteen cysteines, 
by two more than those observed in </TIMP and vertebrate TIMPs. This is also the case 
for the two TIMP alleles present in hydra: a total of fourteen cysteines would account for 
seven disulphide bonds. As seen from Figure 4.14, hydra and insect TIMPs appear 
‘earlier’ in the phylogenetic tree than some of their vertebrate homologues (with the 
exception of ATIMP1), possibly suggesting that that the total number of cysteines, 
conserved in more ancestral TIMPs, are fourteen and the conserved disulphide bonds are 
therefore seven. The reduction in the number of disulphide bonds observed in dTIMP and 
vertebrate TIMPs can be considered to be a result of evolution and the different needs of 
different species. Even if this is the case however, <iTIMP differs from the rest TIMPs 
that have six disulphide bonds, in that the organisation of these bonds is not the same as
185
that seen in its vertebrate homologues. Based on these findings, it is possible to suggest 
that d llM ?  is an ‘evolutionary intermediate’, between the most ancestral TIMP form and 
the vertebrate TIMPs which appeared later.
4.6 Conclusion and future work
The turnover of the extracellular matrix is a crucial process proven to control cellular 
behaviour. Normal physiological processes depend on the turnover of the components of 
the extracellular matrix (Nagase and Woessner, 1999; Lund et al., 1999), which upon 
misregulation leads to several pathological conditions (see Chapter II -  Introduction to 
angiogenesis) (Halpert et al., 1996; Konttinen et al., 1999; Nelson et al., 2000). One of 
the major classes of enzymes, involved in the turnover of the extracellular matrix are the 
MMPs which are responsible for the degradation of the extracellular matrix. Regulation 
of MMP activity, which is crucial for the living organism, occurs either by transcriptional 
control of MMPs, their secretion in an inactive form (zymogens) or by their inhibition. 
Inhibitors of MMPs, the TIMPs, present a potent means for the design of inhibitors of 
MMPs in pathological conditions, where MMPs are overexpressed.
Research on TIMPs and their evolutionary relationship has suggested that of the four 
TIMP alleles (present in humans and most mammals) TIMP1 is most proximal to the 
ancestral TIMP form, from which the rest of the TIMP classes originated, probably via 
gene duplication (Brew et al., 2000). In order to understand the evolutionary relationship 
that links TIMPs from different organisms, a representative of the more ancestral TIMP 
form was examined. dTIMP differs from vertebrate TIMPs in that it lacks one of the 
conserved disulphide bonds from the N-terminal domain, which is the catalytic domain of 
TIMPs, while it has an extra disulphide bond in the C-terminal domain, thought to assist 
in the orientation and binding of TIMPs to the MMPs they inhibit. It was not clear 
whether this difference represented an indication of ancestry. Bioinformatic and 
modeling analyses on JTIMP against vertebrate, invertebrate and two insect TIMPs 
provided a wealth of information regarding the conserved disulphide bonds, their possible 
organisation and the evolutionary relationship that links TIMPs from different species.
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Sequence homology and phylogenetic tree analysis of vertebrate TIMPs against cTTIMP, 
revealed that, ATIMPland /zTIMP3 are most proximal to the ancestral TIMP form, 
represented in that comparison by cTTIMP. Interestingly this result is in agreement with 
two previous findings, one of which suggested that TIMP1 is most proximal to the 
ancestral TIMP form, from which the rest of the TIMP classes originated via gene 
duplication (Brew et al., 2000), while the other suggested that dTIMP is most similar to 
mammalian TIMP3 (Wei et al., 2003). As the structure of </TIMP has not yet been 
reported, it would not be possible to be conclusive on its proximity to either ATIMP1 or 
/iTIMP3, at the structural level. Sequence homology of vertebrate TIMP2 and TIMP4 
against dTIMP is around the same range, indicating that these two TIMP classes probably 
evolved in parallel, although the phylogenetic tree analysis places TIMP2 directly after 
TIMP1. Alignment of the different vertebrate TIMP classes against the homology model 
generated for cTTIMP revealed only a few differences, as expressed by the low deviation 
of the rmsd calculated for the above structural alignments. It is important to note that all 
members of vertebrate TIMPs have conserved organisation of disulphide bonds, which 
differs from that observed in *fTIMP.
Sequence homology and phylogenetic tree analysis of invertebrate TIMPs against ifTIMP 
provided some interesting information. The low overall sequence homology, can be most 
probably attributed to the lack of one domain from the two representatives of invertebrate 
TIMPs, P.pacificus TIMP and N.americanus TIMP. Proximal to dTIMP however were 
shown to be the two TIMPs from hydra, as expressed by the sequence homology and 
their proximity in the phylogenetic tree analysis. The two TIMP alleles present in hydra 
yielded an rmsd of 1.4-1.5 A, similar to that obtained from the alignments of vertebrate 
TIMPs against dTIMP. Phylogenetic tree analysis revealed that hydra TIMPs form 
probably the root of TIMPs, from which the rest originated. Interestingly, the more 
ancestral, rooting hydra TIMPs, have more disulphide bonds than their vertebrate 
homologues, probably suggesting that the number and organisation of disulphide bonds 
in vertebrate TIMPs are an evolutionary acquisition.
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Including insect TIMPs in the analysis provided some novel results. As seen from the 
primary sequence of the two insect TIMPs and the phylogenetic tree analysis, they both 
contain an extra disulphide bond from dTIMP and vertebrate TIMPs. If the disulphide 
bonds and their organisation are used as a basis for the analysis, it would be possible to 
suggest that the two TIMPs from A.gambiae and A.aegypti are more proximal to the 
ancestral TIMP form (e.g. hydra). The organisation of disulphide bonds in dTIMP would 
classify it as an intermediate, between the ancestral TIMPs (an extra disulphide bond, 
resulting in extra stabilisation in the C rather than the N-terminal domain of TIMPs) and 
the more recent vertebrate TIMPs (different organisation of disulphide bonds in the two 
domains). This hypothesis would explain the differences between </TIMP, hydra and 
insect TIMPs, as well as between JTIMP and vertebrate TIMPs.
As an intermediate, */TIMP could offer a wealth of information on the evolutionary 
relationship of TIMPs as well as on the significance and role of the conserved disulphide 
bonds, a characteristic TIMP feature. f/TIMP has been shown to be a potent inhibitor of 
MMPs and TACE, indicating that the lack of one disulphide bond from the N-terminal 
domain does not reduce or abolish its enzymatic activity. Further work on more ancestral 
TIMP representatives, such as TIMPs from A.gambiae and A.aegypti as well as the two 
TIMP alleles from hydra, would indicate whether the different organisation of the 
disulphide bonds allow these molecules to still be active, even against the vertebrate 
MMPs.
Identification of more ancestral MMPs forms, such as those preset in insects and hydra 
would show whether there are any differences with their vertebrate homologues. It is 
possible that the higher number of disulphide bonds observed in more ancestral TIMP 
forms, were required for the inhibition of MMPs of these organisms. It is thus possible 
that also the MMPs in insects and hydra also have differences from those present in 
Drosophila melanogaster or vertebrates.
Structural studies on TIMPs from different species would provide further information on 
the significance of conserved features and how these could be used for the design of new
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drugs, specific for the inhibition of MMPs. Structural studies on more ancestral TIMP 
forms would enhance the understanding of the structural features of these molecules and 
their significance. Biological experiments on ancestral TIMP forms and the MMPs they 
inhibit would provide interesting and novel information on the evolution of these 
molecules and their potential use in therapeutics. It would be interesting to examine 
whether invertebrate TIMPs, which are smaller in size than their vertebrate homologues, 
could be used for drug design against vertebrate MMPs.
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Appendix I -  Fermentation
Protein expression is most commonly carried out in 2L flasks, containing media and 
antibiotics of choice. Cell growth is monitored by measuring the optical density (O.D.) at 
600nm and when it reaches 0.6 to 0.8, protein expression is induced by the addition of 
IPTG (isopropyl P-D-thiogalactoside). IPTG induces the T7 promoter, behind which the 
gene of interest is inserted, inducing in this way the expression of the protein of interest. 
Another commonly used method for protein expression is the use of auto-induction 
media, where expression is not induced by the addition of IPTG. In this case expression 
media contain a mixture of carbon sources, including lactose. Of all carbon sources 
glucose is usually depleted first. Lactose can then enter the cell and induce the expression 
of T7 polymerase, inducing in this way protein expression. This type of protein 
expression is advantageous in that it does not require constant monitoring. These two 
types of protein expression are most commonly tested in order to identify which produces 
a higher protein yield, preferably in the soluble phase. Optimisation of the conditions 
used (e.g. temperature, incubation time post-induction and addition of extra carbon 
sources) is usually required.
Both types of protein expression described above were tested for hTP expression. 
Induction of protein expression using IPTG proved to be advantageous over auto­
induction method. None of the two methods however yielded a satisfactory amount of 
soluble protein. As a large amount of protein is required for biological experiments and 
crystallisation trials, overexpression of hTP was required. In order to achieve a higher 
protein yield a large scale protein expression experiment was set up. Large scale hTP 
expression was carried out in a fermentor, BioFlo 3000 (New Brunswick Scientific), 
where the environment is more ‘controlled’ than that of cultures in 2L flasks. As a new 
method, hTP expression using the fermentor required several rounds of optimisation until 
the protein yield was satisfactory.
Optimal conditions for hTP large-scale expression were 30°C, pH of 6.5 and agitation 
which was set in-loop with the dissolved oxygen (D.O.; see Chapter III, 3.9.2). Antifoam 
was added to the cultures in pi quantities, as excessive addition of antifoam can have
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adverse effects: inhibition of cell growth. Cultures were incubated for 3hrs post-induction 
and harvested through the harvest port of the fermentor (Figure 1; Figure 2).
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Figure 2: Headplate arrangement of the BioFlo 3000 fermentor. Labeled are the ports in 
the headplate for temperature (temperature probe), pH (pH probe), D.O. (D.O. probe) and 
antifoam (antifoam probe). Any foam produced during bacterial growth is discarded 
through the exhaust port. The inoculation port is used for the addition of the inoculating 
culture as well as for antibiotics. The sample port (which essentially is a valve allowing 
for small amounts of sample to be collected) is used for monitoring the culture growth 
while harvesting is done through the harvest port. Two additional ports are also available. 
These are used for the addition of acid and base to the vessel so as to control the pH of 
the culture.
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Large-scale hTP expression (fermentor) resulted in a much higher yield that than 
previously obtained from cultures in 2L flasks. A 3.5L fermentor culture yielded 700pl of 
pure hTP (concentration of 9mg/ml). This is much higher than that previously obtained 
using a standard protocol for 3.5L culture in culture flasks. This standardised method 
usually yielded 200pl of 6-7mg/ml concentration. It is thus evident that large-scale 
expression in a controlled environment proved to be advantageous for hTP expression.
Fermentor preparation
Preparation of the fermentor for use contains several steps which should be followed 
carefully. All parts of the fermentor need to be thoroughly washed with soap water and 
rinsed with de-ionised water. The use of ethanol in the vessel is not recommended, as the 
rubber rings in the vessel can be damaged. The vessel is assembled and all the tubing is 
attached to the respective ports. The tubing used is made of silicon, while plastic strings 
are used to tighten the connection of the tubes to their respective ports. The pH and D.O 
probes require calibration prior to every use. The pH probe, stored in 3M KC1, can be 
calibrated using the solutions typically used for pH meter calibration. The D.O. probe 
requires frequent monitoring as it is very sensitive. To ensure correct use it is essential to 
check that it has sufficient amount of electrolyte, which aids in the sensitivity of the 
measurements for the dissolved oxygen. Once the pH probe is calibrated, the vessel 
(containing the media and attached to all the tubing) can be autoclaved at 121 °C, 15psig 
for 45min. Following autoclave the vessel is allowed to cool down and then attached to 
the main fermentor unit, through which the vessel is controlled.
The vessel is connected to the main unit and to a supply for water and air (Figure 1). 
Water is necessary for the calibration of temperature and air is essential for culture 
growth. Vessel control is done via the screen of the main fermentor unit (Figure 1). The 
main screen allows access to three ‘sub-screens’: 1) a calibration screen - used for 
calibration of the temperature, pH and D.O. probes, 2) a master screen - which allows the 
monitoring of the vessel during the culture and provides readings as well as the user-set
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values and 3) a gases screen - through which control of vessel aeration is done and 
additional air can be supplied to the vessel.
Upon connection of the vessel to the main fermentor unit, the first step is to prime the 
temperature to the required value for culture. To ensure the temperature is measured 
correctly a small amount of glycerol is added to the thermowell before the temperature 
probe is connected. The temperature probe is allowed to equilibrate and once the desired 
temperature is reached the D.O. probe can be calibrated. For calibration of the D.O. probe 
two extremes are required: a minimum and a maximum. Minimum D.O. readings are 
obtained by disconnecting the D.O. probe from the main fermentor unit and setting the 
D.O. reading to zero. The vessel is allowed to equilibrate and the D.O. probe is again 
connected to the vessel. To achieve the maximum readings, the agitation is set to the 
maximum value that will be used during the experiment and the D.O. probe is again 
allowed to equilibrate. In order to ensure the correct amount of air is going into the 
vessel, the D.O. can be set in-loop with agitation, which is a more automatic way of 
controlling vessel aeration.
The additional ports are connected to acid and base solutions (Figure 1), if pH control is 
required for the experiment. Most commonly used acid solution is acetic acid 
(hydrochloric acid is not recommended) while the base solution most commonly used is 
ammonium hydroxide. All solutions should be autoclaved prior to use in order to 
minimise the chance of contamination.
Once the vessel has been correctly calibrated and equilibrated, the media is inoculated 
through the inoculation port. The same port is used for the addition of antibiotics. 
Monitoring of culture growth is facilitated by the sample port which allows for samples 
to be taken during the experiment, without disrupting the rest of the culture. The 
continuous use of agitation ensures that the sample used for monitoring culture growth is 
homogeneous. When cell density reaches 0.6-0.8 at O.D.600 nm the culture can be induced 
via the inoculation port. Upon inoculation a sample is collected, namely To, which can be 
later used for SDS-PAGE analysis against a sample of the harvested culture (assuming
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maximum growth has been reached and the protein has expressed after the addition of 
IPTG).
Typical of culture growth (Figure 3) is the increase in the absorbance readings at 
O.D.6oonm over time which is connected to a decrease in the oxygen available in the 
vessel (Figure 3). To ensure that oxygen depletion in the vessel does not become an 
inhibitory factor for cell growth, the agitation can be set in-loop with the dissolved 
oxygen. In this way agitation increases when D.O. is reduced, allowing in this way for 
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0.5
Figure 3: Plots illustrating bacterial growth during fermentation: the relationship between 
time and absorbance at O.D600 nm is indicative of the growth, which results at the reduction 
of D.O. remaining in the vessel at the same time.
It is likely that during bacterial growth, foam will be formed in the vessel. In this case the 
exhaust port is used. If the foaming is excessive, antifoam solution can be added to the 
vessel via the inoculation port It is essential to add as little as possible, since excessive use 
of antifoam can lead to inhibitory effects on culture growth. Harvesting of the culture 
occurs through the harvesting port.
Upon completion of the experiment the main unit has to be shut down and the water and air 
supply have to be disconnected. Vessel and tubing have to be washed with soap water and
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rinsed with de-ionised water. The probes need to be carefully removed from the vessel 
assembly and rinsed with de-ionised water.
Optimisation steps for protein expression using the fermentor are required, as the use of a 
controlled environment is not always favourable under the same conditions, for the 
expression of all proteins. Once the fermentation conditions are optimised for each type of 
protein expression required, the yield obtained can be much higher. This allows the 
production of the protein of interest in a more efficient way, which is as user friendly as the 
commonly used types of protein expression. hTP is a characteristic example of the 
advantageous method of large-scale expression, as opposed to the standard culture method 
(2L flasks; see Chapter III, 3.9.2).
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Appendix II -  Enzyme kinetics
Enzyme kinetics is the study of the rates of chemical reactions catalysed by enzymes. 
Studying the kinetics of a particular enzyme provides insights into several interesting 
areas, such as: the mechanism of action, ways to control the enzymatic activity and 
possible ways to inhibit the enzymatic activity. Understanding the information obtained 
from enzyme kinetics allows the understanding of the enzyme, its significance and role.
Rate o f an enzymatic reaction
The rate of an enzymatic reaction (as in a chemical reaction) is expressed in terms of the 
change in the concentration of a product or reactant in a given time interval. This is more 
clearly illustrated by:
A + B —-P
where A and B are the substrates in the reaction and P is the product. In this type of 
reaction, the rate will be expressed as:
A[A] A[8] A[P]
Rate= - ---------= -  = --------
At At At
where A is the difference; AA is the difference in concentration of substrate A, over a 
period of time, expressed as At. The rate of the reaction has a negative sign for the 
reactants (as they get consumed) and a positive sign for the product (as its production is 
increasing over time).
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The rate of reaction (at a given time) is proportional to the product of the concentration of 
the reactants raised to the appropriate powers. More specifically,
Rate = k [A / [B]8
Where K  is the rate constant and where and 8 are the exponents which must be 
determined experimentally.
The overall rate of a reaction is given by the sum of all the exponents. For example, a 
reaction where a reactant is directly converted to product, is a first order reaction. An 
example of a first order reaction is given below:
A —► P
Rate = /: [A]1 
First order reaction
When two reactants are required to form the product, then the rate of reaction for each of 
the reactants will still be one, but the reaction will overall be a second rate reaction. An 
example is given below:
A + B —► C + D
Rate = fc[A]'[B]1 
Second order reaction
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Several enzymes require a substrate in order to be active, the binding of which might 
trigger some changes in the conformation of the enzyme. Two models are mainly used in 
order to describe the enzyme-substrate binding: the lock-and-key model and the induced- 
fit model.
Lock-and-key model
In this type of model, a high degree of similarity is assumed to exist between the 
substrate (S) and the geometry of the active site cleft of the enzyme (E). Hence, the 
substrate binds the active site of the enzyme and ‘locks’ there upon formation of the 
enzyme substrate complex (ES), as illustrated below (Figure 1). There is however a 
disadvantage in this type of model: it does not account for any flexibility, a property 





Figure 1: Lock-and-key model for enzyme-substrate complex formation. The active site 
of the enzyme is considered to have a high degree of similarity with the substrate. Upon 
binding, the substrate ‘locks’ in the active site of the enzyme and the reaction can occur.
2 0 0
Induced-fit model
Induced-fit model differs from lock-and-key in that it takes into account the 
conformational flexibility of biological macromolecules and does not assume that the 
geometry of the active site is highly similar to the geometry of the substrate. In this type 
of model, the binding of substrate is considered to induce a conformational change in the 






Figure 2: Induced-fit model for enzyme-substrate complex formation. The active site of 
the enzyme does not have similar geometry to the substrate. Binding of substrate induces 
conformational changes in the active site of the enzyme and its geometry now becomes 
complementary to that of the substrate.
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Michaelis-Menten model
This model is the basic model used for the study of enzyme kinetics, especially for 
enzyme catalysed reactions. The main feature of the Michaelis-Menten model is the 
formation of an enzyme -  substrate complex, as an intermediate of the reaction, which is 
relatively low but remains unchanged over the course of the reaction. Enzyme (E) and 
substrate (S) form a complex (ES) and although product (P) is formed during the course 
of the reaction, a low concentration of the complex (ES) always remains.
E  +  S  ,  ♦  E S  k ' t  E  +  P
k-i
To measure the rate of reaction (Vo) in this type of model, varying substrate 
concentrations ([S]) are required. In First-order kinetics, the rate of the reaction depends 
on the available concentration of substrate [S], When the active site of all enzyme 
molecules are saturated with substrate, Zero-order kinetics are observed, where the rate of 
the reaction does not depend on concentration of [S] anymore (Figure 3).
Zero order kinetics
First order kinetics
Figure 3: This figure illustrates the rate of an enzymatic reaction and its dependence on 
the available concentration of substrate. In the beginning of the reaction, when the active 
site of all enzyme molecules is not saturated, the rate of the reaction depends solely on
2 0 2
the available substrate concentration. When the enzyme becomes saturated with substrate, 
the available concentration of the latter does not affect the rate of the reaction.
According to the Michaelis-Menten model for enzyme catalysed reactions, an enzyme- 
substrate complex is always present during the course of the reaction. The rate of 
formation of the enzyme-substrate complex, is given by the following equation:
A[ES]
Rate of formation = -----------------= k\ [E] [S] (1)
At
The formed ES complex breaks down to free enzyme [E] and to product [P], while a part 
of the ES complex still remains present. The rate of breakdown of the ES complex, which 
leads to the formation of the product, is given by the following equation (The negative 
sign signifies the breakdown of the ES complex):
A[ES]
Rate of formation = _    = k.\ [ES] + ki [ES] (2)
At
A steady-state is reached when the rate of formation of the ES complex equals the rate of 
its breakdown. At this point,
A[ES] = AtESl ^
At At
and subsequently, ki [E] [S] = k.\ [ES] + ki [ES] (4)
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In equation (4) the enzyme and the substrate concentrations are known, as they are 
defined by the experimenter. The concentration of the ES complex as well as the enzyme 
which is still reacting are however not known. Hence, in order to solve this equation it is 
essential to know the concentration of all species in the reaction. From the initial enzyme 
concentration used for the reaction [E]t a part is present as free enzyme while some is 
involved in the formation of the ES complex. Hence the free enzyme, which still reacts 
will be given by:
[E] = [E]t - [ES] (5) 
substituting (5) in (4)
*i([E]t  -  [ES]) [S] = k.\ [ES] + *2 [ES] (6)
collecting all the individual rate constants in (6),leads to (7):
[E]X[S] -  [ES] [S] k_l + k2
________________ =    =  Km (7)
[ES] *i
Solving (7) for [ES]:
[E]t [S]
[ES] =    (8)
Km+[S]
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In the Michaelis -  Menten model, the initial rate (F0) of product formation depends only 
on the rate of the breakdown of the [ES], and hence
V0 = k2 [ES] (9)
substituting for [ES] in (9):
*2[E]t [S]
(10)
Vo "  ---------------------------
Km +[S]
When the substrate concentration is too high all the enzyme is saturated and
[ES] = [E]t
At this point, the reaction proceeds at its maximum velocity and
V0=Vmax=k2[E]T
The original concentration of the enzyme is however constant. Hence
Emax=constant





In general, the rate of reaction V in the Michaelis -  Menten model, is given by the 
equation:
m^ax [S] Michaelis -  Menten
equation
* m+[S]
By taking a reciprocal on both sides of the Michaelis -  Menten equation results in a 
straight line which allows the calculation of Km and Vmax with more accuracy. This 
double reciprocal of the Michaelis -  Menten equation is known as Lineweaver -  Burk, 
and expressed as:
1 Km 4- [S] Rm 1 1
v  ~ Vmai[S\ -  Vmai [S] +  vmai







From this plot Km and Vmax can be calculated with more accuracy. The x-axis represents 
the reciprocal of substrate concentration while the y-axis represents the reciprocal of
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velocity. Km is calculated from the x-axis intercept while Vmax is calculated from the y- 
axis intercept. Hence the units of Km are the same as those of the substrate and the units 
of Vmax are expressed as concentration per time. It is essential to mention that the lower 
the value of Km the higher the affinity of the enzyme for the substrate.
Apart from the Lineweaver -  Burk plot for calculating Km and Fmax, other methods are 
also available. These include the Eadie -  Hofstee, the Hanes - Woolf and the Direct 
Linear methods.
(All methods described below produce linear plots and can be used for the accurate 
calculation of Km and Fmax.)
Eadie -  Hofstee
In Eadie -  Hofstee method the velocity is plotted on the x-axis while the y-axis represents 
velocity of substrate concentration.
Slope = -1 lKm
max
207
The equation describing this method is the following:
[S] Km Kn
The gradient is used for the calculation of Km:
1
Gradient = _ ___________
Km
While Fmax is calculated from the x-axis intercept.
x-intercept = Fmax
Hanes -  Woolf
In Hanes -  Woolf method the substrate concentration is plotted on the x-axis while the y- 





The equation describing this method is:
[S] ^  K"
+
Vmax is calculated from the gradient,
Gradient =
and Km is calculated from the x-axis intercept,
x-intercept = -Kn
Direct linear
The direct linear method is considered to be one of the more accurate methods for the 
calculation of the kinetic parameters. In this type of method, lines are drawn for each of 
the substrate concentrations which are tested experimentally (e.g. SI, S2, S3, etc). Where 
these lines intersect on the x- and y-axis, the coordinates give Km and Vmax respectively. 
Due to the averaging of the data, direct linear is considered as a very precise method for 
the calculation of Km and Fmax. An example of the direct linear plot is given below:
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VThe x-axis represents the substrate concentration and the y-axis represents the velocity of 
the reaction. The averaging of the data in this type of plot allows for a more precise 
calculation of the kinetic parameters Km and Fmax.
Once the values for Xm and Vmax have been determined, it is essential to know how 
efficient the enzyme is in catalysing that particular reaction. This can be determined by 
the turnover number, which can also be calculated experimentally. The turnover number 
is the number of moles of substrate that react to form product per mole of enzyme per 
unit time. The units of the turnover number are sec'1.
V
'  max
----------------------------  — Turnover number = kcat
Et
This is indicative of the efficacy of the enzyme and can be used to illustrate how active 
the enzyme is as well as whether it is a good catalyst of a particular substrate.
A simple enzymatic reaction can be described by the values obtained for Km, Fmax and 
&cat. For the study of enzyme catalysed reactions where inhibitors are also present, more 
information is required for the description of the reaction.
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In such cases the primary enquiry is the nature of the inhibitor and the type of inhibition. 
Once the type of inhibition is determined, the effect of the inhibition on Km and Vmax has 
to be determined.
Inhibitors can be generally described as substances that interfere with the activity of the 
enzyme, either reducing or abolishing it. In both cases the overall rate of the reaction is 
reduced and the effect of each type of inhibition can be determined. There are two main 
types of inhibitors: Reversible inhibitors bind the enzyme and are later released, leaving 
the enzyme in its original condition. Irreversible inhibitors react with the enzyme and the 
product is an enzymatically inactive protein. There are two major classes of reversible 
inhibitors: Competitive inhibitors and Noncompetitive inhibitors.
Competitive inhibition
In competitive inhibition, the inhibitor is very similar in structure with the substrate. It 
binds thus to the active site of the enzyme and blocks subsequent binding of the substrate. 







It is evident that once the inhibitor binds to the active site of the enzyme, the substrate 
cannot bind and hence the reaction is inhibited.
* E + P
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The Lineweaver -  Burk plot of competitive inhibition compared to the plot of the same 
reaction, in the absence of inhibitor, is shown below:
The Lineweaver -  Burk plot for the enzyme catalysed reaction (without inhibitor) is 
illustrated in blue, while the reaction where inhibitor is also present is illustrated in red. 
From the plot it is evident that competitive inhibition yields a higher Km value (as the 
enzyme’s affinity for the substrate is lower since the inhibitor is competing with the 
enzyme for the active site occupation) while Vmax is unaffected. A way to overcome this 
type of inhibition is to increase the concentration of substrate, as this would allow for 
more substrate to occupy the enzyme and drive the reaction.
Noncompetitive inhibition
In noncompetitive inhibition, the inhibitor binds at sites other than the active site of the 
enzyme. In this way, the substrate can still bind and the reaction can still proceed, 













Binding of the inhibitor does not block the binding of substrate. A complex of enzyme- 
substrate and inhibitor is formed and the reaction can proceed. This reaction however will 
not be very efficient as the presence of the inhibitor will reduce the reaction rate. The 
Lineweaver -  Burk plot of noncompetitive inhibition compared to the plot of the same 




- 1  IK.
1/[S]
The Lineweaver -  Burk plot for the enzyme catalysed reaction (without inhibitor) is 
illustrated in blue, while the reaction where noncompetitive inhibitor is also present, is
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illustrated in red. From the plot it is evident that noncompetitive inhibition does not affect 
the Km (as the inhibitor does not compete with the substrate for occupation of the active 
site of the enzyme) while VmaK is reduced as the rate of the reaction is lower. As the 
inhibitor and the substrate are not ‘competing’ for occupation of the active, increasing the 
substrate concentration will not have any effect on the reaction.
Apart from the two most common types of inhibition, other types of inhibition also exist. 
These include uncompetitive inhibition, mixed type inhibition and suicide inhibition. 
In uncompetitive inhibition the inhibitor binds to the enzyme only after the appropriate 
substrate has bound. In this way the inhibitor inactivates the enzyme only after the 
formation of the ES complex. This type of inhibition can be described as:




Uncompetitive inhibitors do not bind to free enzyme molecules; only after the binding of 
the substrate to the active site of the enzyme, and the formation of the enzyme-substrate 
complex, will the uncompetitive inhibitor bind and inhibit the reaction. The Lineweaver -  







The Lineweaver -  Burk plot for the enzyme catalysed reaction (without inhibitor) is 
illustrated in blue, while the reaction where uncompetitive inhibitor is present, is 
illustrated in red. From the plot it is evident that uncompetitive inhibition affects both Km 
and Vmax by reducing them. Increasing the substrate concentration does not affect the 
reaction in uncompetitive inhibition.
Mixed type inhibition
In this type of inhibition, the inhibitor can bind both to the free enzyme to give an 
enzyme-inhibitor complex, and to the enzyme-substrate complex to give an unreactive 
enzyme-substrate-inhibitor complex As shown below, both inhibitor-binding reactions 
are dead-end reactions and therefore reach equilibria.





Mixed type inhibitors can bind both the free enzyme and to enzyme-substrate complexes, 
inhibiting in this way the progression of the reaction. The Lineweaver -  Burk plot for this 
type of inhibition is shown below:
The Lineweaver -  Burk plot for the enzyme catalysed reaction (without inhibitor) is 
illustrated in blue, while the reactions where mixed type inhibitor is present, are 
illustrated in red, green, cyan and purple. From the plot it is evident that mixed type 
inhibition reduces the Vmax, while Km might increase or decrease.
Suicide inhibitors
Suicide inhibitors bind the enzyme and ‘kill’ it (inactivate it) while the inhibitor also 
‘dies’ in the process. The reaction is irreversible: the enzyme and inhibitor are not 
released back into solution. These inhibitors are also known as mechanism-based 
inhibitors. Such inhibition is exploited in drug design and development (inhibitors 
targeting specifically an enzyme). The only way to understand this type of inhibition is 
by understanding the mechanism of enzymatic reaction and understanding how the 




A table summarising the different types of inhibition and the effect they have on Fmax and 
Km is given below (Table 1).
Table 1: Type of inhibitors and effect on the reaction
Type of inhibitor Effect Comments
Competitive Increases Km but does not Binds specifically at the active
affect Fmax site, where it competes with 
the substrate for binding.
Noncompetitive Reduces Fmax but does not Binds E or ES complex other
affect Km than at the catalytic site. 
Substrate binding unaltered, 
but ESI complex cannot form 
products.
Inhibition cannot be reversed 
by substrate.
Uncompetitive Reduces both Km and Fmax Binds only to ES complexes at 
locations other than the 
catalytic site.
Substrate binding modifies 
enzyme structure, making 
inhibitor- binding site 
available. Inhibition cannot be 
reversed by substrate.




To ‘measure’ how efficient an inhibitor is, a constant can be used to describe its effect on 
the enzyme catalysed reaction. Inhibitor constant kx is the equilibrium constant of the 
reversible combination of the enzyme with an inhibitor. kx values can either be calculated 
or derived from Dixon plots. Dixon plots are plots of the inhibitor concentration versus 
the reciprocal of velocity. Each type of inhibition produces a different type of plot. Hence 
it is an accurate and easy way to determine both the type of inhibition as well as the 
efficiency of the inhibitor present. These plots however cannot be used to derive any 
information for the Km and Vmax parameters. Examples of Dixon plots for different types 






In competitive inhibition, when 1/v is plotted against [I], the substrate concentrations 
tested ‘meet’ above the x-axis. This plot allows the calculation of the Ki value for the 
inhibitor directly. In contrast, a plot of [S]/v against [I] (in competitive inhibition) 
produces parallel lines.
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N on-com petitive inhibition
[S]/v1/v
[I]
In non-competitive inhibition, when 1/v is plotted against [I], the substrate concentrations 
tested ‘meet’ on the x-axis, where -KpKV In this type of inhibition, a plot of [S]/v 






In un-competitive inhibition, when 1/v is plotted against [I], the substrate concentrations 
tested produce parallel lines. In contrast, the plot of [S]/v against [I] produces lines that 




In mixed-type inhibition, when 1/v is plotted against [I], the substrate concentrations 
tested meet above the x-axis, in contrast to the plot of [S]/v against [I], where the lines 
meet below the x-axis. The K; value can be calculated from both plots, using the formula 
[l-(Kj-K’i)/V],
It is thus evident that Dixon plots are an efficient and convenient way for determining 
both the type of inhibition as well as the Kj value for a given inhibitor. These plots have 
been used for the determination of the type of inhibitor 5IUR is as well as for the 
calculation of its efficacy, as shown by the Kj value (see Chapter ID; 3.9.10).
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